1. Induced Disease Models Products Antibody-drug Conjugate/ADC Related Cell Cycle/DNA Damage Epigenetics PI3K/Akt/mTOR Autophagy Apoptosis Anti-infection
  2. Cardiovascular System Disease Models ADC Cytotoxin Antibiotic Bacterial Topoisomerase AMPK HIV Autophagy Mitophagy Apoptosis HBV
  3. Heart Disease Models
  4. Doxorubicin

Doxorubicin (Hydroxydaunorubicin), a broad-spectrum anthracycline antibiotic with cytotoxic properties, is an anti-cancer chemotherapy agent. Doxorubicin has fluorescence properties. Doxorubicin inhibits topoisomerase II with an IC50 of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy. Doxorubicin inhibits human DNA topoisomerase I with an IC50 of 0.8 μM.

For research use only. We do not sell to patients.

Doxorubicin Chemical Structure

Doxorubicin Chemical Structure

CAS No. : 23214-92-8

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Doxorubicin:

Other Forms of Doxorubicin:

Top Publications Citing Use of Products

476 Publications Citing Use of MCE Doxorubicin

WB
IF
IHC
Cell Viability Assay

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 May 9;23(1):83.  [Abstract]

    Exhausted T-cells (NExT) loaded with Doxorubicin (5–50 nM; 48 h) significantly reduces the viability of SUM159 cells.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2024 May 11:38:384-398.  [Abstract]

    Doxorubicin hydrochloride (10 μM; 3-5 days) significantly reduces the viability of lung cancer organoid-2 (LCO-2) and LCO-3, while showing no significant effect on LCO-1 viability.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Adv Funct Mater. 23 October 2021.

    Cell viability after incubated with free DOX under normoxia and hypoxia at various DOX (Doxorubicin) (0.65-20 μg/mL) concentrations for 24 h determined by MTT assay.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2020 Sep;22(9):1056-1063.  [Abstract]

    UFMylation of endogenous p53 was analysed by western blot in HCT116 p53+/+ cells depleted of UFL1 or DDRGK1 upon DNA damage induced by doxorubicin (doxo; 1 µM; 24 h) or etoposide (eto; 25 µg ml−1; 12 h).

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887.  [Abstract]

    Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Western blotting analysis and quantification of KRT8 protein expression (normalized to GAPDH expression).

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887.  [Abstract]

    Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Representative images of immunofluorescence staining of KRT8 of CM318 and UCH1 cell line.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2019 Jan;130:557-567.  [Abstract]

    Representative pictures of Live/Dead staining of effects of 7,8-DHF on high dose of Dox-induced cell death and MMP reduction of H9c2 cells.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2019 Sep;23(9):6034-6047.  [Abstract]

    Effects of YWPC (50 mg/L for 24 h) on DOX (5 μM for 24 h)-induces dissipation of mitochondrial membrane potential measured in H9C2 cells loaded with JC-1 using fluorescence microscopy.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Oct 8;9(1):4139.  [Abstract]

    One hour after treated with UV or 2 h after treated with MMS, Camptothecin (CPT) (10 μM), or Doxorubicin (DOX; 0.5 μM), HEK293T cells expressing HA-SUMO2 and His-RhoB are subjected to sumoylation assay to detect the SUMO2 conjugation of RhoB.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2018 Jan 2;128(1):483-499.  [Abstract]

    Immunoblotting for EZH2 in lysates of immortalized mouse podocytes after treatment with Adriamycin (300 ng/mL) for 48 hours (n=6).

    Doxorubicin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Sep 19;37(1):232.  [Abstract]

    Immunoblotting shows that both P-gp protein expression is significantly decreased in 24 h after US exposure in MCF-7/ADR and HEPG2/ADM cells.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Nanoscale Res Lett. 2018 Nov 3;13(1):350.  [Abstract]

    HY-15142

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2017;42(3):965-973.  [Abstract]

    U937 cells are treated with Thapsigargin (TG, 1 μM), NSC 125973 (PTX, 5nM) as well as Doxorubincin (DOX, 1 μM) for 12 hours and the indicated proteins are detected by Western blot.

    Doxorubicin purchased from MedChemExpress. Usage Cited in: Nat Med. 2016 May;22(5):547-56.  [Abstract]

    Immunofluorescent staining for α-actinin (ACTN2) and cardiac troponin T (TNNT2) to demonstrate sarcomeric organization in hiPSC–CMs derived from patients who do not experience Doxorubicin–induced cardiotoxicity (DOX) versus those who do experience Doxorubicin-induced cardiotoxicity (DOXTOX) after 24 h treatment with Doxorubicin. Scale bar, 20 µm.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Doxorubicin (Hydroxydaunorubicin), a broad-spectrum anthracycline antibiotic with cytotoxic properties, is an anti-cancer chemotherapy agent. Doxorubicin has fluorescence properties. Doxorubicin inhibits topoisomerase II with an IC50 of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy[1][2]. Doxorubicin inhibits human DNA topoisomerase I with an IC50 of 0.8 μM[3].

    IC50 & Target[1][2][3][7]

    Topoisomerase I

    0.8 μM (IC50)

    Topoisomerase II

    2.67 μM (IC50)

    Daunorubicins/Doxorubicins

     

    HIV-1

     

    Cellular Effect
    Cell Line Type Value Description References
    143B IC50
    0.1 μM
    Compound: DOX
    Cytotoxicity against human 143B cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human 143B cells measured after 72 hrs by Celltiter-Glo assay
    [PMID: 31820976]
    16HBE14o- GI50
    0.18 μM
    Compound: Adriamycin
    Growth inhibition of human 16HBE cells by sulforhodamine B assay
    Growth inhibition of human 16HBE cells by sulforhodamine B assay
    [PMID: 24650643]
    184B5 GI50
    1.15 μM
    Compound: Doxorubicin
    Cytotoxicity against human 184B5 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human 184B5 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 29670691]
    184B5 GI50
    1.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human 184B5 cells after 72 hrs by MTT assay
    Antiproliferative activity against human 184B5 cells after 72 hrs by MTT assay
    [PMID: 30071406]
    1A9 EC50
    0.1 μM
    Compound: doxorubicin
    Cytotoxicity against human 1A9 cells after 72 hrs
    Cytotoxicity against human 1A9 cells after 72 hrs
    [PMID: 17378530]
    3Y1 cell line GI50
    3.8 nM
    Compound: adriamycin
    Cytotoxicity against rat 3Y1 cells after 72 hrs by MTT assay
    Cytotoxicity against rat 3Y1 cells after 72 hrs by MTT assay
    [PMID: 10691710]
    4T1 IC50
    0.481 μM
    Compound: Doxorubicin
    Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 30433783]
    4T1 IC50
    0.99 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    [PMID: 27496212]
    4T1 IC50
    90 nM
    Compound: Doxorubicin
    Cytotoxicity against mouse 4T1 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    Cytotoxicity against mouse 4T1 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    [PMID: 35213166]
    5637 IC50
    0.02 μM
    Compound: doxo
    Antiproliferative activity against human 5637 cell line by MTT assay
    Antiproliferative activity against human 5637 cell line by MTT assay
    [PMID: 16913700]
    5-8F IC50
    0.34 μM
    Compound: DOX
    Antiproliferative activity against human 5-8F cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human 5-8F cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 36709571]
    769-P IC50
    0.45 μM
    Compound: Doxorubicin
    Anticancer activity against human 769-P cells by MTT assay
    Anticancer activity against human 769-P cells by MTT assay
    [PMID: 31404864]
    786-0 GI50
    < 0.046 μM
    Compound: Dox
    Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by SRB assay
    [PMID: 26454648]
    786-0 GI50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human 786-0 cells by sulforhodamine B assay
    Cytotoxicity against human 786-0 cells by sulforhodamine B assay
    [PMID: 26913941]
    786-0 GI50
    0.025 μg/mL
    Compound: DOX; Doxo
    Antiproliferative activity against human 786-0 cells after 48 hrs by SRB assay
    Antiproliferative activity against human 786-0 cells after 48 hrs by SRB assay
    [PMID: 26859070]
    786-0 GI50
    0.04 μg/mL
    Compound: DOX
    Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay
    [PMID: 21041092]
    786-0 GI50
    0.11 μM
    Compound: Dox
    Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    [PMID: 28505535]
    786-0 IC50
    0.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human 786-O cells assessed as growth inhibition by MTS assay
    Cytotoxicity against human 786-O cells assessed as growth inhibition by MTS assay
    [PMID: 24824796]
    786-0 GI50
    0.13 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human 786-0 cells after 48 hrs by SRB assay
    Cytotoxicity against human 786-0 cells after 48 hrs by SRB assay
    [PMID: 23871905]
    786-0 GI50
    0.13 μM
    Compound: Doxorubicin
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 29102177]
    786-0 GI50
    0.13 μM
    Compound: Doxorubicin
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28329730]
    786-0 GI50
    0.15 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    [PMID: 26561866]
    786-0 GI50
    0.15 μg/mL
    Compound: DOX
    Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    [PMID: 25062010]
    786-0 GI50
    0.15 μM
    Compound: DOXO
    Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    [PMID: 31247374]
    786-0 GI50
    0.16 μM
    Compound: Doxorubicin
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 33477019]
    786-0 GI50
    0.18 μg/mL
    Compound: Doxorubicin
    Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay
    [PMID: 22410248]
    A 172 IC50
    0.13 μM
    Compound: DOX
    Antiproliferative activity against human A-172 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Antiproliferative activity against human A-172 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    [PMID: 34968902]
    A 172 IC50
    0.2 μM
    Compound: Dox
    Cytotoxicity against human A172 cells after 72 hrs by MTT assay
    Cytotoxicity against human A172 cells after 72 hrs by MTT assay
    [PMID: 30659997]
    A204 IC50
    0.006482 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A204 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay
    Antiproliferative activity against human A204 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay
    [PMID: 30540463]
    A2058 CC50
    1.79 μM
    Compound: Doxorubicin
    Cytotoxicity against human A2058 cells after 72 hrs by MTT assay
    Cytotoxicity against human A2058 cells after 72 hrs by MTT assay
    [PMID: 29792325]
    A2058 EC50
    6.5 μM
    Compound: 12
    Dark toxicity in human A2058 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Dark toxicity in human A2058 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    [PMID: 29172528]
    A2780 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells after 48 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 48 hrs by SRB assay
    [PMID: 20673627]
    A2780 GI50
    < 0.1 μM
    Compound: ADR
    Anticancer activity against human A2780 cells by SRB method
    Anticancer activity against human A2780 cells by SRB method
    [PMID: 22104151]
    A2780 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay
    [PMID: 21737288]
    A2780 IC50
    0.0096 μM
    Compound: Doxirubicin
    Concentration required to inhibit A2780-cell growth by 50%
    Concentration required to inhibit A2780-cell growth by 50%
    [PMID: 9703471]
    A2780 EC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    [PMID: 33049606]
    A2780 EC50
    0.01 μM
    Compound: DR
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    [PMID: 32956968]
    A2780 IC50
    0.01 μM
    Compound: DX
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    [PMID: 32422522]
    A2780 IC50
    0.02 μM
    Compound: doxorubicin
    Antiproliferative activity against human A2780 cells after 3 days by MTT assay
    Antiproliferative activity against human A2780 cells after 3 days by MTT assay
    [PMID: 19093883]
    A2780 IC50
    0.044 μM
    Compound: Doxorubicin
    Cytotoxicity against human A2780 cells assessed as intracellular ATP level after 72 hrs by luminometry
    Cytotoxicity against human A2780 cells assessed as intracellular ATP level after 72 hrs by luminometry
    [PMID: 21354800]
    A2780 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 33823396]
    A2780 IC50
    0.1 μM
    Compound: adriamycin
    Cytotoxicity against human A2780 cells by MTT assay
    Cytotoxicity against human A2780 cells by MTT assay
    [PMID: 17190442]
    A2780 IC50
    0.123 μM
    Compound: Dox
    Cytotoxicity against human A2780 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human A2780 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    [PMID: 30599418]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Growth inhibition of human A2780 cells after 48 hrs by SRB assay
    Growth inhibition of human A2780 cells after 48 hrs by SRB assay
    [PMID: 20031423]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Growth inhibition of human A2780 cells by SRB assay
    Growth inhibition of human A2780 cells by SRB assay
    [PMID: 22361684]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Anticancer activity against human A2780 cells by SRB method
    Anticancer activity against human A2780 cells by SRB method
    [PMID: 21676506]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay
    [PMID: 23849207]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay
    [PMID: 22364746]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay
    [PMID: 18657979]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells after 24 hrs by WST-1 assay
    Cytotoxicity against human A2780 cells after 24 hrs by WST-1 assay
    [PMID: 20732817]
    A2780 GI50
    0.17 μM
    Compound: adriamycin
    Cytotoxicity against human A2780 cells after 24 hrs by SRB method
    Cytotoxicity against human A2780 cells after 24 hrs by SRB method
    [PMID: 18262426]
    A2780 GI50
    0.17 μM
    Compound: ADR, Adriamycin
    Growth inhibition of human A2780 cells by SRB method
    Growth inhibition of human A2780 cells by SRB method
    [PMID: 18207392]
    A2780 IC50
    0.18 μM
    Compound: ADM; DOX
    Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 31491611]
    A2780 IC50
    0.27 μM
    Compound: DOX
    Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
    Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
    [PMID: 26386603]
    A2780 IC50
    0.33 μM
    Compound: Adriamycin
    Cytotoxicity against human A2780 cells by MTT assay
    Cytotoxicity against human A2780 cells by MTT assay
    [PMID: 22070654]
    A2780 IC50
    0.5 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells by SRB assay
    Cytotoxicity against human A2780 cells by SRB assay
    [PMID: 18656370]
    A2780 IC50
    0.5 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells by sulforhodamine B assay
    Cytotoxicity against human A2780 cells by sulforhodamine B assay
    [PMID: 17822905]
    A2780 IC50
    0.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTS assay
    Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTS assay
    [PMID: 33348171]
    A2780 IC50
    0.6 μM
    Compound: Adriamycin
    Cytotoxicity against human A2780 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A2780 cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 26356746]
    A2780 IC50
    0.71 μM
    Compound: DOX
    Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 32996316]
    A2780 IC50
    0.98 μM
    Compound: DOX
    Cytotoxicity against human A2780 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A2780 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 27149641]
    A2780 IC50
    1.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human A2780 cells after 24 hrs by MTT assay
    Cytotoxicity against human A2780 cells after 24 hrs by MTT assay
    [PMID: 26252628]
    A2780 IC50
    1.9 μM
    Compound: DOX
    Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method
    Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method
    [PMID: 25061803]
    A2780 IC50
    23 nM
    Compound: doxorubicin
    Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
    Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
    [PMID: 23886686]
    A-375 EC50
    0.009 μM
    Compound: Doxorubicin
    Induction of senescence in human A-375 cells treated for 3 days by Hoechst staining based imaging analysis
    Induction of senescence in human A-375 cells treated for 3 days by Hoechst staining based imaging analysis
    [PMID: 33859796]
    A-375 EC50
    0.009 μM
    Compound: Dox
    Induction of senescence-like phenotype in human A-375 cells assessed as increase in morphological changes after 72 hrs by staining based imaging assay
    Induction of senescence-like phenotype in human A-375 cells assessed as increase in morphological changes after 72 hrs by staining based imaging assay
    [PMID: 33268144]
    A-375 IC50
    0.01 μM
    Compound: doxorubicin
    Cytotoxicity against human A375 cells after 24 hrs by MTT assay
    Cytotoxicity against human A375 cells after 24 hrs by MTT assay
    [PMID: 18281125]
    A-375 IC50
    0.01 μM
    Compound: doxorubicin
    Cytotoxicity against human A375 cells after 24 hrs by MTT assay
    Cytotoxicity against human A375 cells after 24 hrs by MTT assay
    [PMID: 17400463]
    A-375 IC50
    0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    [PMID: 25937235]
    A-375 IC50
    0.024 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 30433783]
    A-375 IC50
    0.13 μM
    Compound: DOX
    Antiproliferative activity against human A375 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A375 cells after 72 hrs by MTT assay
    [PMID: 21496972]
    A-375 IC50
    0.19 μM
    Compound: ADM; DOX
    Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 31491611]
    A-375 IC50
    0.26 μM
    Compound: DOX
    Cytotoxicity against human A-375 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
    Cytotoxicity against human A-375 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
    [PMID: 35612499]
    A-375 IC50
    0.33 μM
    Compound: DOX
    Antiproliferative activity against human A-375 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A-375 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    [PMID: 35818137]
    A-375 IC50
    0.37 μM
    Compound: DOX
    Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay
    [PMID: 29597166]
    A-375 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 29789258]
    A-375 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
    Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
    [PMID: 35271771]
    A-375 IC50
    0.75 μM
    Compound: ADM
    Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay
    [PMID: 23639650]
    A-375 IC50
    1 μM
    Compound: ADM
    Cytotoxicity against human A375 cells after 72 hrs by MTT assay
    Cytotoxicity against human A375 cells after 72 hrs by MTT assay
    [PMID: 26280921]
    A-375 IC50
    1 μM
    Compound: ADM
    Cytotoxicity against human A375 cells after 72 hrs by MTT assay
    Cytotoxicity against human A375 cells after 72 hrs by MTT assay
    [PMID: 25874331]
    A-375 IC50
    1.2 μM
    Compound: Doxorubicin
    Anticancer activity against human A375 cells by MTT assay
    Anticancer activity against human A375 cells by MTT assay
    10.1039/C4MD00219A
    A-375 IC50
    1.8 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A375 cells after 24 hrs by MTT assay
    Cytotoxicity against human A375 cells after 24 hrs by MTT assay
    [PMID: 12608856]
    A-375 IC50
    2.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human A-375 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A-375 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 32975117]
    A-375 IC50
    5.51 μM
    Compound: Doxorubicin
    Anticancer activity against human A375 cells after 48 hrs by MTT assay
    Anticancer activity against human A375 cells after 48 hrs by MTT assay
    [PMID: 22136907]
    A-375 IC50
    6.35 μM
    Compound: Dox
    Antiproliferative activity against human A375 cells for 24 hrs by MTT assay
    Antiproliferative activity against human A375 cells for 24 hrs by MTT assay
    [PMID: 24929289]
    A-375 IC50
    7.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human A375 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A375 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay
    [PMID: 30433783]
    A-375 IC50
    7.2 μM
    Compound: Doxo
    Cytotoxicity against human A375 cells after 48 hrs by MTT assay
    Cytotoxicity against human A375 cells after 48 hrs by MTT assay
    [PMID: 25563891]
    A-431 GI50
    0.0012 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A431 cells by SRB assay
    Antiproliferative activity against human A431 cells by SRB assay
    [PMID: 19394218]
    A-431 IC50
    0.03 μM
    Compound: Dox
    Anticancer activity against human A431 cells after 48 hrs by MTT assay
    Anticancer activity against human A431 cells after 48 hrs by MTT assay
    [PMID: 22209733]
    A-431 IC50
    0.05 μM
    Compound: adriamycin
    Growth inhibition of human A431 cells by MTT assay
    Growth inhibition of human A431 cells by MTT assay
    [PMID: 17049252]
    A-431 IC50
    0.16 μM
    Compound: DOX
    Cytotoxicity against human A431 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human A431 cells measured after 72 hrs by Celltiter-Glo assay
    [PMID: 31820976]
    A-431 GI50
    0.18 μM
    Compound: Doxorubicin
    Growth inhibition of human A431 cells after 2 days by SRB assay
    Growth inhibition of human A431 cells after 2 days by SRB assay
    [PMID: 22000924]
    A-431 GI50
    0.18 μM
    Compound: Doxorubicine
    Growth inhibition of human A431 cells after 2 days by sulforhodamine B assay
    Growth inhibition of human A431 cells after 2 days by sulforhodamine B assay
    [PMID: 20045222]
    A-431 IC50
    0.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human A431 cells after 72 hrs by MTT assay
    Cytotoxicity against human A431 cells after 72 hrs by MTT assay
    [PMID: 18692939]
    A-431 IC50
    0.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human A431 cells after 48 hrs by MTT assay
    Cytotoxicity against human A431 cells after 48 hrs by MTT assay
    [PMID: 20846862]
    A-431 EC50
    0.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 35567964]
    A-431 ED50
    1.2 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A431 cells by MTT assay
    Cytotoxicity against human A431 cells by MTT assay
    [PMID: 7714533]
    A-431 IC50
    1.35 nM
    Compound: DOX
    Cytotoxicity against human A431 cells by SRB assay
    Cytotoxicity against human A431 cells by SRB assay
    [PMID: 24890652]
    A-431 IC50
    1.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 31546197]
    A498 ED50
    0.00286 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    [PMID: 11087592]
    A498 ED50
    0.0156 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A-498 cells after 7 days by MTT assay
    Cytotoxicity against human A-498 cells after 7 days by MTT assay
    [PMID: 10514307]
    A498 IC50
    0.035 μM
    Compound: adriamycin
    Antitumor activity against human A498 cells by methylene blue staining method
    Antitumor activity against human A498 cells by methylene blue staining method
    [PMID: 17656091]
    A498 GI50
    0.1 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human A498 cells after 48 hrs by SRB assay
    Cytotoxicity against human A498 cells after 48 hrs by SRB assay
    [PMID: 23871905]
    A498 GI50
    0.1 μM
    Compound: Doxorubicin
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 29102177]
    A498 GI50
    0.1 μM
    Compound: Doxorubicin
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28329730]
    A498 ED50
    1 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    [PMID: 9214729]
    A498 ED50
    1 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    [PMID: 8882434]
    A498 ED50
    1.1 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    10.1021/np970510f
    A498 IC50
    1.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A498 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A498 cells after 48 hrs by SRB assay
    [PMID: 30503942]
    A498 ED50
    1.13 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    [PMID: 9322367]
    A498 ED50
    1.22 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    [PMID: 9134750]
    A498 ED50
    1.58 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    [PMID: 9584396]
    A498 ED50
    1.78 ng/mL
    Compound: Adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    [PMID: 8946743]
    A498 ED50
    1.9 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    [PMID: 10395501]
    A498 ED50
    1.9 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A-498 cells by MTT assay
    Cytotoxicity against human A-498 cells by MTT assay
    [PMID: 9917277]
    A498 ED50
    1.97 ng/mL
    Compound: Adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    [PMID: 7494147]
    A498 ED50
    1.98 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    [PMID: 9599253]
    A498 ED50
    2.26 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    [PMID: 11325235]
    A498 ED50
    2.86 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A-498 cells after 7 days by MTT assay
    Cytotoxicity against human A-498 cells after 7 days by MTT assay
    [PMID: 15730242]
    A498 ED50
    3.2 ng/mL
    Compound: Adriamycin
    Cytotoxicity against human A498 cells by MTT assay
    Cytotoxicity against human A498 cells by MTT assay
    [PMID: 7714533]
    A498 ED50
    3.66 x 10-4 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    [PMID: 8676130]
    A498 ED50
    4.24 ng/mL
    Compound: adr
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    [PMID: 9461654]
    A498 IC50
    4.9 ng/mL
    Compound: Adriamycin
    Cytotoxicity against human A498 cells by MTT assay
    Cytotoxicity against human A498 cells by MTT assay
    [PMID: 9644064]
    A498 IC50
    6.1 μM
    Compound: DOX
    Antiproliferative activity against human A498 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A498 cells after 72 hrs by MTT assay
    [PMID: 30429098]
    A498 ED50
    6.2 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    [PMID: 9599260]
    A498 ED50
    6.49 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    Cytotoxicity against human A498 cells after 7 days by MTT assay
    [PMID: 8904848]
    A549 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition of human A549 cells after 48 hrs by SRB assay
    Growth inhibition of human A549 cells after 48 hrs by SRB assay
    10.1039/C6MD00097E
    A549 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition in human A549 cells after 48 hrs by SRB assay
    Growth inhibition in human A549 cells after 48 hrs by SRB assay
    [PMID: 31546197]
    A549 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    [PMID: 26994690]
    A549 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition of human A549 cells after 48 hrs by SRB assay
    Growth inhibition of human A549 cells after 48 hrs by SRB assay
    [PMID: 26067381]
    A549 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    [PMID: 25827522]
    A549 IC50
    < 0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 22330634]
    A549 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    [PMID: 21737288]
    A549 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by MTT assay
    10.1007/s00044-011-9884-x
    A549 GI50
    < 1 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    [PMID: 31990554]
    A549 IC50
    < 1 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 33847126]
    A549 IC50
    > 100 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    [PMID: 33340938]
    A549 ED50
    0.001 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    [PMID: 19783438]
    A549 ED50
    0.001 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by sulforhodamine B method
    Cytotoxicity against human A549 cells by sulforhodamine B method
    [PMID: 12193011]
    A549 IC50
    0.001 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 22951040]
    A549 IC50
    0.0014 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by sulforhodamine B bioassay
    Cytotoxicity against human A549 cells by sulforhodamine B bioassay
    [PMID: 25098650]
    A549 IC50
    0.002 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    [PMID: 25981688]
    A549 IC50
    0.002 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    [PMID: 25466198]
    A549 IC50
    0.002 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    [PMID: 22483395]
    A549 GI50
    0.003 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells by SRB assay
    Antiproliferative activity against human A549 cells by SRB assay
    [PMID: 19394218]
    A549 IC50
    0.004 μM
    Compound: Doxorubicin
    Inhibitory activity against A549 cell line using MTT assay(Wild type p53)
    Inhibitory activity against A549 cell line using MTT assay(Wild type p53)
    [PMID: 10780913]
    A549 ED50
    0.0043 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 10514307]
    A549 ED50
    0.00622 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 11087592]
    A549 GI50
    0.007 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 19405508]
    A549 IC50
    0.007 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 19435339]
    A549 ED50
    0.007 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 18314958]
    A549 IC50
    0.009 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 27010926]
    A549 ED50
    0.01 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    [PMID: 15921415]
    A549 IC50
    0.01 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by sulforhodamine B assay
    Cytotoxicity against human A549 cells by sulforhodamine B assay
    [PMID: 21684168]
    A549 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 20719504]
    A549 ED50
    0.012 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB method
    Cytotoxicity against human A549 cells by SRB method
    [PMID: 16252909]
    A549 IC50
    0.015 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 27668963]
    A549 GI50
    0.016 μM
    Compound: Doxorubicin
    Cytostatic activity against human A549 cells after 5 days by SRB assay
    Cytostatic activity against human A549 cells after 5 days by SRB assay
    [PMID: 21711054]
    A549 ED50
    0.02 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    [PMID: 15730260]
    A549 ED50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    [PMID: 11325244]
    A549 IC50
    0.02 μg/mL
    Compound: doxorubicin
    Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time
    Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time
    [PMID: 8496904]
    A549 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay
    Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay
    [PMID: 23634786]
    A549 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by sulforhodamine B assay
    Cytotoxicity against human A549 cells by sulforhodamine B assay
    [PMID: 23815260]
    A549 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    [PMID: 25937235]
    A549 IC50
    0.02 μM
    Compound: 2
    Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation
    Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation
    10.1016/S0960-894X(97)10122-6
    A549 IC50
    0.021 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
    [PMID: 27856237]
    A549 IC50
    0.021 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 20594848]
    A549 IC50
    0.022 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 3 days by SRB assay
    Cytotoxicity against human A549 cells after 3 days by SRB assay
    [PMID: 18321715]
    A549 IC50
    0.025 μg/mL
    Compound: ADR
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 18590312]
    A549 IC50
    0.025 μM
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    [PMID: 19028425]
    A549 ED50
    0.03 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 24 hrs by SRB assay
    Cytotoxicity against human A549 cells after 24 hrs by SRB assay
    [PMID: 20850305]
    A549 IC50
    0.03 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    [PMID: 25937235]
    A549 IC50
    0.031 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by SRB method
    Cytotoxicity against human A549 cells after 24 hrs by SRB method
    [PMID: 18429610]
    A549 GI50
    0.04 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 11000028]
    A549 IC50
    0.04 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 15921426]
    A549 IC50
    0.04 μg/mL
    Compound: doxorubicin
    Anticancer activity against human A549 cells after 72 hrs by sulforhodamine B assay
    Anticancer activity against human A549 cells after 72 hrs by sulforhodamine B assay
    [PMID: 19342127]
    A549 IC50
    0.04 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by WST-8 assay
    Cytotoxicity against human A549 cells after 72 hrs by WST-8 assay
    [PMID: 25534608]
    A549 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 29275232]
    A549 IC50
    0.04 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
    [PMID: 35255689]
    A549 IC50
    0.049 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 23544451]
    A549 ED50
    0.05 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    10.1021/np960188t
    A549 IC50
    0.05 μg/mL
    Compound: doxorubicin
    Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time
    Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time
    [PMID: 8496904]
    A549 IC50
    0.056 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    [PMID: 32755677]
    A549 IC50
    0.057 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell viability by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell viability by MTT assay
    [PMID: 32223924]
    A549 GI50
    0.06 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human A549/ATCC cells after 48 hrs by SRB assay
    Cytotoxicity against human A549/ATCC cells after 48 hrs by SRB assay
    [PMID: 23871905]
    A549 GI50
    0.06 μM
    Compound: Doxorubicin
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 29102177]
    A549 GI50
    0.06 μM
    Compound: Doxorubicin
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28329730]
    A549 GI50
    0.062 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    [PMID: 20014800]
    A549 GI50
    0.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    [PMID: 24158013]
    A549 IC50
    0.074 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31999451]
    A549 IC50
    0.075 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells by sulforhodamine B assay
    Anticancer activity against human A549 cells by sulforhodamine B assay
    [PMID: 19819696]
    A549 IC50
    0.08 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 19361894]
    A549 IC50
    0.08 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    [PMID: 30106296]
    A549 IC50
    0.09 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 27060757]
    A549 IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) A549 cells after 72 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) A549 cells after 72 hr by MTT assay
    10.1007/s00044-010-9517-9
    A549 IC50
    0.09 μM
    Compound: Dox
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    [PMID: 34116381]
    A549 IC50
    0.092 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells incubated for 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human A549 cells incubated for 72 hrs by sulforhodamine B assay
    [PMID: 32432867]
    A549 ED50
    0.1 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    [PMID: 16252910]
    A549 IC50
    0.1 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 2 days by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 2 days by sulforhodamine B assay
    [PMID: 17067159]
    A549 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay
    Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay
    [PMID: 28398051]
    A549 IC50
    0.1 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    [PMID: 24050254]
    A549 IC50
    0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    [PMID: 18063366]
    A549 GI50
    0.1 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 19007287]
    A549 GI50
    0.1 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 17512741]
    A549 IC50
    0.1 μM
    Compound: DOX
    Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction)
    Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction)
    10.1016/S0960-894X(01)81264-6
    A549 IC50
    0.11 μM
    Compound: DOX
    Cytotoxicity against human A549 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human A549 cells measured after 72 hrs by Celltiter-Glo assay
    [PMID: 31820976]
    A549 IC50
    0.118 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells after 48 hrs by SRB assay
    Anticancer activity against human A549 cells after 48 hrs by SRB assay
    [PMID: 17070967]
    A549 ED50
    0.12 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 9392887]
    A549 IC50
    0.12 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    [PMID: 27886545]
    A549 IC50
    0.12 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs
    Cytotoxicity against human A549 cells after 48 hrs
    [PMID: 17673337]
    A549 IC50
    0.124 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 25462279]
    A549 IC50
    0.124 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 28139925]
    A549 IC50
    0.13 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human A549 cells incubated for 48 hrs by SRB assay
    Cytotoxicity activity against human A549 cells incubated for 48 hrs by SRB assay
    [PMID: 34119830]
    A549 IC50
    0.13 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    [PMID: 30106296]
    A549 IC50
    0.14 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 35694689]
    A549 IC50
    0.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
    [PMID: 26280922]
    A549 IC50
    0.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 26873414]
    A549 GI50
    0.15 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    [PMID: 20673627]
    A549 IC50
    0.15 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 17194596]
    A549 IC50
    0.16 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 24 hrs by SRB assay
    Cytotoxicity against human A549 cells after 24 hrs by SRB assay
    [PMID: 24370114]
    A549 GI50
    0.16 μM
    Compound: Doxorubicin
    Growth inhibition of human A549 cells after 72 hrs by SRB assay
    Growth inhibition of human A549 cells after 72 hrs by SRB assay
    [PMID: 18585035]
    A549 IC50
    0.16 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 20176479]
    A549 IC50
    0.17 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 6 days by MTT method
    Cytotoxicity against human A549 cells after 6 days by MTT method
    [PMID: 16309317]
    A549 IC50
    0.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    [PMID: 30902399]
    A549 IC50
    0.17 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    [PMID: 20593838]
    A549 IC50
    0.18 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB microtiter plate assay
    Cytotoxicity against human A549 cells by SRB microtiter plate assay
    [PMID: 17585747]
    A549 IC50
    0.19 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    [PMID: 15387653]
    A549 IC50
    0.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by XTT assay
    Cytotoxicity against human A549 cells after 24 hrs by XTT assay
    [PMID: 27227682]
    A549 IC50
    0.2 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 18973388]
    A549 IC50
    0.2 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT colorimetric method
    Cytotoxicity against human A549 cells by MTT colorimetric method
    [PMID: 17125220]
    A549 IC50
    0.2 μM
    Compound: adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 17190442]
    A549 GI50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    [PMID: 29112820]
    A549 ED50
    0.21 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 17315955]
    A549 IC50
    0.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTS assay
    Cytotoxicity against human A549 cells after 24 hrs by MTS assay
    [PMID: 30289713]
    A549 IC50
    0.22 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 96 hrs by MTT assay
    Cytotoxicity against human A549 cells after 96 hrs by MTT assay
    [PMID: 24852278]
    A549 IC50
    0.22 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells by MTT reduction assay
    Antiproliferative activity against human A549 cells by MTT reduction assay
    [PMID: 33421712]
    A549 IC50
    0.223 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells incubated for 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells incubated for 24 hrs by MTT assay
    [PMID: 29409753]
    A549 IC50
    0.23 μM
    Compound: Doxo
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay
    [PMID: 27036521]
    A549 IC50
    0.24 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells incubated for 48 hrs by WST8 assay
    Antiproliferative activity against human A549 cells incubated for 48 hrs by WST8 assay
    [PMID: 31679979]
    A549 IC50
    0.258 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 25019480]
    A549 IC50
    0.27 μg/mL
    Compound: Doxorubicin
    Cytotoxic activity against human A549 cells by MTT assay
    Cytotoxic activity against human A549 cells by MTT assay
    [PMID: 28366267]
    A549 GI50
    0.27 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human A549 assessed as growth inhibition after 48 hrs by SRB assay
    [PMID: 21875046]
    A549 IC50
    0.29 μM
    Compound: DOX
    Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method
    Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method
    [PMID: 25061803]
    A549 IC50
    0.29 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by XTT assay
    Cytotoxicity against human A549 cells after 72 hrs by XTT assay
    [PMID: 19647439]
    A549 IC50
    0.32 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    [PMID: 25737400]
    A549 IC50
    0.33 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    [PMID: 20732814]
    A549 IC50
    0.33 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay
    [PMID: 26496013]
    A549 IC50
    0.34 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 30389295]
    A549 IC50
    0.34 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 21174408]
    A549 IC50
    0.35 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    [PMID: 19691312]
    A549 IC50
    0.35 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Anticancer activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    [PMID: 33940466]
    A549 IC50
    0.36 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 21641694]
    A549 IC50
    0.36 μM
    Compound: Doxorubucin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 20718475]
    A549 IC50
    0.36 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT colorimetric method
    Cytotoxicity against human A549 cells after 72 hrs by MTT colorimetric method
    [PMID: 17622129]
    A549 IC50
    0.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 26397393]
    A549 IC50
    0.37 μM
    Compound: DOX
    Cytotoxicity against human A549 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
    [PMID: 35612499]
    A549 IC50
    0.38 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) A549 cells assessed as survival after 3 days by crystal violet staining
    Cytotoxicity against Homo sapiens (human) A549 cells assessed as survival after 3 days by crystal violet staining
    10.1007/s00044-012-0025-y
    A549 IC50
    0.39 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) A549 cells after 3 days by MTT assay
    Cytotoxicity against Homo sapiens (human) A549 cells after 3 days by MTT assay
    10.1007/s00044-011-9903-y
    A549 IC50
    0.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 16724859]
    A549 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by Alamar Blue assay
    Cytotoxicity against human A549 cells by Alamar Blue assay
    [PMID: 27536968]
    A549 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay
    Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay
    [PMID: 30869892]
    A549 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    [PMID: 18547115]
    A549 IC50
    0.4 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 4 days by MTT assay
    Cytotoxicity against human A549 cells after 4 days by MTT assay
    [PMID: 19824618]
    A549 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 28927795]
    A549 IC50
    0.4 μM
    Compound: Doxo
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 20334960]
    A549 IC50
    0.41 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 23548547]
    A549 IC50
    0.411 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    [PMID: 24231309]
    A549 IC50
    0.414 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 25497963]
    A549 IC50
    0.42 μg/mL
    Compound: doxo
    Cytotoxicity against human A549 cells by MTT method
    Cytotoxicity against human A549 cells by MTT method
    [PMID: 17417907]
    A549 IC50
    0.42 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    [PMID: 35818137]
    A549 IC50
    0.43 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
    [PMID: 29597166]
    A549 IC50
    0.44 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    10.1007/s00044-013-0777-z
    A549 IC50
    0.44 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 25078311]
    A549 IC50
    0.44 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 24836071]
    A549 IC50
    0.45 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay
    [PMID: 26947606]
    A549 IC50
    0.459 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 2 days by MTT assay
    Cytotoxicity against human A549 cells after 2 days by MTT assay
    [PMID: 23932340]
    A549 IC50
    0.459 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 24287557]
    A549 IC50
    0.46 μM
    Compound: Doxorubicin
    In vitro cytotoxicity against human A549 cells assessed as growth inhibition by MTT assay
    In vitro cytotoxicity against human A549 cells assessed as growth inhibition by MTT assay
    [PMID: 24742385]
    A549 IC50
    0.47 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31704206]
    A549 IC50
    0.477 μM
    Compound: Dox
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 21983438]
    A549 IC50
    0.477 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells by MTT assay
    Anticancer activity against human A549 cells by MTT assay
    [PMID: 21570750]
    A549 IC50
    0.477 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    10.1039/C0MD00219D
    A549 IC50
    0.48 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    [PMID: 31671309]
    A549 IC50
    0.48 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
    [PMID: 30576904]
    A549 IC50
    0.48 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
    Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
    [PMID: 30253344]
    A549 IC50
    0.48 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells after 24 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 24 hrs by SRB assay
    [PMID: 30106296]
    A549 IC50
    0.5 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    [PMID: 35526504]
    A549 IC50
    0.5 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    [PMID: 31148449]
    A549 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 27015002]
    A549 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay
    Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay
    [PMID: 23664877]
    A549 IC50
    0.51 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 21708464]
    A549 IC50
    0.51 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 26356746]
    A549 IC50
    0.52 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 18590313]
    A549 IC50
    0.52 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    [PMID: 21071221]
    A549 IC50
    0.53 μM
    Compound: Doxorubicin
    Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    [PMID: 28923382]
    A549 IC50
    0.54 μg/mL
    Compound: Doxorubicin
    Anticancer activity against human A549 cells by MTT assay
    Anticancer activity against human A549 cells by MTT assay
    [PMID: 31404864]
    A549 IC50
    0.54 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 23434227]
    A549 IC50
    0.55 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay
    [PMID: 28159416]
    A549 IC50
    0.55 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by Alamar blue assay
    Cytotoxicity against human A549 cells by Alamar blue assay
    [PMID: 27256910]
    A549 IC50
    0.55 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    [PMID: 30654238]
    A549 IC50
    0.55 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 30615450]
    A549 IC50
    0.56 μM
    Compound: ADM
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    [PMID: 23639650]
    A549 IC50
    0.58 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    [PMID: 31820976]
    A549 IC50
    0.59 μM
    Compound: Doxo
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    [PMID: 21800859]
    A549 IC50
    0.59 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    [PMID: 33276990]
    A549 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
    [PMID: 36693198]
    A549 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 29702447]
    A549 GI50
    0.6 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    [PMID: 34634616]
    A549 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 29975532]
    A549 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 25172418]
    A549 IC50
    0.63 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 21106454]
    A549 IC50
    0.63 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
    [PMID: 29614418]
    A549 IC50
    0.63 μM
    Compound: Dox
    Cytotoxicity activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 30031974]
    A549 IC50
    0.63 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
    [PMID: 31884407]
    A549 GI50
    0.66 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    [PMID: 21885166]
    A549 IC50
    0.665 μg/mL
    Compound: E; DOX
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    [PMID: 35963130]
    A549 IC50
    0.69 μM
    Compound: adriamycin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    [PMID: 26295905]
    A549 IC50
    0.69 μM
    Compound: ADM
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    [PMID: 25089733]
    A549 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    [PMID: 32324401]
    A549 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) A549 cells assessed as inhibition of cell growth after 3 days by MTT assay
    Cytotoxicity against Homo sapiens (human) A549 cells assessed as inhibition of cell growth after 3 days by MTT assay
    10.1007/s00044-012-0402-6
    A549 IC50
    0.7 μM
    Compound: Dox
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 28865276]
    A549 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) A549 cells by MTT assay
    Cytotoxicity against Homo sapiens (human) A549 cells by MTT assay
    10.1007/s00044-012-0370-x
    A549 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 24300737]
    A549 IC50
    0.7 μM
    Compound: Doxorubicine
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 22014995]
    A549 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    Cytotoxicity against human A549 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    [PMID: 36970146]
    A549 IC50
    0.72 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 19406535]
    A549 IC50
    0.72 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 22070654]
    A549 IC50
    0.73 μM
    Compound: Doxo
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    10.1039/C2MD20302B
    A549 IC50
    0.73 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 23992864]
    A549 IC50
    0.74 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 46 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 46 hrs by MTT assay
    [PMID: 29138027]
    A549 IC50
    0.74 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 23806110]
    A549 IC50
    0.75 μM
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 48 hrs
    Cytotoxicity against human A549 cells after 48 hrs
    [PMID: 17583953]
    A549 IC50
    0.76 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    [PMID: 27397495]
    A549 IC50
    0.766 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    [PMID: 30599418]
    A549 IC50
    0.79 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    [PMID: 16252914]
    A549 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    [PMID: 26252628]
    A549 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay
    [PMID: 24780595]
    A549 IC50
    0.8 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay
    [PMID: 24507927]
    A549 IC50
    0.8 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 30679134]
    A549 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 26551342]
    A549 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 21035234]
    A549 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    [PMID: 26774921]
    A549 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    [PMID: 26646219]
    A549 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 25241926]
    A549 IC50
    0.8 μM
    Compound: ADM
    Cytotoxicity against human A549 cells by SRB method
    Cytotoxicity against human A549 cells by SRB method
    [PMID: 29144133]
    A549 IC50
    0.8 μM
    Compound: ADM
    Cytotoxic activity against human A549 cells by SRB method
    Cytotoxic activity against human A549 cells by SRB method
    [PMID: 25611519]
    A549 IC50
    0.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    [PMID: 31404864]
    A549 IC50
    0.837 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 19860383]
    A549 IC50
    0.84 μM
    Compound: Doxorubicin
    Antitumor activity against Homo sapiens (human) A549 cells assessed as cell growth inhibition after 48 hr by MTT assay
    Antitumor activity against Homo sapiens (human) A549 cells assessed as cell growth inhibition after 48 hr by MTT assay
    10.1007/s00044-013-0497-4
    A549 IC50
    0.84 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 19689125]
    A549 IC50
    0.86 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    Cytotoxicity against human A549 cells after 3 days by MTT assay
    [PMID: 18419154]
    A549 IC50
    0.86 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by WST-8 assay
    Cytotoxicity against human A549 cells by WST-8 assay
    [PMID: 29295796]
    A549 IC50
    0.87 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 25419616]
    A549 IC50
    0.89 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    [PMID: 30773423]
    A549 IC50
    0.89 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 28554092]
    A549 IC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    10.1039/C3MD00166K
    A549 IC50
    0.9 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    [PMID: 34323485]
    A549 EC50
    0.9 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs
    Cytotoxicity against human A549 cells after 72 hrs
    [PMID: 17378530]
    A549 IC50
    0.91 μM
    Compound: Dox
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 35339100]
    A549 IC50
    0.95 μM
    Compound: DOXO
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by alamar blue assay
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by alamar blue assay
    [PMID: 21797280]
    A549 IC50
    0.95 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by Alamar blue assay
    Cytotoxicity against human A549 cells after 48 hrs by Alamar blue assay
    [PMID: 20931970]
    A549 IC50
    0.95 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay
    [PMID: 31784322]
    A549 IC50
    0.95 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 27016707]
    A549 IC50
    0.96 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    [PMID: 32438251]
    A549 GI50
    0.97 μM
    Compound: Dox
    Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    [PMID: 35533562]
    A549 IC50
    0.97 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 32531682]
    A549 IC50
    0.97 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 17827007]
    A549 IC50
    0.97 μM
    Compound: Doxorubicin
    Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.
    Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.
    [PMID: 14643344]
    A549 IC50
    0.98 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 25747499]
    A549 IC50
    1 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 22044164]
    A549 IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    [PMID: 32915576]
    A549 IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 23079527]
    A549 IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 21996519]
    A549 IC50
    1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay
    Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay
    [PMID: 27555286]
    A549 ED50
    1.01 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 8676130]
    A549 ED50
    1.01 x 10-2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 7673926]
    A549 IC50
    1.01 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    [PMID: 34363936]
    A549 IC50
    1.02 μM
    Compound: Dox
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 22209733]
    A549 IC50
    1.05 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 35341920]
    A549 IC50
    1.06 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    [PMID: 31962262]
    A549 IC50
    1.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 26708114]
    A549 IC50
    1.07 μM
    Compound: DOX
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 31057738]
    A549 ED50
    1.1 ng/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 7714532]
    A549 ED50
    1.1 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days
    Cytotoxicity against human A549 cells after 7 days
    [PMID: 8021648]
    A549 IC50
    1.1 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells by MTT assay
    Anticancer activity against human A549 cells by MTT assay
    10.1039/C4MD00219A
    A549 GI50
    1.1 μM
    Compound: Dox
    Antiproliferative activity against human A549 cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human A549 cells incubated for 72 hrs and measured by MTT assay
    [PMID: 35973342]
    A549 IC50
    1.11 μM
    Compound: DOX
    Cytotoxicity against human A549 cells after 48 hrs by SRB method
    Cytotoxicity against human A549 cells after 48 hrs by SRB method
    [PMID: 25933593]
    A549 ED50
    1.13 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 11325235]
    A549 IC50
    1.15 μM
    Compound: ADM
    Antiproliferative activity against human A549 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    [PMID: 35803175]
    A549 IC50
    1.18 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 22472043]
    A549 IC50
    1.2 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 17918910]
    A549 IC50
    1.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells measured after 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay
    Antiproliferative activity against human A549 cells measured after 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay
    [PMID: 32682198]
    A549 IC50
    1.2 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by SRB protein staining method
    Cytotoxicity against human A549 cells by SRB protein staining method
    [PMID: 25781655]
    A549 GI50
    1.21 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    [PMID: 31128433]
    A549 IC50
    1.21 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    [PMID: 31108261]
    A549 IC50
    1.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 25172420]
    A549 IC50
    1.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 24113366]
    A549 IC50
    1.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 23911578]
    A549 IC50
    1.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 23764302]
    A549 IC50
    1.28 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 25703298]
    A549 ED50
    1.3 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 10395501]
    A549 IC50
    1.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by WST assay
    Cytotoxicity against human A549 cells after 24 hrs by WST assay
    [PMID: 25881821]
    A549 IC50
    1.303 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 29501940]
    A549 IC50
    1.32 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    [PMID: 32682198]
    A549 IC50
    1.4 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 22413887]
    A549 IC50
    1.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 29035560]
    A549 IC50
    1.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 31546197]
    A549 IC50
    1.445 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 28462842]
    A549 ED50
    1.48 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days
    Cytotoxicity against human A549 cells after 7 days
    [PMID: 8201311]
    A549 ED50
    1.48 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days
    Cytotoxicity against human A549 cells after 7 days
    [PMID: 1593281]
    A549 IC50
    1.495 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 30433783]
    A549 IC50
    1.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay
    [PMID: 33421712]
    A549 IC50
    1.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 25453799]
    A549 IC50
    1.58 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 26330077]
    A549 IC50
    1.58 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 26264845]
    A549 IC50
    1.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    [PMID: 28818768]
    A549 IC50
    1.65 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 24418772]
    A549 IC50
    1.68 μM
    Compound: II
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 29289881]
    A549 ED50
    1.7 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 9917277]
    A549 IC50
    1.7 μM
    Compound: Doxorubicin
    Growth inhibition of human A549 cells by MTT assay
    Growth inhibition of human A549 cells by MTT assay
    [PMID: 28916158]
    A549 IC50
    1.778 μM
    Compound: Doxorubicin
    Anti-proliferative activity against human A549 cells measured after 48 hrs by MTT assay
    Anti-proliferative activity against human A549 cells measured after 48 hrs by MTT assay
    [PMID: 27744185]
    A549 ED50
    1.78 ng/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 8946743]
    A549 IC50
    1.78 μM
    Compound: Doxorubicin
    Cytotoxic activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxic activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 25966052]
    A549 IC50
    1.79 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 35339645]
    A549 IC50
    1.86 μM
    Compound: Doxo
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 29129513]
    A549 IC50
    1.88 μM
    Compound: Dox
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    10.1007/s00044-013-0584-6
    A549 IC50
    1.9 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    [PMID: 32631552]
    A549 IC50
    1.9 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 25615796]
    A549 IC50
    1.9 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    [PMID: 19632833]
    A549 IC50
    1.9 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 24012378]
    A549 IC50
    1.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 19394829]
    A549 GI50
    1.9 μM
    Compound: Doxorubicin
    Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay
    Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay
    [PMID: 26163220]
    A549 ED50
    1.91 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 9599260]
    A549 IC50
    1.945 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 28482219]
    A549 IC50
    1.986 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 26301558]
    A549 IC50
    1.99 μM
    Compound: Doxorubicin
    Cytotoxicity against human lung carcinoma A549 cell line using MTT assay
    Cytotoxicity against human lung carcinoma A549 cell line using MTT assay
    [PMID: 9873387]
    A549 IC50
    10.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    [PMID: 28886509]
    A549 IC50
    10.28 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    [PMID: 35635947]
    A549 CC50
    10.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 29792325]
    A549 IC50
    10.55 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    10.1039/C3MD00013C
    A549 IC50
    10.76 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability measured after 24 hrs by MTT assay
    [PMID: 33183865]
    A549 IC50
    10.83 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    [PMID: 36463726]
    A549 IC50
    11 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 28919340]
    A549 IC50
    11.62 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay
    [PMID: 28129977]
    A549 GI50
    13.01 μM
    Compound: ADR
    Anticancer activity against human A549 cells by SRB method
    Anticancer activity against human A549 cells by SRB method
    [PMID: 22104151]
    A549 IC50
    13.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 24681979]
    A549 IC50
    14 μM
    Compound: Doxo
    Cytotoxicity against human A549 cells after 48 hrs by alamar blue assay
    Cytotoxicity against human A549 cells after 48 hrs by alamar blue assay
    [PMID: 25468043]
    A549 IC50
    14.7 nM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
    [PMID: 31655432]
    A549 IC50
    140 nM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    [PMID: 35213166]
    A549 IC50
    149 nM
    Compound: DX
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
    [PMID: 34592435]
    A549 IC50
    15.07 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    10.1039/C2MD20023F
    A549 IC50
    15.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 22386528]
    A549 ED50
    152 μM
    Compound: doxorubicin
    Antitumor activity against human A549 cells after 24 hrs by MTT assay
    Antitumor activity against human A549 cells after 24 hrs by MTT assay
    [PMID: 17482824]
    A549 IC50
    17 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    [PMID: 34838335]
    A549 IC50
    172 nM
    Compound: DX
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    [PMID: 33611191]
    A549 IC50
    18.56 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 28262524]
    A549 IC50
    190 nM
    Compound: DX
    Antiproliferative activity against human A549 cells assessed as inhibition of proliferation after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as inhibition of proliferation after 72 hrs by SRB assay
    [PMID: 34116158]
    A549 ED50
    2 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 8882437]
    A549 IC50
    2.04 μM
    Compound: DOX
    Cytotoxicity against against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 30340899]
    A549 IC50
    2.1 μM
    Compound: Doxo (I)
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    10.1039/C4MD00228H
    A549 IC50
    2.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay
    [PMID: 34838335]
    A549 IC50
    2.1 μM
    Compound: Dox
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay
    [PMID: 31765156]
    A549 IC50
    2.12 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
    [PMID: 26874744]
    A549 IC50
    2.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 25462233]
    A549 IC50
    2.17 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 27149641]
    A549 IC50
    2.18 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    Anticancer activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 22136907]
    A549 IC50
    2.2 ng/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 9644064]
    A549 IC50
    2.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 21425785]
    A549 IC50
    2.2 μM
    Compound: adriamycin
    Cytotoxicity against human A549 cells by rapid colorimetric assay
    Cytotoxicity against human A549 cells by rapid colorimetric assay
    [PMID: 19585998]
    A549 IC50
    2.23 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    [PMID: 20171108]
    A549 IC50
    2.3 μM
    Compound: DOX
    Inhibition of topoisomerase 2 in human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Inhibition of topoisomerase 2 in human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    [PMID: 30846253]
    A549 IC50
    2.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 29789258]
    A549 IC50
    2.31 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    [PMID: 33352388]
    A549 IC50
    2.34 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 26948541]
    A549 ED50
    2.43 x 10-2 μg/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 8904848]
    A549 IC50
    2.48 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 24 hrs by MTT assay
    10.1039/C5MD00581G
    A549 IC50
    2.58 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31883489]
    A549 IC50
    2.6 x 10-1 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by XTT assay
    Cytotoxicity against human A549 cells after 72 hrs by XTT assay
    [PMID: 20619940]
    A549 IC50
    2.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    [PMID: 25300819]
    A549 IC50
    2.67 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs
    [PMID: 32736079]
    A549 IC50
    2.7 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT colorimetric method
    Cytotoxicity against human A549 cells by MTT colorimetric method
    [PMID: 23043498]
    A549 IC50
    2.8 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 22647719]
    A549 IC50
    2.8 μM
    Compound: Adriamycin
    Growth inhibition of human A549 cells by MTT assay
    Growth inhibition of human A549 cells by MTT assay
    [PMID: 21721519]
    A549 IC50
    2.81 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 27015609]
    A549 IC50
    2.905 μM
    Compound: DOX
    Growth inhibition of human A549 cells after 48 hrs by MTT assay
    Growth inhibition of human A549 cells after 48 hrs by MTT assay
    [PMID: 29509413]
    A549 ED50
    2.94 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 9584396]
    A549 ED50
    2.94 ng/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 7673936]
    A549 IC50
    22 nM
    Compound: doxorubicin
    Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay.
    Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay.
    [PMID: 10956214]
    A549 IC50
    228.2 nM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 29886322]
    A549 IC50
    24.27 μM
    Compound: DOX
    Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay
    10.1007/s00044-012-0018-x
    A549 IC50
    258 nM
    Compound: DOX; DX
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay
    [PMID: 31653441]
    A549 IC50
    258 nM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay
    [PMID: 33465696]
    A549 IC50
    26.81 μM
    Compound: DOX
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
    [PMID: 25912674]
    A549 IC50
    3 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by DAPI staining based assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by DAPI staining based assay
    [PMID: 33461146]
    A549 IC50
    3.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25594739]
    A549 IC50
    3.08 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 32996316]
    A549 ED50
    3.1 x 10-4 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 7714533]
    A549 IC50
    3.118 μg/mL
    Compound: ADM
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 25862199]
    A549 IC50
    3.13 μM
    Compound: Dox
    Antiproliferative activity against human A549 cells after 72 hrs by cell titer glo assay
    Antiproliferative activity against human A549 cells after 72 hrs by cell titer glo assay
    [PMID: 24161704]
    A549 IC50
    3.13 μM
    Compound: Doxo
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 25563891]
    A549 IC50
    3.14 μM
    Compound: DOX
    Cytotoxicity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 27149641]
    A549 IC50
    3.16 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    [PMID: 30500683]
    A549 IC50
    3.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 33148490]
    A549 IC50
    3.2 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    10.1039/C4MD00566J
    A549 IC50
    3.24 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay
    [PMID: 32631524]
    A549 IC50
    3.28 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    [PMID: 22542958]
    A549 IC50
    3.3 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    [PMID: 27055942]
    A549 IC50
    3.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    [PMID: 31546197]
    A549 IC50
    3.35 μM
    Compound: DOX
    Antineoplastic activity against human A549 cells measured after 36 hrs by MTT assay
    Antineoplastic activity against human A549 cells measured after 36 hrs by MTT assay
    [PMID: 30746067]
    A549 IC50
    3.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 25453802]
    A549 IC50
    3.4 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    [PMID: 30398868]
    A549 ED50
    3.41 ng/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 7494147]
    A549 IC50
    3.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by CCK8 assay
    Cytotoxicity against human A549 cells by CCK8 assay
    [PMID: 29452840]
    A549 ED50
    3.56 ng/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 7673935]
    A549 ED50
    3.56 ng/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 7494150]
    A549 IC50
    3.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 94 hrs by MTT assay
    Cytotoxicity against human A549 cells after 94 hrs by MTT assay
    [PMID: 21868138]
    A549 ED50
    3.67 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 9599253]
    A549 IC50
    3.69 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 22472043]
    A549 ED50
    3.93 ng/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 9322367]
    A549 IC50
    3.97 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 31404864]
    A549 IC50
    3.98 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    10.1007/s00044-013-0784-0
    A549 IC50
    4 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 23792352]
    A549 IC50
    4 μM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 23748152]
    A549 IC50
    4.11 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    [PMID: 24095746]
    A549 IC50
    4.36 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
    [PMID: 30503942]
    A549 ED50
    4.47 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    10.1021/np970510f
    A549 IC50
    4.91 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 6 days by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 6 days by MTT assay
    [PMID: 32653698]
    A549 IC50
    4.91 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    [PMID: 30746062]
    A549 IC50
    4.91 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 28427016]
    A549 IC50
    4.91 μM
    Compound: DOX
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    [PMID: 28135634]
    A549 IC50
    4.91 μM
    Compound: Dox
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    [PMID: 27231128]
    A549 IC50
    4.91 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    [PMID: 26720155]
    A549 ED50
    4.99 ng/mL
    Compound: adr
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 9461654]
    A549 ED50
    4.99 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 9014350]
    A549 IC50
    426 nM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by XTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by XTT assay
    [PMID: 29190084]
    A549 IC50
    459 nM
    Compound: DOX
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    [PMID: 30878835]
    A549 IC50
    5 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells by MTT assay
    Antiproliferative activity against human A549 cells by MTT assay
    [PMID: 29072457]
    A549 ED50
    5.04 x 10-4 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days
    Cytotoxicity against human A549 cells after 7 days
    [PMID: 1453182]
    A549 ED50
    5.06 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 8882434]
    A549 IC50
    5.1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    [PMID: 27894044]
    A549 IC50
    5.13 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    [PMID: 35367708]
    A549 ED50
    5.3 ng/mL
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 9214729]
    A549 IC50
    5.3 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    [PMID: 31589431]
    A549 IC50
    5.32 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
    [PMID: 27476117]
    A549 IC50
    5.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay
    [PMID: 34223162]
    A549 IC50
    5.58 nM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell viability after 5 days by cell viability analyzer
    Cytotoxicity against human A549 cells assessed as cell viability after 5 days by cell viability analyzer
    [PMID: 26291039]
    A549 IC50
    5.93 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    [PMID: 32311607]
    A549 ED50
    59.5 nM
    Compound: doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 17655260]
    A549 IC50
    6.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell viability by SRB assay
    Cytotoxicity against human A549 cells assessed as cell viability by SRB assay
    [PMID: 26022842]
    A549 ED50
    6.22 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    Cytotoxicity against human A549 cells after 7 days by MTT assay
    [PMID: 15730242]
    A549 IC50
    6.22 μM
    Compound: Doxo
    Cytotoxicity against human A549 cells measured after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells measured after 24 hrs by MTT assay
    [PMID: 31104996]
    A549 IC50
    6.61 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    [PMID: 22182926]
    A549 IC50
    69.33 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells by MTT assay
    Anticancer activity against human A549 cells by MTT assay
    [PMID: 25743216]
    A549 IC50
    7.1 μM
    Compound: DX
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    10.1039/C5MD00513B
    A549 GI50
    7.25 μM
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 24 hrs by SRB method
    Cytotoxicity against human A549 cells after 24 hrs by SRB method
    [PMID: 18262426]
    A549 GI50
    7.25 μM
    Compound: ADR
    Growth inhibition of human A549 cells after 48 hrs by SRB assay
    Growth inhibition of human A549 cells after 48 hrs by SRB assay
    [PMID: 20031423]
    A549 GI50
    7.25 μM
    Compound: ADR
    Growth inhibition of human A549 cells by SRB assay
    Growth inhibition of human A549 cells by SRB assay
    [PMID: 22361684]
    A549 GI50
    7.25 μM
    Compound: ADR
    Anticancer activity against human A549 cells by SRB method
    Anticancer activity against human A549 cells by SRB method
    [PMID: 21676506]
    A549 GI50
    7.25 μM
    Compound: ADR, Adriamycin
    Growth inhibition of human A549 cells by SRB method
    Growth inhibition of human A549 cells by SRB method
    [PMID: 18207392]
    A549 GI50
    7.25 μM
    Compound: ADR
    Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
    [PMID: 23849207]
    A549 GI50
    7.25 μM
    Compound: ADR
    Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
    [PMID: 22364746]
    A549 GI50
    7.25 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    [PMID: 18657979]
    A549 GI50
    7.25 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 24 hrs by WST-1 assay
    Cytotoxicity against human A549 cells after 24 hrs by WST-1 assay
    [PMID: 20732817]
    A549 IC50
    7.47 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 24607876]
    A549 IC50
    7.52 μM
    Compound: Dox
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 26494582]
    A549 IC50
    7.86 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 30108986]
    A549 IC50
    7.88 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 18440233]
    A549 IC50
    740 nM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 30172625]
    A549 IC50
    8.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 25140752]
    A549 GI50
    8.14 μM
    Compound: Doxo
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 26513642]
    A549 IC50
    8.5 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells incubated for 48 hrs by SRB assay
    Cytotoxicity against human A549 cells incubated for 48 hrs by SRB assay
    [PMID: 26048808]
    A549 IC50
    8.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 33766771]
    A549 IC50
    8.73 μM
    Compound: Doxorubicin
    Anticancer activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 36439979]
    A549 ED50
    9.2 ng/mL
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 7 hrs by MTT assay
    Cytotoxicity against human A549 cells after 7 hrs by MTT assay
    [PMID: 7623031]
    A549 IC50
    9.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 20846862]
    A549 IC50
    9.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    [PMID: 35526504]
    A549 IC50
    9.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25655719]
    A549 IC50
    90 μM
    Compound: Doxorubicin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay
    [PMID: 33016067]
    A549/CDDP IC50
    4.59 μM
    Compound: DOX
    Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay
    Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay
    [PMID: 29509413]
    A673 IC50
    0.1 μM
    Compound: DOX
    Cytotoxicity against human A673 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human A673 cells measured after 72 hrs by Celltiter-Glo assay
    [PMID: 31820976]
    A673 IC50
    0.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human A673 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    Cytotoxicity against human A673 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    [PMID: 23600925]
    A673 EC50
    0.39 μM
    Compound: Doxorubicin
    Induction of apoptosis in human A673 cells assessed as caspase-3 activation after 24 hrs by luminescence assay
    Induction of apoptosis in human A673 cells assessed as caspase-3 activation after 24 hrs by luminescence assay
    [PMID: 23600925]
    A704 IC50
    2 μM
    Compound: Doxorubicin
    Cytotoxicity against human A704 cells after 72 hrs by MTT assay
    Cytotoxicity against human A704 cells after 72 hrs by MTT assay
    [PMID: 19406535]
    ACHN IC50
    0.001 μM
    Compound: doxo
    Antiproliferative activity against human ACHN cell line by MTT assay
    Antiproliferative activity against human ACHN cell line by MTT assay
    [PMID: 16913700]
    ACHN IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human ACHN cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against human ACHN cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    [PMID: 34851111]
    ACHN IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human ACHN cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    Cytotoxicity against human ACHN cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    [PMID: 28617598]
    ACHN IC50
    0.04 μM
    Compound: Doxo
    Antiproliferative activity against human ACHN cells assessed as cell viability measured after 4 days by MTT assay
    Antiproliferative activity against human ACHN cells assessed as cell viability measured after 4 days by MTT assay
    [PMID: 31869654]
    ACHN IC50
    0.04 μM
    Compound: Doxorubicin
    Antiproliferative activity against human ACHN cells after 96 hrs by MTT assay
    Antiproliferative activity against human ACHN cells after 96 hrs by MTT assay
    [PMID: 19053767]
    ACHN GI50
    0.08 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human ACHN cells after 48 hrs by SRB assay
    Cytotoxicity against human ACHN cells after 48 hrs by SRB assay
    [PMID: 23871905]
    ACHN GI50
    0.08 μM
    Compound: ADR
    Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by SRB assay
    [PMID: 30253887]
    ACHN GI50
    0.08 μM
    Compound: ADR
    Cytotoxicity against human ACHN cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Cytotoxicity against human ACHN cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    [PMID: 28870801]
    ACHN GI50
    0.08 μM
    Compound: Doxorubicin
    Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 29102177]
    ACHN GI50
    0.08 μM
    Compound: Doxorubicin
    Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28329730]
    ACHN GI50
    0.088 μM
    Compound: ADR
    Anticancer activity against human ACNH cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
    Anticancer activity against human ACNH cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
    [PMID: 34500188]
    ACHN GI50
    0.0995 μM
    Compound: ADR
    Cytotoxicity against human ACHN cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human ACHN cells after 72 hrs by sulforhodamine B assay
    [PMID: 27096046]
    ACHN GI50
    0.2 μM
    Compound: ADR
    Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    [PMID: 25953156]
    ACHN GI50
    0.22 μM
    Compound: Doxorubicin
    Anticancer activity against human ACHN cells by SRB assay
    Anticancer activity against human ACHN cells by SRB assay
    [PMID: 20732810]
    ACHN GI50
    0.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human ACHN cells by SRB assay
    Cytotoxicity against human ACHN cells by SRB assay
    [PMID: 19596579]
    ACHN IC50
    0.79 μM
    Compound: Doxorubicin
    Anticancer activity against human ACHN cells after 48 hrs by MTT assay
    Anticancer activity against human ACHN cells after 48 hrs by MTT assay
    [PMID: 22136907]
    ACHN GI50
    1.63 μM
    Compound: ADR
    Antiproliferative activity against human ACHN cells by SRB method
    Antiproliferative activity against human ACHN cells by SRB method
    [PMID: 24835787]
    ACHN GI50
    1.63 μM
    Compound: ADR
    Antiproliferative activity against human ACHN cells by SRB assay
    Antiproliferative activity against human ACHN cells by SRB assay
    [PMID: 22738641]
    ACHN IC50
    14.2 μM
    Compound: doxorubicin
    Cytotoxicity against multidrug-resistant human ACHN cells after 72 hrs by fluorometric microculture cytotoxicity assay
    Cytotoxicity against multidrug-resistant human ACHN cells after 72 hrs by fluorometric microculture cytotoxicity assay
    [PMID: 16562840]
    ACHN GI50
    2 μM
    Compound: Doxorubicin
    Cytotoxicity against human ACHN cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human ACHN cells after 48 hrs by sulforhodamine B assay
    [PMID: 23964644]
    ACHN IC50
    2.08 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human ACHN cells by MTT assay
    Cytotoxicity against human ACHN cells by MTT assay
    10.1039/C4MD00566J
    ADR5000 cell line IC50
    > 10 μM
    Compound: Doxo
    Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 24 hrs by MTT assay
    [PMID: 24484281]
    ADR5000 cell line IC50
    > 10 μM
    Compound: Doxorubicin
    Cytotoxicity against human CEM/ADR5000 cells after 48 hrs by MTT assay
    Cytotoxicity against human CEM/ADR5000 cells after 48 hrs by MTT assay
    [PMID: 32496057]
    ADR5000 cell line IC50
    > 5.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human CEM/ADR5000 by CCK-8 assay
    Cytotoxicity against human CEM/ADR5000 by CCK-8 assay
    [PMID: 22884578]
    ADR5000 cell line IC50
    > 5.2 μM
    Compound: doxorubicin
    Cytotoxicity against human CEM/ADR5000 by XTT assay
    Cytotoxicity against human CEM/ADR5000 by XTT assay
    [PMID: 20527917]
    ADR5000 cell line IC50
    0.009 μM
    Compound: Doxorubicin
    Antiproliferative activity against human CEM/ADR5000 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human CEM/ADR5000 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 27010926]
    ADR5000 cell line IC50
    1.61 μM
    Compound: Doxorubicin
    Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 72 hrs by resazurin assay
    Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 72 hrs by resazurin assay
    [PMID: 26260339]
    ADR5000 cell line IC50
    1.61 μM
    Compound: Doxorubicin
    Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay
    Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay
    [PMID: 28456567]
    ADR5000 cell line IC50
    122.96 μM
    Compound: Doxorubicin
    Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by RRA assay
    Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by RRA assay
    [PMID: 33508467]
    ADR5000 cell line IC50
    23.27 μM
    Compound: Doxorubicin
    Cytotoxicity against human multidrug-resistant CEM/ADR5000 cells expressing p-glycoprotein by resazurin assay
    Cytotoxicity against human multidrug-resistant CEM/ADR5000 cells expressing p-glycoprotein by resazurin assay
    [PMID: 24561670]
    ADR5000 cell line EC50
    23.27 μM
    Compound: Doxorubicin
    Cytotoxicity against human CEM/ADR5000 cells overexpressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    Cytotoxicity against human CEM/ADR5000 cells overexpressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    [PMID: 29937978]
    ADR5000 cell line IC50
    30.07 μM
    Compound: Doxorubicin
    Growth inhibition of human multi-drug resistant CEM/ADR5000 cells by resazurin assay
    Growth inhibition of human multi-drug resistant CEM/ADR5000 cells by resazurin assay
    [PMID: 28121440]
    ADR5000 cell line IC50
    30.07 μM
    Compound: Doxorubicin
    Antileukemic activity against human CEM/ADR5000 cells after 24 to 48 hrs by resazurin dye based fluorescence assay
    Antileukemic activity against human CEM/ADR5000 cells after 24 to 48 hrs by resazurin dye based fluorescence assay
    [PMID: 29560715]
    ADR5000 cell line IC50
    30.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay
    Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay
    [PMID: 32663024]
    ADR5000 cell line EC50
    41.54 μM
    Compound: Doxorubicin
    Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    [PMID: 29887512]
    AGS GI50
    0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human AGS assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human AGS assessed as growth inhibition after 48 hrs by SRB assay
    [PMID: 21875046]
    AGS GI50
    0.02 μM
    Compound: Doxorubicin
    Growth inhibition of Homo sapiens (human) AGS cells after 48 hr by MTT assay
    Growth inhibition of Homo sapiens (human) AGS cells after 48 hr by MTT assay
    10.1007/s00044-012-0232-6
    AGS IC50
    0.31 μM
    Compound: adriamycin
    Cytotoxicity against human AGS cells by MTT assay
    Cytotoxicity against human AGS cells by MTT assay
    [PMID: 17125240]
    AGS IC50
    1.2 μM
    Compound: doxorubicin
    Cytotoxicity against human AGS cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human AGS cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 23806110]
    AGS IC50
    10.9 μM
    Compound: ADR
    Cytotoxicity against human AGS cells after 48 hrs by MTT assay
    Cytotoxicity against human AGS cells after 48 hrs by MTT assay
    10.1039/C2MD20270K
    ARPE-19 IC50
    0.76 μM
    Compound: Doxorubicin
    Cytotoxicity against human ARPE19 cells after 48 hrs by Alamar blue assay
    Cytotoxicity against human ARPE19 cells after 48 hrs by Alamar blue assay
    [PMID: 20931970]
    ASPC1 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human ASPC1 cells assessed as reduction in cell growth by MTT assay
    Cytotoxicity against human ASPC1 cells assessed as reduction in cell growth by MTT assay
    [PMID: 36734533]
    ASPC1 IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human ASPC1 cells by SRB assay
    Cytotoxicity against human ASPC1 cells by SRB assay
    [PMID: 33371684]
    ASPC1 IC50
    0.86 μM
    Compound: Doxorubicin
    Cytotoxicity against human AsPC1 cells deficit of P53 gene incubated for 72 hrs by MTS assay
    Cytotoxicity against human AsPC1 cells deficit of P53 gene incubated for 72 hrs by MTS assay
    [PMID: 31158748]
    ASPC1 IC50
    1.87 μM
    Compound: Adriamycin
    Cytotoxicity against human AsPC1 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
    Cytotoxicity against human AsPC1 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
    [PMID: 24717154]
    AT3B-1 IC50
    167.5 μM
    Compound: 1, Dox
    Tumor killing activity in AT3B1 drug-resistant cell line by MTT assay
    Tumor killing activity in AT3B1 drug-resistant cell line by MTT assay
    [PMID: 16168650]
    B16 IC50
    < 0.001 μg/mL
    Compound: 1 (doxorubicin)
    In vitro cytotoxic concentration against mouse melanoma cell line (B16) using MTT coloration
    In vitro cytotoxic concentration against mouse melanoma cell line (B16) using MTT coloration
    [PMID: 15013011]
    B16 IC50
    < 0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    [PMID: 22330634]
    B16 IC50
    0.001 μg/mL
    Compound: 1 (doxorubicin)
    In vitro inhibitory activity against mouse melanoma cell line (B16) using CV coloration
    In vitro inhibitory activity against mouse melanoma cell line (B16) using CV coloration
    [PMID: 15013011]
    B16 IC50
    0.03 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    [PMID: 18586355]
    B16 IC50
    0.03 μg/mL
    Compound: doxorubicin
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    [PMID: 17827021]
    B16 IC50
    0.03 μg/mL
    Compound: doxorubicin
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    [PMID: 15787450]
    B16 IC50
    0.03 μM
    Compound: Doxorubicin
    Anticancer activity against mouse B16 cells after 48 hrs by MTT assay
    Anticancer activity against mouse B16 cells after 48 hrs by MTT assay
    [PMID: 22668451]
    B16 IC50
    0.1 μM
    Compound: doxorubicin
    Cytotoxicity against murine B16 cells by MTT assay
    Cytotoxicity against murine B16 cells by MTT assay
    [PMID: 17256903]
    B16 IC50
    0.14 μM
    Compound: DOX
    Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
    [PMID: 21496972]
    B16 IC50
    0.18 μM
    Compound: ADM
    Antiproliferative activity against mouse B16 cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 25984840]
    B16 IC50
    0.18 μM
    Compound: ADM
    Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
    [PMID: 25529742]
    B16 IC50
    0.18 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse B16 cells after 72 hrs MTT assay
    Antiproliferative activity against mouse B16 cells after 72 hrs MTT assay
    [PMID: 25247772]
    B16 IC50
    0.2 μM
    Compound: Dox
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
    [PMID: 30659997]
    B16 IC50
    0.43 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse B16 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    [PMID: 26934105]
    B16 IC50
    1.7 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay
    Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay
    [PMID: 22304344]
    B16 IC50
    17.67 μM
    Compound: doxorubicin
    Cytotoxicity against mouse B16 cells assessed as inhibition of cell viability after 24 hrs by MTT assay
    Cytotoxicity against mouse B16 cells assessed as inhibition of cell viability after 24 hrs by MTT assay
    [PMID: 26200396]
    B16 IC50
    2.78 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25594739]
    B16 IC50
    21.5 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    [PMID: 21620529]
    B16 IC50
    3.16 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against mouse B16 cells by MTT assay
    Cytotoxicity against mouse B16 cells by MTT assay
    10.1039/C4MD00566J
    B16 IC50
    670 nM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay
    Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay
    [PMID: 30172625]
    B16 IC50
    7.6 nM
    Compound: Adriamycin
    Inhibition of murine B16 melanoma cell proliferation measured by the MTT assay
    Inhibition of murine B16 melanoma cell proliferation measured by the MTT assay
    [PMID: 10377224]
    B16-BL6 IC50
    3.07 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
    [PMID: 19689125]
    B16-BL6 IC50
    8.05 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
    [PMID: 18440233]
    B16-F1 IC50
    0.23 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse B16-F1 cells after 72 hrs by MTT reduction assay
    Antiproliferative activity against mouse B16-F1 cells after 72 hrs by MTT reduction assay
    [PMID: 28551177]
    B16-F10 IC50
    0.016 μM
    Compound: DOX
    Cytotoxicity against mouse B16/F10 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against mouse B16/F10 cells measured after 72 hrs by Celltiter-Glo assay
    [PMID: 31820976]
    B16-F10 IC50
    0.072 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16F10 cells after 48 hrs by CCK8 assay
    Cytotoxicity against mouse B16F10 cells after 48 hrs by CCK8 assay
    [PMID: 23777898]
    B16-F10 IC50
    0.12 μM
    Compound: Adriamycin
    Cytotoxicity against mouse B16F10 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
    Cytotoxicity against mouse B16F10 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
    [PMID: 24717154]
    B16-F10 IC50
    0.19 μM
    Compound: ADM
    Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay
    Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay
    [PMID: 30344912]
    B16-F10 IC50
    0.346 μM
    Compound: Doxorubicin
    Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 30433783]
    B16-F10 IC50
    0.663 μM
    Compound: Dox
    Cytotoxicity against mouse B16F10 cells assessed as cell killing effect after 72 hrs by MTT assay
    Cytotoxicity against mouse B16F10 cells assessed as cell killing effect after 72 hrs by MTT assay
    [PMID: 26005543]
    B16-F10 IC50
    2.3 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay
    Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay
    [PMID: 27300257]
    B16-F10 IC50
    3.28 μM
    Compound: Doxorubicin
    Anticancer activity against mouse B16-F10 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Anticancer activity against mouse B16-F10 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    [PMID: 34124677]
    B16-F10 IC50
    4.23 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16F10 cells after 72 hrs by alamar blue assay
    Cytotoxicity against mouse B16F10 cells after 72 hrs by alamar blue assay
    [PMID: 24969014]
    B16-F10 IC50
    4.33 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse B16F10 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay
    Cytotoxicity against mouse B16F10 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay
    [PMID: 30433783]
    B16-F10-luc2 IC50
    0.04 μM
    Compound: 1
    Cytotoxicity against mouse B16-F10-Luc2 cells expressing human EGFR measured after 72 hrs by resazurin assay
    Cytotoxicity against mouse B16-F10-Luc2 cells expressing human EGFR measured after 72 hrs by resazurin assay
    [PMID: 34411983]
    B16-F10-luc2 IC50
    0.04 μM
    Compound: 1
    Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in absence of cetuximab by resazurin assay
    Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in absence of cetuximab by resazurin assay
    [PMID: 34411983]
    B16-F10-luc2 IC50
    0.09 μM
    Compound: 1
    Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in presence of 3.3 uM cetuximab by resazurin assay
    Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in presence of 3.3 uM cetuximab by resazurin assay
    [PMID: 34411983]
    B16-F10-luc2 IC50
    0.11 μM
    Compound: 1
    Cytotoxicity against mouse B16-F10-Luc2 cells measured after 72 hrs by resazurin assay
    Cytotoxicity against mouse B16-F10-Luc2 cells measured after 72 hrs by resazurin assay
    [PMID: 34411983]
    BALB/3T3 IC50
    0.092 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by sulforhodamine B assay
    Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by sulforhodamine B assay
    [PMID: 32432867]
    BALB/3T3 IC50
    0.11 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse BALB/3T3 cells after 72 hrs by SRB assay
    Cytotoxicity against mouse BALB/3T3 cells after 72 hrs by SRB assay
    [PMID: 26639764]
    BALB/3T3 IC50
    0.18 μM
    Compound: doxorubicin
    Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method
    Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method
    [PMID: 25644674]
    BALB/3T3 IC50
    0.31 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs
    Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs
    [PMID: 26163197]
    BALB/3T3 GI50
    0.6 μM
    Compound: Dox
    Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    [PMID: 34634616]
    BALB/3T3 GI50
    0.62 μM
    Compound: Dox
    Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs and measured by MTT assay
    [PMID: 35973342]
    BALB/3T3 IC50
    1.08 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse BALB/3T3 cells assessed as cell viability after 1 hr by sulforhodamine B assay
    Cytotoxicity against mouse BALB/3T3 cells assessed as cell viability after 1 hr by sulforhodamine B assay
    [PMID: 26496013]
    BALB/3T3 IC50
    1.91 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay
    [PMID: 23079523]
    BALB/3T3 IC50
    166 nM
    Compound: DOX; DX
    Antiproliferative activity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay
    Antiproliferative activity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay
    [PMID: 31653441]
    BALB/3T3 IC50
    166 nM
    Compound: Doxorubicin
    Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs by SRB assay
    Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs by SRB assay
    [PMID: 33465696]
    BALB/3T3 IC50
    200 nM
    Compound: DX
    Antiproliferative activity against mouse BALB/3T3 cells assessed as inhibition of proliferation after 72 hrs by SRB assay
    Antiproliferative activity against mouse BALB/3T3 cells assessed as inhibition of proliferation after 72 hrs by SRB assay
    [PMID: 34116158]
    BALB/3T3 IC50
    315 nM
    Compound: DX
    Cytotoxicity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    [PMID: 34592435]
    BALB/3T3 IC50
    32.3 nM
    Compound: DX
    Cytotoxicity against mouse BALB/3T3 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    Cytotoxicity against mouse BALB/3T3 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
    [PMID: 33611191]
    BC IC50
    0.17 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human BC cells by colorimetric method
    Cytotoxicity against human BC cells by colorimetric method
    [PMID: 16989536]
    BC IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human BC cells by SRB assay
    Cytotoxicity against human BC cells by SRB assay
    [PMID: 20038128]
    BC IC50
    2.88 x 10-4 mM
    Compound: doxorubicin
    Cytotoxicity against human BC cells by SRB assay
    Cytotoxicity against human BC cells by SRB assay
    [PMID: 16933890]
    Bcap37 IC50
    1.12 μM
    Compound: AMD
    Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay
    Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay
    [PMID: 26900656]
    Bcap37 IC50
    1.19 μM
    Compound: AMD
    Antiproliferative activity against human Bcap37 cells after 48 hrs by MTT assay
    Antiproliferative activity against human Bcap37 cells after 48 hrs by MTT assay
    [PMID: 26807545]
    Bcap37 IC50
    1.2 μM
    Compound: ADM
    Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
    Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
    [PMID: 26280921]
    Bcap37 IC50
    1.2 μM
    Compound: ADM
    Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
    Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
    [PMID: 25874331]
    Bcap37 IC50
    1.28 μM
    Compound: ADM
    Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay
    [PMID: 23124210]
    Bcap37 IC50
    1.9 μM
    Compound: ADM
    Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
    Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
    10.1007/s00044-013-0854-3
    Bcap37 IC50
    2 μM
    Compound: ADM
    Antiproliferative against human Bcap37 cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative against human Bcap37 cells assessed as growth inhibition after 72 hrs by MTT assay
    10.1039/C1MD00038A
    Bcap37 IC50
    2.87 μM
    Compound: ADM
    Cytotoxicity against human Bcap37 cells after 38 hrs by MTT assay
    Cytotoxicity against human Bcap37 cells after 38 hrs by MTT assay
    [PMID: 25965778]
    BEAS-2B GI50
    0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay
    Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay
    [PMID: 30071406]
    BEAS-2B GI50
    0.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human BEAS2B cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human BEAS2B cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 29670691]
    BEAS-2B IC50
    18.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 70 hrs by alamar blue assay
    Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 70 hrs by alamar blue assay
    [PMID: 29471119]
    BEAS-2B IC50
    2.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human BEAS2B cells after 70 hrs by alamar blue assay
    Antiproliferative activity against human BEAS2B cells after 70 hrs by alamar blue assay
    [PMID: 29471119]
    Bel-7402 GI50
    < 1 μM
    Compound: DOX
    Antiproliferative activity against human Bel7402 cells by MTT assay
    Antiproliferative activity against human Bel7402 cells by MTT assay
    [PMID: 31990554]
    Bel-7402 IC50
    < 1 μM
    Compound: doxorubicin
    Cytotoxicity against human Bel-7402 cells by SRB assay
    Cytotoxicity against human Bel-7402 cells by SRB assay
    [PMID: 33847126]
    Bel-7402 IC50
    > 1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Bel-7402 cells by MTT assay
    Antiproliferative activity against human Bel-7402 cells by MTT assay
    [PMID: 36089748]
    Bel-7402 IC50
    0.01 μg/mL
    Compound: ADR
    Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
    [PMID: 18590312]
    Bel-7402 IC50
    0.01 μg/mL
    Compound: ADR
    Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
    Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
    [PMID: 18590312]
    Bel-7402 IC50
    0.021 μM
    Compound: adriamycin
    Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
    Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
    [PMID: 19028425]
    Bel-7402 IC50
    0.049 μM
    Compound: Doxorubicin
    Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
    [PMID: 20846862]
    Bel-7402 IC50
    0.067 μM
    Compound: ADR
    Cytotoxicity against human Bel7402 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human Bel7402 cells after 72 hrs by sulforhodamine B assay
    [PMID: 20949916]
    Bel-7402 IC50
    0.12 μM
    Compound: Adriamycin
    Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
    Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
    [PMID: 20593838]
    Bel-7402 IC50
    0.22 μM
    Compound: ADM
    Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 25984840]
    Bel-7402 IC50
    0.22 μM
    Compound: ADM
    Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
    [PMID: 25529742]
    Bel-7402 IC50
    0.22 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Bel7402 cells after 72 hrs MTT assay
    Antiproliferative activity against human Bel7402 cells after 72 hrs MTT assay
    [PMID: 25247772]
    Bel-7402 IC50
    0.53 μM
    Compound: Adriamycin
    Cytotoxicity against human Bel7402 cells by MTT assay
    Cytotoxicity against human Bel7402 cells by MTT assay
    [PMID: 22070654]
    Bel-7402 IC50
    0.58 μM
    Compound: Doxorubicin
    Antiproliferative activity human Bel7402 cells after 20 hrs by MTT assay
    Antiproliferative activity human Bel7402 cells after 20 hrs by MTT assay
    [PMID: 20149494]
    Bel-7402 IC50
    0.6 μM
    Compound: ADM
    Cytotoxic activity against human Bel7402 cells by MTT method
    Cytotoxic activity against human Bel7402 cells by MTT method
    [PMID: 25611519]
    Bel-7402 IC50
    0.9 μM
    Compound: ADM
    Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay
    Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay
    [PMID: 20932754]
    Bel-7402 IC50
    1 μM
    Compound: adriamycin
    Cytotoxicity against human Bel-7402 cells by MTT assay
    Cytotoxicity against human Bel-7402 cells by MTT assay
    [PMID: 17190442]
    Bel-7402 IC50
    1.36 μM
    Compound: DOX
    Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
    [PMID: 26386603]
    Bel-7402 IC50
    5 μM
    Compound: Doxorubicin
    Antitumor activity against human Bel7402 cells after 48 hrs by SRB assay
    Antitumor activity against human Bel7402 cells after 48 hrs by SRB assay
    [PMID: 20884091]
    Bel-7402 IC50
    578.2 nM
    Compound: Doxorubicin
    Antiproliferative against human Bel7402 cells assessed as cell viability after 96 hrs by MTT assay
    Antiproliferative against human Bel7402 cells assessed as cell viability after 96 hrs by MTT assay
    [PMID: 24211639]
    BEL-7404 tumor cell line IC50
    0.13 μM
    Compound: DOX
    Cytotoxicity against human Bel7404 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human Bel7404 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 27668963]
    BeWo IC50
    1.07 μM
    Compound: Doxorubicin
    Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay
    Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay
    [PMID: 25160837]
    BeWo IC50
    6.24 μg/mL
    Compound: (20) adriamycin
    In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay
    In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay
    [PMID: 12620075]
    BGC-823 IC50
    0.35 μM
    Compound: adriamycin
    Cytotoxicity against human BGC823 cells after 48 hrs
    Cytotoxicity against human BGC823 cells after 48 hrs
    [PMID: 17583953]
    BGC-823 IC50
    0.405 μM
    Compound: ADR
    Antiproliferative activity against human BGC823 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human BGC823 cells after 72 hrs by sulforhodamine B assay
    [PMID: 30241010]
    BGC-823 IC50
    0.66 μM
    Compound: DOX
    Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 35341920]
    BGC-823 IC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    [PMID: 22749279]
    BGC-823 IC50
    1 μM
    Compound: adriamycin
    Cytotoxicity against human BGC-823 cells by MTT assay
    Cytotoxicity against human BGC-823 cells by MTT assay
    [PMID: 17190442]
    BGC-823 IC50
    1.33 μM
    Compound: Adriamycin
    Cytotoxicity against human BGC823 cells by MTT assay
    Cytotoxicity against human BGC823 cells by MTT assay
    [PMID: 23434227]
    BGC-823 IC50
    1.48 μM
    Compound: Adriamycin
    Cytotoxicity against human BGC823 cells by MTT assay
    Cytotoxicity against human BGC823 cells by MTT assay
    [PMID: 24182355]
    BGC-823 IC50
    2.6 μM
    Compound: ADM
    Antiproliferative against human BGC823 cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative against human BGC823 cells assessed as growth inhibition after 72 hrs by MTT assay
    10.1039/C1MD00038A
    BGC-823 IC50
    4.8 μM
    Compound: Doxorubicin
    Antitumor activity against human BGC823 cells after 48 hrs by SRB assay
    Antitumor activity against human BGC823 cells after 48 hrs by SRB assay
    [PMID: 20884091]
    BJ IC50
    2.33 μM
    Compound: DOXO
    Cytotoxicity against human BJ cells assessed as cell viability after 48 hrs by alamar blue assay
    Cytotoxicity against human BJ cells assessed as cell viability after 48 hrs by alamar blue assay
    [PMID: 21797280]
    BJ IC50
    2.33 μM
    Compound: Doxorubicin
    Cytotoxicity against human BJ cells after 48 hrs by Alamar blue assay
    Cytotoxicity against human BJ cells after 48 hrs by Alamar blue assay
    [PMID: 20931970]
    BJ IC50
    2.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human BJ cells after 48 hrs by Alamar Blue assay
    Cytotoxicity against human BJ cells after 48 hrs by Alamar Blue assay
    [PMID: 19473028]
    BMDM IC50
    4.6 μM
    Compound: Adriamycin
    Cytotoxicity against mouse BMDM cells after 72 hrs by MTT assay
    Cytotoxicity against mouse BMDM cells after 72 hrs by MTT assay
    [PMID: 22616554]
    BT-474 IC50
    0.041 μM
    Compound: DOX
    Antiproliferative activity against human BT474 cells after 48 hrs by CellTiter-Glo assay
    Antiproliferative activity against human BT474 cells after 48 hrs by CellTiter-Glo assay
    [PMID: 27769032]
    BT-474 IC50
    0.053 μM
    Compound: DOX
    Antiproliferative activity against human BT474 cells after 24 hrs by CellTiter-Glo assay
    Antiproliferative activity against human BT474 cells after 24 hrs by CellTiter-Glo assay
    [PMID: 27769032]
    BT-474 IC50
    0.07 μM
    Compound: Dox
    Cytotoxicity against human BT474 cells after 3 days by MTT assay
    Cytotoxicity against human BT474 cells after 3 days by MTT assay
    [PMID: 21741833]
    BT-474 IC50
    0.18 μM
    Compound: DOX
    Antiproliferative activity against human BT474 spheroids after 3 days by CellTiter-Glo assay
    Antiproliferative activity against human BT474 spheroids after 3 days by CellTiter-Glo assay
    [PMID: 27769032]
    BT-474 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human BT474 cells assessed as reduction in cell survival after 48 hrs by MTT assay
    Cytotoxicity against human BT474 cells assessed as reduction in cell survival after 48 hrs by MTT assay
    [PMID: 28494255]
    BT-474 IC50
    1.9 μM
    Compound: DOX
    Cytotoxicity against human BT474 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human BT474 cells measured after 72 hrs by Celltiter-Glo assay
    [PMID: 31820976]
    BT-474 IC50
    8.92 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human BT474 cells after 3 days by MTT assay
    Cytotoxicity against human BT474 cells after 3 days by MTT assay
    [PMID: 19456120]
    BT-549 IC50
    < 0.55 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay
    [PMID: 19105653]
    BT-549 IC50
    < 0.55 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) BT549 cells by neutral red staining
    Cytotoxicity against Homo sapiens (human) BT549 cells by neutral red staining
    10.1007/s00044-011-9587-3
    BT-549 IC50
    < 1.1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay
    Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay
    [PMID: 11374943]
    BT-549 IC50
    0.008 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay
    Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay
    [PMID: 8984156]
    BT-549 IC50
    0.009 μM
    Compound: Doxorubicin
    Antiproliferative activity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 27010926]
    BT-549 GI50
    0.01 μM
    Compound: Doxorubicin
    Cytostatic activity against human BT549 cells after 5 days by SRB assay
    Cytostatic activity against human BT549 cells after 5 days by SRB assay
    [PMID: 21711054]
    BT-549 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human BT549 cells assessed as growth inhibition after 72 hrs by SRB assay
    [PMID: 30457333]
    BT-549 IC50
    0.045 μM
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye based assay
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye based assay
    [PMID: 29317147]
    BT-549 IC50
    0.11 μM
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    Cytotoxicity against human BT549 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
    [PMID: 23600925]
    BT-549 IC50
    0.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay relative to control
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay relative to control
    [PMID: 25975638]
    BT-549 GI50
    0.23 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human BT549 cells after 48 hrs by SRB assay
    Cytotoxicity against human BT549 cells after 48 hrs by SRB assay
    [PMID: 23871905]
    BT-549 GI50
    0.23 μM
    Compound: Doxorubicin
    Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 29102177]
    BT-549 GI50
    0.23 μM
    Compound: Doxorubicin
    Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28329730]
    BT-549 IC50
    0.6 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human BT549 cells by neutral red assay
    Cytotoxicity against human BT549 cells by neutral red assay
    [PMID: 17976995]
    BT-549 IC50
    0.8 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human BT549 cells after 48 hrs by Neutral Red dye
    Cytotoxicity against human BT549 cells after 48 hrs by Neutral Red dye
    [PMID: 20550123]
    BT-549 IC50
    1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red staining
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red staining
    [PMID: 15165136]
    BT-549 IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells after 48 hrs by Neutral red assay
    Cytotoxicity against human BT549 cells after 48 hrs by Neutral red assay
    [PMID: 19658408]
    BT-549 IC50
    1.3 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye staining
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye staining
    [PMID: 19928902]
    BT-549 IC50
    1.35 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay
    Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay
    [PMID: 27769668]
    BT-549 IC50
    1.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red assay
    Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red assay
    [PMID: 26005918]
    BT-549 IC50
    1.96 μM
    Compound: doxorubicin
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay
    Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay
    [PMID: 19879765]
    BT-549 IC50
    2.6 μM
    Compound: doxorubicin
    Cytotoxicity against human BT549 cells assessed as viable cells by neutral red dye method
    Cytotoxicity against human BT549 cells assessed as viable cells by neutral red dye method
    [PMID: 22530813]
    BT-549 IC50
    3.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human BT549 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    Cytotoxicity against human BT549 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    [PMID: 27618204]
    BT-549 IC50
    3.7 μM
    Compound: doxorubicin
    Cytotoxicity against human BT549 cells assessed as growth inhibition measured after 48 hrs by XTT assay
    Cytotoxicity against human BT549 cells assessed as growth inhibition measured after 48 hrs by XTT assay
    [PMID: 23547843]
    BXPC-3 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human BxPC3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human BxPC3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    [PMID: 25937235]
    BXPC-3 IC50
    0.4 μM
    Compound: DOX, Doxorubicin
    Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
    [PMID: 24095089]
    BXPC-3 IC50
    0.56 μM
    Compound: Doxorubicin
    Antiproliferative activity against human BxPC3 cells after 48 hrs by MTT assay
    Antiproliferative activity against human BxPC3 cells after 48 hrs by MTT assay
    [PMID: 28554092]
    BXPC-3 IC50
    1.78 μM
    Compound: Doxorubicin
    Antiproliferative activity against human BxPC3 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human BxPC3 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    [PMID: 26253231]
    BXPC-3 IC50
    13 μM
    Compound: Doxorubicin
    Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay
    [PMID: 27173802]
    BXPC-3 IC50
    13.56 μM
    Compound: Doxorubicin
    Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay
    [PMID: 29573910]
    BXPC-3 IC50
    14.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 28254167]
    BXPC-3 IC50
    9.12 μM
    Compound: Doxorubicin
    Growth inhibition of human BxPC3 cells after 48 hrs by MTT assay
    Growth inhibition of human BxPC3 cells after 48 hrs by MTT assay
    [PMID: 30072225]
    C2D cell line IC50
    46.5 nM
    Compound: Doxorubicin
    Inhibitory concentration to inhibit growth of C2D prostate cancer cell line by using MTT assay
    Inhibitory concentration to inhibit growth of C2D prostate cancer cell line by using MTT assay
    [PMID: 14971910]
    C2G cell line IC50
    28.7 nM
    Compound: Doxorubicin
    Inhibitory concentration to inhibit growth of C2G prostate cancer cell line by using MTT assay
    Inhibitory concentration to inhibit growth of C2G prostate cancer cell line by using MTT assay
    [PMID: 14971910]
    C-33-A IC50
    0.28 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human C33A cells after 48 hrs by SRB assay
    Cytotoxicity against human C33A cells after 48 hrs by SRB assay
    [PMID: 20732814]
    C-33-A IC50
    0.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human C33A cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human C33A cells after 48 hrs by sulforhodamine B assay
    [PMID: 21071221]
    C3H IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse C3H cells after 72 hrs by MTS assay
    Cytotoxicity against mouse C3H cells after 72 hrs by MTS assay
    [PMID: 26810263]
    C6 IC50
    0.1 μM
    Compound: Dox
    Cytotoxicity against rat C6 cells after 72 hrs by MTT assay
    Cytotoxicity against rat C6 cells after 72 hrs by MTT assay
    [PMID: 30659997]
    C6 IC50
    0.5 μM
    Compound: Dox
    Cytotoxicity against rat C6 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against rat C6 cells after 72 hrs by sulforhodamine B assay
    [PMID: 28504888]
    C6 IC50
    25.64 μM
    Compound: Dox
    Cytotoxicity against rat C6 cells assessed as cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against rat C6 cells assessed as cell viability measured after 24 hrs by MTT assay
    [PMID: 33183865]
    C8166 IC50
    0.02 μM
    Compound: doxo
    Antiproliferative activity against human C8166 cell line by MTT assay
    Antiproliferative activity against human C8166 cell line by MTT assay
    [PMID: 16913700]
    Ca9-22 IC50
    0.09 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human sCa9-22 cells by MTT assay
    Cytotoxicity against human sCa9-22 cells by MTT assay
    [PMID: 18590313]
    Ca9-22 IC50
    0.1 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human Ca9-22 cells by MTT assay
    Cytotoxicity against human Ca9-22 cells by MTT assay
    [PMID: 18973388]
    Ca9-22 IC50
    0.14 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay
    Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay
    [PMID: 19691312]
    Ca9-22 IC50
    0.26 μM
    Compound: Doxo
    Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay
    Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay
    [PMID: 21800859]
    Ca9-22 IC50
    0.31 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human Ca9-22 cells by MTT assay
    Cytotoxicity against human Ca9-22 cells by MTT assay
    [PMID: 22413887]
    Ca9-22 CC50
    0.7 μM
    Compound: DXR
    Cytotoxicity against human Ca9-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human Ca9-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 31532650]
    Ca9-22 IC50
    1.3 μM
    Compound: Doxo
    Cytotoxicity against human Ca9-22 cells after 72 hrs by MTT assay
    Cytotoxicity against human Ca9-22 cells after 72 hrs by MTT assay
    [PMID: 20334960]
    Ca9-22 IC50
    14.47 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Ca9-22 cells by MTT assay
    Cytotoxicity against human Ca9-22 cells by MTT assay
    [PMID: 21106454]
    Caco-2 IC50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Caco2 cells after 72 hrs by WST-8 assay
    Cytotoxicity against human Caco2 cells after 72 hrs by WST-8 assay
    [PMID: 25534608]
    Caco-2 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs
    Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs
    [PMID: 34601029]
    Caco-2 IC50
    0.05 μM
    Compound: Doxorubicine
    Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    [PMID: 33422908]
    Caco-2 IC50
    0.09 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay
    Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay
    [PMID: 30655216]
    Caco-2 IC50
    0.17 μM
    Compound: Doxorubicin
    Toxicity in human Caco-2 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    Toxicity in human Caco-2 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    [PMID: 31753515]
    Caco-2 GI50
    0.32 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Caco2 cells after 2 days by sulforhodamine B assay
    Antiproliferative activity against human Caco2 cells after 2 days by sulforhodamine B assay
    [PMID: 24184076]
    Caco-2 IC50
    0.35 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Caco2 cells after 24 and 72 hrs by MTT assay
    Antiproliferative activity against human Caco2 cells after 24 and 72 hrs by MTT assay
    [PMID: 24941130]
    Caco-2 IC50
    0.6 μM
    Compound: Doxorubicin
    Antitumor activity against human differentiated Caco2 cells after 24 to 48 hrs by MTT assay
    Antitumor activity against human differentiated Caco2 cells after 24 to 48 hrs by MTT assay
    [PMID: 21553829]
    Caco-2 IC50
    0.73 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Caco2 cells after 48 hrs by neutral red assay
    Antiproliferative activity against human Caco2 cells after 48 hrs by neutral red assay
    [PMID: 29885574]
    Caco-2 IC50
    0.96 μM
    Compound: Doxorubicin
    Cytotoxicity against human Caco2 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human Caco2 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 26874404]
    Caco-2 IC50
    1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Caco-2 cells after 24 hrs
    Cytotoxicity against human Caco-2 cells after 24 hrs
    [PMID: 20207452]
    Caco-2 IC50
    1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Caco2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human Caco2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31546197]
    Caco-2 IC50
    2.7 μM
    Compound: Adriamycin
    Cytotoxicity against human Caco2 cells by MTT assay
    Cytotoxicity against human Caco2 cells by MTT assay
    [PMID: 22946634]
    Caco-2 IC50
    21 μM
    Compound: 21
    Cytotoxicity against human Caco2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human Caco2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 32435401]
    Caco-2 IC50
    26.79 μM
    Compound: DOX
    Antiproliferative activity against human Caco2 cells by MTT assay
    Antiproliferative activity against human Caco2 cells by MTT assay
    [PMID: 30216848]
    Caco-2 IC50
    3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
    [PMID: 26874744]
    Caco-2 IC50
    3.83 μM
    Compound: Dox
    Antiproliferative activity against human Caco2 cells by MTT assay
    Antiproliferative activity against human Caco2 cells by MTT assay
    [PMID: 28802125]
    Caco-2 IC50
    48.1 nM
    Compound: DOX
    Anticancer activity against human Caco-2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Anticancer activity against human Caco-2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 33901898]
    Caco-2 IC50
    5 μM
    Compound: Doxorubicin
    Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay
    Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay
    [PMID: 24099994]
    Caco-2 IC50
    5.13 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Caco2 cells after 72 hrs by ELISA
    Antiproliferative activity against human Caco2 cells after 72 hrs by ELISA
    [PMID: 31404864]
    Caco-2 IC50
    6.7 μM
    Compound: Doxorubicin
    Antitumor activity against human undifferentiated Caco2 cells after 24 to 48 hrs by MTT assay
    Antitumor activity against human undifferentiated Caco2 cells after 24 to 48 hrs by MTT assay
    [PMID: 21553829]
    Caco-2 IC50
    63.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
    [PMID: 28463785]
    Caco-2 IC50
    64.2 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Caco2 cells assessed as cell growth inhibition measured after 24 by MTT assay
    Cytotoxicity against human Caco2 cells assessed as cell growth inhibition measured after 24 by MTT assay
    [PMID: 35526504]
    Caco-2 IC50
    9.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 27843113]
    CAKI-1 GI50
    0.95 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human Caki1 cells after 48 hrs by SRB assay
    Cytotoxicity against human Caki1 cells after 48 hrs by SRB assay
    [PMID: 23871905]
    CAKI-1 GI50
    0.95 μM
    Compound: Doxorubicin
    Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 29102177]
    CAL-27 IC50
    0.18 μM
    Compound: DOX
    Antiproliferative activity against human CAL-27 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human CAL-27 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 36709571]
    Calu-1 GI50
    < 1 x 10-2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HTB-54 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HTB-54 cells after 72 hrs by MTT assay
    [PMID: 30071406]
    Calu-1 GI50
    < 1 x 10-2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HTB-54 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HTB-54 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 29670691]
    Calu-3 IC50
    0.11 μM
    Compound: DOX
    Antiproliferative activity against human Calu3 cells after 48 hrs by CellTiter-Glo assay
    Antiproliferative activity against human Calu3 cells after 48 hrs by CellTiter-Glo assay
    [PMID: 27769032]
    Calu-3 IC50
    0.27 μM
    Compound: DOX
    Antiproliferative activity against human Calu3 cells after 24 hrs by CellTiter-Glo assay
    Antiproliferative activity against human Calu3 cells after 24 hrs by CellTiter-Glo assay
    [PMID: 27769032]
    Cancer cell lines GI50
    0.065 μM
    Compound: Doxorubicin
    Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay
    Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay
    [PMID: 20884089]
    Cancer cell lines GI50
    0.065 μM
    Compound: Doxorubicin
    Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay
    Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay
    [PMID: 20884089]
    Cancer cell lines GI50
    0.065 μM
    Compound: Doxorubicin
    Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay
    Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay
    [PMID: 20884089]
    Caov-3 cell line IC50
    < 0.1 μM
    Compound: DOX, Doxorubicin
    Antiproliferative activity against human Caov3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Caov3 cells after 72 hrs by MTT assay
    [PMID: 24095089]
    CAPAN-1 IC50
    1.7 μM
    Compound: Doxorubicin
    Cytotoxicity in human CAPAN-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human CAPAN-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 34082225]
    CAPAN-1 IC50
    1.7 μM
    Compound: Dox
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    [PMID: 32428792]
    CAPAN-1 IC50
    1.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay
    [PMID: 30660827]
    carcinoma cell line IC50
    < 0.01 μM
    Compound: doxorubicin
    Inhibitory effect against murine renal cell carcinoma cell line (RENCA cells) using a BrdU-incorporation assay
    Inhibitory effect against murine renal cell carcinoma cell line (RENCA cells) using a BrdU-incorporation assay
    [PMID: 11454467]
    CCD-841CoN IC50
    1.5 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human CCD-841CoN cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human CCD-841CoN cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    [PMID: 35526504]
    CCRF S-180 IC50
    29.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    [PMID: 21620529]
    CCRF S-180 IC50
    9.25 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse S180 cells assessed as cell viability after 48 hrs by MTT assay
    Antiproliferative activity against mouse S180 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25648297]
    CCRF-CEM IC50
    0.003 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay
    [PMID: 26260339]
    CCRF-CEM IC50
    0.003 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay
    [PMID: 28456567]
    CCRF-CEM IC50
    0.009 μM
    Compound: Doxorubicin
    Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 27010926]
    CCRF-CEM IC50
    0.009 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells by resazurin assay
    Cytotoxicity against human CCRF-CEM cells by resazurin assay
    [PMID: 24561670]
    CCRF-CEM EC50
    0.009 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    [PMID: 29937978]
    CCRF-CEM IC50
    0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay
    Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay
    [PMID: 27808511]
    CCRF-CEM EC50
    0.015 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
    [PMID: 29887512]
    CCRF-CEM IC50
    0.017 μM
    Compound: Doxorubicin
    Growth inhibition of human CCRF-CEM cells by resazurin assay
    Growth inhibition of human CCRF-CEM cells by resazurin assay
    [PMID: 28121440]
    CCRF-CEM IC50
    0.017 μM
    Compound: Doxorubicin
    Antileukemic activity against human CCRF-CEM cells after 24 to 48 hrs by resazurin dye based fluorescence assay
    Antileukemic activity against human CCRF-CEM cells after 24 to 48 hrs by resazurin dye based fluorescence assay
    [PMID: 29560715]
    CCRF-CEM IC50
    0.02 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human CEM cells after 72 hrs by MTT assay
    Cytotoxicity against human CEM cells after 72 hrs by MTT assay
    [PMID: 18586355]
    CCRF-CEM IC50
    0.02 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human CEM cells after 72 hrs by MTT assay
    Cytotoxicity against human CEM cells after 72 hrs by MTT assay
    [PMID: 15787450]
    CCRF-CEM GI50
    0.02 μM
    Compound: Doxorubicin
    Growth inhibition of human CCRF-CEM cells after 2 days by MTT assay
    Growth inhibition of human CCRF-CEM cells after 2 days by MTT assay
    [PMID: 20570145]
    CCRF-CEM IC50
    0.02 μM
    Compound: Doxo
    Antiproliferative activity against human CCRF-CEM cells assessed as cell viability measured after 4 days by MTT assay
    Antiproliferative activity against human CCRF-CEM cells assessed as cell viability measured after 4 days by MTT assay
    [PMID: 31869654]
    CCRF-CEM EC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay
    Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay
    [PMID: 26320088]
    CCRF-CEM CC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay
    Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay
    [PMID: 26119992]
    CCRF-CEM IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay
    Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay
    [PMID: 19053767]
    CCRF-CEM IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by RRA assay
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by RRA assay
    [PMID: 33508467]
    CCRF-CEM IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay
    [PMID: 32663024]
    CCRF-CEM IC50
    0.03 μM
    Compound: doxo
    Antiproliferative activity against human CCRF-CEM cell line by MTT assay
    Antiproliferative activity against human CCRF-CEM cell line by MTT assay
    [PMID: 16913700]
    CCRF-CEM IC50
    0.037 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells by CCK-8 assay
    Cytotoxicity against human CCRF-CEM cells by CCK-8 assay
    [PMID: 22884578]
    CCRF-CEM IC50
    0.052 μM
    Compound: Doxorubicin
    Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay
    Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay
    [PMID: 27060757]
    CCRF-CEM IC50
    0.06 μM
    Compound: 1; Dox
    Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
    Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
    [PMID: 26633734]
    CCRF-CEM IC50
    0.06 μM
    Compound: Dox
    Cytotoxicity against human CEM cells after 72 hrs by MTT assay
    Cytotoxicity against human CEM cells after 72 hrs by MTT assay
    [PMID: 21144624]
    CCRF-CEM IC50
    0.06 μM
    Compound: adriamycin
    Cytotoxicity against drug-sensitive CCRF-CEM cells after 72 hrs
    Cytotoxicity against drug-sensitive CCRF-CEM cells after 72 hrs
    [PMID: 17323939]
    CCRF-CEM GI50
    0.08 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB assay
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB assay
    [PMID: 23871905]
    CCRF-CEM GI50
    0.08 μM
    Compound: Doxorubicin
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 29102177]
    CCRF-CEM GI50
    0.08 μM
    Compound: Doxorubicin
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28329730]
    CCRF-CEM IC50
    0.09 μM
    Compound: Doxorubicin
    Antiproliferative activity against human CCRF-CEM cells assessed as cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human CCRF-CEM cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 24012378]
    CCRF-CEM IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay
    Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay
    [PMID: 19394829]
    CCRF-CEM IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
    Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
    [PMID: 36691388]
    CCRF-CEM IC50
    0.1 mM
    Compound: Dox
    Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
    Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
    [PMID: 29459273]
    CCRF-CEM IC50
    0.1 μM
    Compound: 2
    Antiproliferative activity against human CEM cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human CEM cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 33974416]
    CCRF-CEM IC50
    0.1 μM
    Compound: Dox
    Antiproliferative activity in human CEM cells after 72 hrs by MTT assay
    Antiproliferative activity in human CEM cells after 72 hrs by MTT assay
    [PMID: 30268824]
    CCRF-CEM IC50
    0.1 μM
    Compound: 5
    Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
    Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
    [PMID: 29137865]
    CCRF-CEM IC50
    0.11 μM
    Compound: doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
    [PMID: 22582991]
    CCRF-CEM IC50
    0.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by MTT assay
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by MTT assay
    [PMID: 32496057]
    CCRF-CEM IC50
    0.39 μM
    Compound: Doxorubicin
    Cytostatic activity against human CEM/0 after 72 hrs by cell counting
    Cytostatic activity against human CEM/0 after 72 hrs by cell counting
    [PMID: 22555152]
    CCRF-CEM EC50
    0.4654 μM
    Compound: doxorubicin
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
    [PMID: 19743858]
    CCRF-CEM IC50
    0.5 μM
    Compound: doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay
    [PMID: 25993619]
    CCRF-CEM IC50
    0.5 μM
    Compound: Doxo
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay
    [PMID: 24484281]
    CCRF-CEM IC50
    1.05 μM
    Compound: Dox
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by resazurin assay
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by resazurin assay
    [PMID: 29107422]
    CCRF-CEM IC50
    1.05 μM
    Compound: DOX
    Antiproliferative activity against human CCRF-CEM cells after 48 hrs by resazurin dye-based fluorescence assay
    Antiproliferative activity against human CCRF-CEM cells after 48 hrs by resazurin dye-based fluorescence assay
    [PMID: 29665526]
    CCRF-CEM IC50
    2.14 μM
    Compound: doxorubicin
    Cytotoxicity against human CCRF-CEM cells by XTT assay
    Cytotoxicity against human CCRF-CEM cells by XTT assay
    [PMID: 22663190]
    CCRF-CEM GI50
    3 x 10-2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay
    Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay
    [PMID: 30071406]
    CCRF-CEM EC50
    3.078 μM
    Compound: doxorubicin
    Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
    [PMID: 19743858]
    CCRF-CEM IC50
    3.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human CEM cells after 48 hrs by alamar blue assay
    Cytotoxicity against human CEM cells after 48 hrs by alamar blue assay
    [PMID: 22272829]
    CCRF-CEM IC50
    3.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human CEM cells after 48 hrs
    Cytotoxicity against human CEM cells after 48 hrs
    [PMID: 20873721]
    CCRF-CEM GI50
    3.3 x 10-2 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 29670691]
    CCRF-CEM IC50
    36.9 nM
    Compound: doxorubicin
    Cytotoxicity against human CCRF-CEM by XTT assay
    Cytotoxicity against human CCRF-CEM by XTT assay
    [PMID: 20527917]
    CCRF-CEM IC50
    45 nM
    Compound: Dox
    Inhibition of cell proliferation of human CCRF-CEM cells after 96 hrs by CellTiter assay
    Inhibition of cell proliferation of human CCRF-CEM cells after 96 hrs by CellTiter assay
    [PMID: 22276998]
    CCRF-CEM IC50
    55.91 μM
    Compound: Dox
    Antiproliferative activity against human CCRF-CM cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay
    Antiproliferative activity against human CCRF-CM cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay
    [PMID: 27687968]
    CCRF-SB EC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay
    Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay
    [PMID: 26320088]
    CCRF-SB IC50
    0.02 μM
    Compound: doxo
    Antiproliferative activity against human CCRF-SB cell line by MTT assay
    Antiproliferative activity against human CCRF-SB cell line by MTT assay
    [PMID: 16913700]
    CCRF-SB IC50
    0.03 μM
    Compound: Doxo
    Antiproliferative activity against human CCRF-SB cells assessed as cell viability measured after 4 days by MTT assay
    Antiproliferative activity against human CCRF-SB cells assessed as cell viability measured after 4 days by MTT assay
    [PMID: 31869654]
    CCRF-SB CC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay
    Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay
    [PMID: 26119992]
    CCRF-SB IC50
    0.03 μM
    Compound: Doxorubicin
    Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay
    Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay
    [PMID: 19053767]
    CEM/VLB100 IC50
    3.71 μM
    Compound: adriamycin
    Cytotoxicity against vinblastine-resistant CEM/VLB100 cells after 72 hrs
    Cytotoxicity against vinblastine-resistant CEM/VLB100 cells after 72 hrs
    [PMID: 17323939]
    CEM-VM1 IC50
    0.55 μM
    Compound: adriamycin
    Cytotoxicity against teniposide-resistant CEM/VM1 cells after 72 hrs
    Cytotoxicity against teniposide-resistant CEM/VM1 cells after 72 hrs
    [PMID: 17323939]
    CH1 IC50
    0.0063 μM
    Compound: Doxirubicin
    Concentration required to inhibit CH1-cell growth by 50%
    Concentration required to inhibit CH1-cell growth by 50%
    [PMID: 9703471]
    CHO IC50
    0.08 μM
    Compound: Adriamycin
    Cytotoxicity against CHO cells after 72 hrs by MTT assay
    Cytotoxicity against CHO cells after 72 hrs by MTT assay
    [PMID: 21721528]
    CHO CC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against CHO cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against CHO cells assessed as cell viability after 24 hrs by MTT assay
    [PMID: 25791675]
    CHO IC50
    3.6 μM
    Compound: Doxorubicin
    Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 34782182]
    CHO CC50
    4.65 μM
    Compound: Doxorubicin
    Cytotoxicity against CHO cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against CHO cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 32088496]
    CHO IC50
    6 μM
    Compound: DOX
    Compound was tested for the drug concentration that inhibited cell growth by 50% compared to untreated control cultures of CHO /DOX cell line
    Compound was tested for the drug concentration that inhibited cell growth by 50% compared to untreated control cultures of CHO /DOX cell line
    [PMID: 9526570]
    CHO IC50
    6.0 x 10-8 M
    Compound: DOX
    Drug concentration that inhibit cell growth by 50% compared to untreated control cultures of CHO cells (for 6 days at 37 degree Celsius)
    Drug concentration that inhibit cell growth by 50% compared to untreated control cultures of CHO cells (for 6 days at 37 degree Celsius)
    [PMID: 9526570]
    CHO IC50
    9.7 μM
    Compound: Adriamycin
    Cytotoxicity against CHO cells selected at 1 ug/mL colchicine after 72 hrs by MTT assay
    Cytotoxicity against CHO cells selected at 1 ug/mL colchicine after 72 hrs by MTT assay
    [PMID: 21721528]
    CHO-K1 IC50
    4.2 μM
    Compound: Doxorubicin
    Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 27843113]
    CNE IC50
    0.22 μM
    Compound: DOX
    Antiproliferative activity against human CNE cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human CNE cells after 72 hrs by CCK-8 assay
    [PMID: 29614418]
    CNE-2 IC50
    3.52 μM
    Compound: Doxorubicin
    Cytotoxicity against human CNE2 cells by CCK8 assay
    Cytotoxicity against human CNE2 cells by CCK8 assay
    [PMID: 29452840]
    CNS cell GI50
    94 μM
    Compound: doxorubicin
    Cytotoxicity against human CNS cells after 48 hrs by SRB assay
    Cytotoxicity against human CNS cells after 48 hrs by SRB assay
    [PMID: 19070942]
    COLO 201 IC50
    0.8 μM
    Compound: Doxorubicin
    Growth inhibition of human Colo-201 cells by MTT assay
    Growth inhibition of human Colo-201 cells by MTT assay
    [PMID: 33901643]
    COLO 205 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
    [PMID: 20673627]
    COLO 205 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B assay
    [PMID: 21737288]
    COLO 205 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human COLO205 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human COLO205 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    [PMID: 25937235]
    COLO 205 GI50
    0.14 μM
    Compound: adriamycin
    Cytotoxicity against human Colo205 cells after 24 hrs by SRB method
    Cytotoxicity against human Colo205 cells after 24 hrs by SRB method
    [PMID: 18262426]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Growth inhibition of human COLO205 cells after 48 hrs by SRB assay
    Growth inhibition of human COLO205 cells after 48 hrs by SRB assay
    [PMID: 20031423]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Growth inhibition of human COLO205 cells by SRB assay
    Growth inhibition of human COLO205 cells by SRB assay
    [PMID: 22361684]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Anticancer activity against human COLO205 cells by SRB method
    Anticancer activity against human COLO205 cells by SRB method
    [PMID: 21676506]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay
    [PMID: 23849207]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay
    [PMID: 22364746]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human Colo205 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human Colo205 cells after 48 hrs by sulforhodamine B assay
    [PMID: 18657979]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human COLO205 cells after 24 hrs by WST-1 assay
    Cytotoxicity against human COLO205 cells after 24 hrs by WST-1 assay
    [PMID: 20732817]
    COLO 205 GI50
    0.15 μM
    Compound: ADR, Adriamycin
    Growth inhibition of human Colo205 cells by SRB method
    Growth inhibition of human Colo205 cells by SRB method
    [PMID: 18207392]
    COLO 205 GI50
    0.18 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
    [PMID: 23871905]
    COLO 205 GI50
    0.18 μM
    Compound: Doxorubicin
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 29102177]
    COLO 205 GI50
    0.18 μM
    Compound: Doxorubicin
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28329730]
    COLO 205 IC50
    0.26 μM
    Compound: adriamycin
    Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay
    Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay
    [PMID: 17107806]
    COLO 205 IC50
    0.37 μM
    Compound: Doxo
    Cytotoxicity against human COLO205 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human COLO205 cells assessed as cell viability after 48 hrs by MTT assay
    10.1039/C2MD20302B
    COLO 205 IC50
    0.4 μM
    Compound: Doxorubicin
    Anticancer activity against human COLO205 cells by MTT assay
    Anticancer activity against human COLO205 cells by MTT assay
    [PMID: 21570750]
    COLO 205 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human COLO205 cells by MTT assay
    Cytotoxicity against human COLO205 cells by MTT assay
    [PMID: 24300737]
    COLO 205 IC50
    0.52 μM
    Compound: DOX
    Antiproliferative activity against human COLO205 cells after 72 hrs by Sulforhodamine B-stain assay
    Antiproliferative activity against human COLO205 cells after 72 hrs by Sulforhodamine B-stain assay
    [PMID: 27484508]
    COLO 205 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay
    [PMID: 24780595]
    COLO 205 IC50
    0.7 μM
    Compound: Dox
    Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay
    Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay
    [PMID: 24507927]
    COLO 205 IC50
    1.43 μM
    Compound: Doxorubicin
    Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 31546197]
    COLO 205 IC50
    1.5 μM
    Compound: Doxorubicin
    Antitumor activity against human COLO205 cells after 24 to 48 hrs by MTT assay
    Antitumor activity against human COLO205 cells after 24 to 48 hrs by MTT assay
    [PMID: 21553829]
    COLO 205 IC50
    1.69 μM
    Compound: Dox
    Anticancer activity against human COLO205 cells after 48 hrs by MTT assay
    Anticancer activity against human COLO205 cells after 48 hrs by MTT assay
    [PMID: 22209733]
    COLO 205 GI50
    14.7 μM
    Compound: ADR
    Anticancer activity against human COLO205 cells by SRB method
    Anticancer activity against human COLO205 cells by SRB method
    [PMID: 22104151]
    COLO 205 IC50
    2 μM
    Compound: ADR
    Cytotoxicity against human Colo205 cells by SRB assay
    Cytotoxicity against human Colo205 cells by SRB assay
    [PMID: 18656370]
    COLO 205 IC50
    2 μM
    Compound: ADR
    Cytotoxicity against human Colo205 cells by sulforhodamine B assay
    Cytotoxicity against human Colo205 cells by sulforhodamine B assay
    [PMID: 17822905]
    COLO 205 IC50
    2.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition by MTT assay
    [PMID: 34838335]
    COLO 205 IC50
    2.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    [PMID: 35293752]
    COLO 205 IC50
    3.8 μM
    Compound: DOX
    Cytotoxicity against human COLO205 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human COLO205 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    [PMID: 31589431]
    COLO 320 IC50
    7.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human COLO 320 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human COLO 320 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    [PMID: 35293752]
    COR-L23 IC50
    20.1 nM
    Compound: Doxorubicin
    Cytotoxicity measured using the COR-L23 parental (COR-L23/P) human non small cell lung carcinoma cell line
    Cytotoxicity measured using the COR-L23 parental (COR-L23/P) human non small cell lung carcinoma cell line
    [PMID: 11806724]
    COS-7 IC50
    2.05 μM
    Compound: Doxorubicin
    Cytotoxicity against African green monkey COS7 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against African green monkey COS7 cells assessed as reduction in cell viability by MTT assay
    [PMID: 31404864]
    COS-7 IC50
    3.04 μM
    Compound: Doxorubicin
    Growth inhibition of African green monkey COS7 cells by MTT assay
    Growth inhibition of African green monkey COS7 cells by MTT assay
    [PMID: 28147307]
    CRL-7065 cell line EC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human CRL7065 cells after 96 hrs by MTT assay
    Cytotoxicity against human CRL7065 cells after 96 hrs by MTT assay
    [PMID: 26320088]
    CWR22R IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human 22Rv1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against human 22Rv1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    [PMID: 34851111]
    CWR22R IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
    [PMID: 28617598]
    CWR22R IC50
    6.32 μM
    Compound: Doxorubicin
    Growth inhibition of human 22Rv1 cells after 48 hrs by MTT assay
    Growth inhibition of human 22Rv1 cells after 48 hrs by MTT assay
    [PMID: 30072225]
    DA-3 cell line IC50
    4 μM
    Compound: DOX
    Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay
    Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay
    [PMID: 24900668]
    Daoy GI50
    0.016 μM
    Compound: Doxorubicin
    Antiproliferative activity against human DaOY cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human DaOY cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 30360625]
    Daoy IC50
    0.0629 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Daoy cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human Daoy cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    [PMID: 34325324]
    Daoy IC50
    8.8 nM
    Compound: 5; Dox
    Cytotoxicity against human DaOY cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue cell viability assay
    Cytotoxicity against human DaOY cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue cell viability assay
    [PMID: 31347843]
    Daudi IC50
    0.127 μM
    Compound: Dox
    Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay
    Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay
    [PMID: 25998504]
    Daudi IC50
    0.3 μM
    Compound: adriamycin
    Cytotoxicity against human Daudi cells under deem light after 96 hrs by MTT assay
    Cytotoxicity against human Daudi cells under deem light after 96 hrs by MTT assay
    [PMID: 17993275]
    Detroit 562 IC50
    1.26 μM
    Compound: Doxorubicin
    Cytotoxicity against human Detroit 562 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    Cytotoxicity against human Detroit 562 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    [PMID: 30773423]
    DLD-1 ED50
    0.1 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human DLD1 cells after 3 days by MTT assay
    Cytotoxicity against human DLD1 cells after 3 days by MTT assay
    [PMID: 16252910]
    DLD-1 IC50
    0.1 μM
    Compound: adriamycin
    Antitumor activity against human DLD1 cells by methylene blue staining method
    Antitumor activity against human DLD1 cells by methylene blue staining method
    [PMID: 17656091]
    DLD-1 ED50
    0.57 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human DLD1 cells by MTT assay
    Cytotoxicity against human DLD1 cells by MTT assay
    [PMID: 15104488]
    DLD-1 IC50
    0.84 μM
    Compound: Dox
    Cytotoxicity against human DLD1 cells after 48 hrs by MTT assay
    Cytotoxicity against human DLD1 cells after 48 hrs by MTT assay
    [PMID: 25247771]
    DLD-1 IC50
    10.2 μM
    Compound: Doxorubicin
    Anticancer activity against human DLD-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Anticancer activity against human DLD-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    [PMID: 30772606]
    DLD-1 IC50
    145 nM
    Compound: Doxorubicin
    Cytotoxicity against human DLD1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human DLD1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    [PMID: 30429975]
    DLD-1 IC50
    2.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human DLD1 cells by Alamar Blue assay
    Cytotoxicity against human DLD1 cells by Alamar Blue assay
    [PMID: 27536968]
    DLD-1 IC50
    2.78 μM
    Compound: Doxorubicin
    Cytotoxicity against human DLD1 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human DLD1 cells after 72 hrs by alamar blue assay
    [PMID: 28159416]
    DLD-1 IC50
    2.78 μM
    Compound: Doxorubicin
    Cytotoxicity against human DLD1 cells by Alamar blue assay
    Cytotoxicity against human DLD1 cells by Alamar blue assay
    [PMID: 27256910]
    DU-145 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition of human DU145 cells after 48 hrs by SRB assay
    Growth inhibition of human DU145 cells after 48 hrs by SRB assay
    10.1039/C6MD00097E
    DU-145 GI50
    < 0.01 μM
    Compound: Doxorubicin
    Growth inhibition in human DU145 cells after 48 hrs by SRB assay
    Growth inhibition in human DU145 cells after 48 hrs by SRB assay
    [PMID: 31546197]
    DU-145 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against 10'5 CFU/mL human DU145 cells after 48 hrs by SRB assay
    Cytotoxicity against 10'5 CFU/mL human DU145 cells after 48 hrs by SRB assay
    [PMID: 21794959]
    DU-145 IC50
    < 2.94 μM
    Compound: Doxorubicin
    Inhibition of proliferation of human DU145 cells after 72 hrs by XTT assay
    Inhibition of proliferation of human DU145 cells after 72 hrs by XTT assay
    [PMID: 20810194]
    DU-145 IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as cell survival after 24 hrs by XTT assay
    Cytotoxicity against human DU145 cells assessed as cell survival after 24 hrs by XTT assay
    [PMID: 25059501]
    DU-145 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human DU145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human DU145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    [PMID: 25937235]
    DU-145 IC50
    0.051 μM
    Compound: DOX
    Cytotoxicity against human DU145 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human DU145 cells measured after 72 hrs by Celltiter-Glo assay
    [PMID: 31820976]
    DU-145 GI50
    0.06 μM
    Compound: Doxorubicin
    Growth inhibition of human DU145 cells after 72 hrs by SRB assay
    Growth inhibition of human DU145 cells after 72 hrs by SRB assay
    [PMID: 18585035]
    DU-145 IC50
    0.07 μM
    Compound: DOX
    Antiproliferative activity against human DU145 cells after 72 hrs by Sulforhodamine B-stain assay
    Antiproliferative activity against human DU145 cells after 72 hrs by Sulforhodamine B-stain assay
    [PMID: 27484508]
    DU-145 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    [PMID: 19361894]
    DU-145 GI50
    0.1081 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    [PMID: 31534659]
    DU-145 GI50
    0.11 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
    Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
    [PMID: 23871905]
    DU-145 GI50
    0.11 μM
    Compound: Doxorubicin
    Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 29102177]
    DU-145 GI50
    0.11 μM
    Compound: Doxorubicin
    Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28329730]
    DU-145 IC50
    0.12 μM
    Compound: Doxorubicin
    Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay
    [PMID: 25799376]
    DU-145 IC50
    0.13 μM
    Compound: doxorubicin
    Cytotoxicity against human DU145 cells by SRB microtiter plate assay
    Cytotoxicity against human DU145 cells by SRB microtiter plate assay
    [PMID: 17585747]
    DU-145 GI50
    0.134 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay
    [PMID: 31059248]
    DU-145 IC50
    0.153 μM
    Compound: Dox
    Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    [PMID: 30108718]
    DU-145 IC50
    0.2 μM
    Compound: DOX
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 23218718]
    DU-145 IC50
    0.2 μM
    Compound: DOX, Doxorubicin
    Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay
    [PMID: 24095089]
    DU-145 EC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 96 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 96 hrs by MTT assay
    [PMID: 26320088]
    DU-145 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU-145 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    Cytotoxicity against human DU-145 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    [PMID: 36970146]
    DU-145 GI50
    0.35 μM
    Compound: Doxorubicin
    Growth inhibition of human DU145 cells after 2 days by MTT assay
    Growth inhibition of human DU145 cells after 2 days by MTT assay
    [PMID: 20138760]
    DU-145 IC50
    0.363 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    [PMID: 30654238]
    DU-145 IC50
    0.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    [PMID: 30660827]
    DU-145 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25655719]
    DU-145 IC50
    0.52 μM
    Compound: adriamycin
    Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay
    Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay
    [PMID: 25936262]
    DU-145 IC50
    0.53 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 24530030]
    DU-145 IC50
    0.534 μM
    Compound: 1
    Cytotoxicity in human DU-145 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
    Cytotoxicity in human DU-145 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
    [PMID: 33064004]
    DU-145 IC50
    0.58 μM
    Compound: Doxo
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 21885273]
    DU-145 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells by MTT assay
    Cytotoxicity against human DU145 cells by MTT assay
    [PMID: 26586599]
    DU-145 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells by MTT assay
    Cytotoxicity against human DU145 cells by MTT assay
    [PMID: 25172418]
    DU-145 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells by MTT assay
    Cytotoxicity against human DU145 cells by MTT assay
    [PMID: 24300737]
    DU-145 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells incubated for 24 hrs by MTT asasy
    Cytotoxicity against human DU145 cells incubated for 24 hrs by MTT asasy
    [PMID: 28615134]
    DU-145 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition by MTT assay
    [PMID: 27187861]
    DU-145 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay
    [PMID: 26774921]
    DU-145 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay
    [PMID: 26646219]
    DU-145 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells by MTT assay
    Cytotoxicity against human DU145 cells by MTT assay
    [PMID: 25241926]
    DU-145 IC50
    0.86 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay
    Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay
    [PMID: 25481396]
    DU-145 IC50
    0.86 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 2 days
    Cytotoxicity against human DU145 cells after 2 days
    [PMID: 22318164]
    DU-145 IC50
    0.895 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 28462842]
    DU-145 IC50
    0.95 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 2 days by CCK8 assay
    Cytotoxicity against human DU145 cells after 2 days by CCK8 assay
    [PMID: 26361737]
    DU-145 GI50
    0.95 μM
    Compound: Doxorubicin
    Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay
    Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay
    [PMID: 26163220]
    DU-145 IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 2 days
    Cytotoxicity against human DU145 cells after 2 days
    [PMID: 21601964]
    DU-145 IC50
    1.08 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 26948541]
    DU-145 IC50
    1.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by XTT assay
    Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by XTT assay
    [PMID: 33540356]
    DU-145 IC50
    1.1 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis
    Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis
    [PMID: 22503656]
    DU-145 IC50
    1.3 μM
    Compound: Doxorubicin
    Anticancer activity against human DU145 cells after 48 hrs by MTT assay
    Anticancer activity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 25615796]
    DU-145 IC50
    1.38 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 26264845]
    DU-145 IC50
    1.4 μM
    Compound: Doxorubicin
    Anticancer activity against human DU-145 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Anticancer activity against human DU-145 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    [PMID: 34363936]
    DU-145 IC50
    1.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 27015609]
    DU-145 IC50
    1.428 μM
    Compound: Doxorubicin
    Anti-proliferative activity against human DU145 cells measured after 48 hrs by MTT assay
    Anti-proliferative activity against human DU145 cells measured after 48 hrs by MTT assay
    [PMID: 27744185]
    DU-145 IC50
    1.57 μM
    Compound: ADR
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    [PMID: 22819942]
    DU-145 IC50
    1.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    [PMID: 27496212]
    DU-145 IC50
    1.622 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 28482219]
    DU-145 IC50
    1.75 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells by MTT assay
    Cytotoxicity against human DU145 cells by MTT assay
    [PMID: 21115246]
    DU-145 IC50
    1.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay
    [PMID: 33421712]
    DU-145 IC50
    1.807 μM
    Compound: Doxorubicin
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 29501940]
    DU-145 IC50
    1.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 26708114]
    DU-145 IC50
    1.86 μM
    Compound: II
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 29289881]
    DU-145 IC50
    1.9 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 4 days by MTT assay
    Cytotoxicity against human DU145 cells after 4 days by MTT assay
    [PMID: 21704436]
    DU-145 IC50
    1.909 μM
    Compound: Doxorubicin
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 26301558]
    DU-145 IC50
    1.91 μM
    Compound: Doxorubicin
    Cytotoxicity in human DU145 cells incubated for 48 hrs by MTT assay
    Cytotoxicity in human DU145 cells incubated for 48 hrs by MTT assay
    [PMID: 28923381]
    DU-145 IC50
    1.94 μM
    Compound: Doxorubicin
    Anticancer activity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 26330077]
    DU-145 IC50
    10.86 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 22818039]
    DU-145 IC50
    12.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 21429743]
    DU-145 IC50
    13.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    [PMID: 22687747]
    DU-145 IC50
    17.67 μM
    Compound: Doxorubicin
    Anticancer activity against human DU145 cells by MTT assay
    Anticancer activity against human DU145 cells by MTT assay
    [PMID: 25743216]
    DU-145 IC50
    2.13 μM
    Compound: Doxo
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 29129513]
    DU-145 IC50
    2.4 μM
    Compound: Doxorubicin
    Anticancer activity against human DU145 cells by MTT assay
    Anticancer activity against human DU145 cells by MTT assay
    10.1039/C4MD00219A
    DU-145 IC50
    2.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    [PMID: 28818768]
    DU-145 IC50
    2.45 μM
    Compound: Doxo (I)
    Antiproliferative activity against human DU145 cells by MTT assay
    Antiproliferative activity against human DU145 cells by MTT assay
    10.1039/C4MD00228H
    DU-145 IC50
    2.49 μM
    Compound: Doxorubicin
    Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 26542964]
    DU-145 IC50
    2.54 μM
    Compound: DOX
    Antiproliferative activity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Antiproliferative activity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    [PMID: 32631552]
    DU-145 IC50
    2.68 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay
    Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay
    [PMID: 24013413]
    DU-145 IC50
    23.48 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    [PMID: 22276650]
    DU-145 IC50
    3.11 μM
    Compound: Doxorubicin
    Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31883489]
    DU-145 IC50
    3.11 μM
    Compound: DOX
    Cytotoxicity against human DU145 cells after 48 hrs by SRB method
    Cytotoxicity against human DU145 cells after 48 hrs by SRB method
    [PMID: 25933593]
    DU-145 IC50
    3.27 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 72 hrs by XTT assay
    Cytotoxicity against human DU145 cells after 72 hrs by XTT assay
    10.1007/s00044-013-0558-8
    DU-145 IC50
    3.9 nM
    Compound: doxorubicin
    Anticancer activity against human DU145 cells after 72 hrs by XTT assay
    Anticancer activity against human DU145 cells after 72 hrs by XTT assay
    [PMID: 18829316]
    DU-145 IC50
    4.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 25462233]
    DU-145 IC50
    4.75 μM
    Compound: Doxorubicin
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 26907155]
    DU-145 IC50
    4.8 μM
    Compound: DOX
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    [PMID: 31589431]
    DU-145 IC50
    4.88 μM
    Compound: Dox
    Cytotoxicity against human DU145 cells after 2 days
    Cytotoxicity against human DU145 cells after 2 days
    [PMID: 24904965]
    DU-145 IC50
    5.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25594739]
    DU-145 IC50
    5.4 μM
    Compound: DX
    Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay
    10.1039/C5MD00513B
    DU-145 IC50
    5.8 μM
    Compound: DXR
    Cytotoxicity against human androgen-independent DU145 cells by MTT assay
    Cytotoxicity against human androgen-independent DU145 cells by MTT assay
    [PMID: 22326399]
    DU-145 IC50
    6 μM
    Compound: doxorubicin
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 23748152]
    DU-145 IC50
    6.24 μM
    Compound: Doxo
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    [PMID: 21885273]
    DU-145 IC50
    8.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 24607876]
    EA.hy 926 IC50
    4.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 27843113]
    EBC-1 IC50
    305.1 nM
    Compound: Doxorubicin
    Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay
    Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay
    [PMID: 28412159]
    ECa-109 cell line IC50
    2.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human ECa-109 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human ECa-109 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 32866757]
    Ehrlich IC50
    > 10 μM
    Compound: doxorubicin
    Cytotoxicity against mouse Ehrlich ascites carcinoma cells after 24 hrs by MTT assay
    Cytotoxicity against mouse Ehrlich ascites carcinoma cells after 24 hrs by MTT assay
    [PMID: 18281125]
    Ehrlich IC50
    > 10 μM
    Compound: doxorubicin
    Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay
    Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay
    [PMID: 17400463]
    Ehrlich IC50
    0.35 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse EAC after 3 days by MTT assay
    Cytotoxicity against mouse EAC after 3 days by MTT assay
    [PMID: 8350087]
    Ehrlich IC50
    37.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against mouse EAC cells assessed as cell growth inhibition measured after 2 hrs by trypan blue exclusion assay
    Cytotoxicity against mouse EAC cells assessed as cell growth inhibition measured after 2 hrs by trypan blue exclusion assay
    [PMID: 27894044]
    Ehrlich IC50
    37.5 μg/mL
    Compound: Doxorubicin
    Antitumor activity against mouse EAC cells assessed as non viable cells after 2 hrs by trypan blue exclusion test
    Antitumor activity against mouse EAC cells assessed as non viable cells after 2 hrs by trypan blue exclusion test
    [PMID: 20149941]
    Ehrlich IC50
    38 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against mouse EAC assessed as non-viable cells after 2 hrs by trypan blue exclusion test
    Cytotoxicity against mouse EAC assessed as non-viable cells after 2 hrs by trypan blue exclusion test
    [PMID: 21112675]
    Ehrlich IC50
    38 μg/mL
    Compound: doxorubicin
    Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion
    Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion
    [PMID: 19944497]
    Ehrlich IC50
    4.18 μM
    Compound: doxorubicin
    Cytotoxicity against mouse EAC after 24 hrs by MTT assay
    Cytotoxicity against mouse EAC after 24 hrs by MTT assay
    [PMID: 19128861]
    Ehrlich IC50
    5.22 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay
    Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay
    [PMID: 22542958]
    Ehrlich IC50
    52 μg/mL
    Compound: Doxorubicin
    Antitumor activity against mouse EAC after 2 hrs by trypan blue exclusion assay
    Antitumor activity against mouse EAC after 2 hrs by trypan blue exclusion assay
    [PMID: 19853327]
    Ehrlich IC50
    69.9 μM
    Compound: Doxorubicin
    Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion assay
    Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion assay
    [PMID: 20413187]
    EKVX GI50
    0.41 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human EKVX cells after 48 hrs by SRB assay
    Cytotoxicity against human EKVX cells after 48 hrs by SRB assay
    [PMID: 23871905]
    EKVX GI50
    0.41 μM
    Compound: Doxorubicin
    Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 29102177]
    EKVX GI50
    0.41 μM
    Compound: Doxorubicin
    Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28329730]
    EL4 IC50
    0.67 μg/mL
    Compound: (20) adriamycin
    In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay
    In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay
    [PMID: 12620075]
    EMT6 ED50
    < 0.0001 μM
    Compound: Adriamycin
    Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition.
    Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition.
    [PMID: 7452674]
    EMT6 ED50
    0.012 μM
    Compound: Adriamycin
    Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition.
    Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition.
    [PMID: 7452674]
    EOL1 IC50
    0.001269 μM
    Compound: Doxorubicin
    Antiproliferative activity against human EOL1 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay
    Antiproliferative activity against human EOL1 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay
    [PMID: 30540463]
    Epithelial cell IC50
    9.787 nM
    Compound: Doxorubicin
    Cytotoxicity against albino rat epithelial rat by MTT assay
    Cytotoxicity against albino rat epithelial rat by MTT assay
    [PMID: 34116327]
    Erythrocyte EC50
    > 200 μg/mL
    Compound: Dox
    Hemolytic toxicity in mouse erythrocytes assessed as induction of cell membrane disruption incubated for 30 mins by hemoglobin release based spectrophotometry
    Hemolytic toxicity in mouse erythrocytes assessed as induction of cell membrane disruption incubated for 30 mins by hemoglobin release based spectrophotometry
    [PMID: 25147145]
    Erythrocyte EC50
    > 50 μg/mL
    Compound: DOXO
    Toxicity in mouse erythrocytes assessed as hemolytic activity after 30 mins by spectrophotometry
    Toxicity in mouse erythrocytes assessed as hemolytic activity after 30 mins by spectrophotometry
    [PMID: 19947600]
    F460pv8/eto IC50
    0.02 μM
    Compound: Doxorubicin
    Inhibitory activity against F460pv8/eto cell line using MTT assay
    Inhibitory activity against F460pv8/eto cell line using MTT assay
    [PMID: 10780913]
    FaDu IC50
    0.16 μM
    Compound: DOX
    Antiproliferative activity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 36709571]
    FaDu IC50
    0.68 μM
    Compound: Doxorubicin
    Cytotoxicity against human FADU cells assessed as reduction in cell viability after 4 hrs by MTT assay
    Cytotoxicity against human FADU cells assessed as reduction in cell viability after 4 hrs by MTT assay
    [PMID: 30773423]
    Fibroblast IC50
    0.005 μM
    Compound: Doxorubicin
    Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay
    Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay
    [PMID: 30655216]
    Fibroblast IC50
    0.015 μM
    Compound: Doxorubicine
    Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    [PMID: 33422908]
    Fibroblast IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human skin fibroblast cells assessed as reduction in cell viability after 48 hrs
    Cytotoxicity against human skin fibroblast cells assessed as reduction in cell viability after 48 hrs
    [PMID: 34601029]
    Fibroblast IC50
    0.03 μM
    Compound: Doxorubicin
    Toxicity in human skin fibroblasts assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    Toxicity in human skin fibroblasts assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    [PMID: 31753515]
    Fibroblast IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity in human Fibroblast cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human Fibroblast cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 34082225]
    Fibroblast IC50
    1.3 x 10-11 μM
    Compound: Doxo
    Cytotoxicity against human gingival fibroblast cells after 48 hrs by alamar blue assay
    Cytotoxicity against human gingival fibroblast cells after 48 hrs by alamar blue assay
    [PMID: 25468043]
    Fibroblast IC50
    67 μM
    Compound: Doxorubicin
    Cytotoxicity against fibroblast (unknown origin) cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
    Cytotoxicity against fibroblast (unknown origin) cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
    [PMID: 36691388]
    Fibroblast IC50
    7.86 μM
    Compound: Doxorubicin
    Antiproliferative activity against human dermal fibroblast cells after 72 hrs
    Antiproliferative activity against human dermal fibroblast cells after 72 hrs
    [PMID: 25127463]
    G-361 GI50
    < 1 x 10-1 μM
    Compound: ADR
    Cytotoxicity against Homo sapiens (human) G361 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) G361 cells by SRB assay
    10.1007/s00044-012-0084-0
    G-361 IC50
    0.09 μM
    Compound: Doxo
    Antiproliferative activity against human G-361 cells assessed as cell viability measured after 4 days by MTT assay
    Antiproliferative activity against human G-361 cells assessed as cell viability measured after 4 days by MTT assay
    [PMID: 31869654]
    G-361 IC50
    0.09 μM
    Compound: doxo
    Antiproliferative activity against human G361 cell line by MTT assay
    Antiproliferative activity against human G361 cell line by MTT assay
    [PMID: 16913700]
    GES1 IC50
    0.53 μM
    Compound: ADM
    Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay
    Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay
    [PMID: 25462264]
    GOTO IC50
    4.73 nM
    Compound: Doxorubicin
    Cytotoxicity against human GOTO cells after 3 days by MTT assay
    Cytotoxicity against human GOTO cells after 3 days by MTT assay
    [PMID: 20356655]
    GOTO IC50
    4.73 nM
    Compound: Doxorubicin
    Cytotoxicity against human GOTO cells by MTT assay
    Cytotoxicity against human GOTO cells by MTT assay
    [PMID: 19345581]
    H22 IC50
    36.51 μM
    Compound: Doxorubicin
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    [PMID: 21620529]
    H69AR IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human NCI-H69AR cells assessed as reduction in cell growth by MTT assay
    Cytotoxicity against human NCI-H69AR cells assessed as reduction in cell growth by MTT assay
    [PMID: 36734533]
    HA22T cell line IC50
    0.31 μM
    Compound: adriamycin
    Cytotoxicity against human HA22T cells after 72 hrs by MTT assay
    Cytotoxicity against human HA22T cells after 72 hrs by MTT assay
    [PMID: 17107806]
    HaCaT GI50
    < 0.025 μg/mL
    Compound: DOX; Doxo
    Cytotoxicity against human HaCaT cells after 48 hrs by SRB assay
    Cytotoxicity against human HaCaT cells after 48 hrs by SRB assay
    [PMID: 26859070]
    HaCaT GI50
    < 0.046 μM
    Compound: Dox
    Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by SRB assay
    [PMID: 26454648]
    HaCaT GI50
    < 0.046 μM
    Compound: Doxorubicin
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
    [PMID: 33214037]
    HaCaT IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 4 days by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 4 days by CellTiter 96 aqueous one solution assay
    [PMID: 31596585]
    HaCaT IC50
    0.03 μM
    Compound: Dox
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 30615450]
    HaCaT IC50
    0.03 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay
    Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay
    [PMID: 30655216]
    HaCaT GI50
    0.11 μg/mL
    Compound: DOX
    Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    [PMID: 25062010]
    HaCaT GI50
    0.2 μM
    Compound: Dox
    Growth inhibition of human HaCaT cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    Growth inhibition of human HaCaT cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
    [PMID: 28505535]
    HaCaT IC50
    0.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    [PMID: 31753514]
    HaCaT IC50
    0.235 μM
    Compound: Doxorubicin
    Cytotoxicity against human HaCaT cells assessed as growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as growth inhibition measured after 72 hrs by MTT assay
    [PMID: 31383628]
    HaCaT IC50
    0.29 μM
    Compound: DOX
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 31678743]
    HaCaT IC50
    0.52 μM
    Compound: Doxorubicin
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 30389295]
    HaCaT IC50
    0.53 μM
    Compound: Doxorubicin
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    [PMID: 26934105]
    HaCaT GI50
    0.64 μM
    Compound: Dox
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    [PMID: 35533562]
    HaCaT GI50
    0.9 μM
    Compound: Dox
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    [PMID: 34634616]
    HaCaT GI50
    0.9 μM
    Compound: Dox
    Antiproliferative activity against human HaCaT cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human HaCaT cells incubated for 72 hrs and measured by MTT assay
    [PMID: 35973342]
    HaCaT IC50
    1.09 μM
    Compound: Dox
    Cytotoxicity activity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity activity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 30031974]
    HaCaT IC50
    3.26 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HaCaT cells assessed as cell shrinkage after 24 hrs by SRB assay
    Cytotoxicity against human HaCaT cells assessed as cell shrinkage after 24 hrs by SRB assay
    [PMID: 24269165]
    HaCaT IC50
    50 μM
    Compound: Doxorubicin
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
    Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
    [PMID: 35271771]
    HBL-100 IC50
    0.08 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HBL100 cells after 70 hrs by alamar blue assay
    Antiproliferative activity against human HBL100 cells after 70 hrs by alamar blue assay
    [PMID: 29471119]
    HBL-100 IC50
    0.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay
    Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay
    [PMID: 19361894]
    HBL-100 IC50
    8.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HBL100 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay
    Cytotoxicity against human HBL100 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay
    [PMID: 29471119]
    HCC 2998 GI50
    0.26 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human HCC2998 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCC2998 cells after 48 hrs by SRB assay
    [PMID: 23871905]
    HCC 2998 GI50
    0.26 μM
    Compound: Doxorubicin
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 29102177]
    HCC 2998 GI50
    0.26 μM
    Compound: Doxorubicin
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28329730]
    HCC1937 IC50
    0.44 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCC1937 cells after 48 hrs by SRB assay
    Antiproliferative activity against human HCC1937 cells after 48 hrs by SRB assay
    [PMID: 29407962]
    HCC1954 IC50
    0.045 μM
    Compound: DOX
    Cytotoxicity against human HCC1954 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human HCC1954 cells measured after 72 hrs by Celltiter-Glo assay
    [PMID: 31820976]
    HCC70 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCC70 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human HCC70 cells assessed as growth inhibition after 72 hrs by SRB assay
    [PMID: 30457333]
    HCT-116 GI50
    < 1 μM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells by MTT assay
    Antiproliferative activity against human HCT116 cells by MTT assay
    [PMID: 31990554]
    HCT-116 IC50
    < 1 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT-116 cells by SRB assay
    Cytotoxicity against human HCT-116 cells by SRB assay
    [PMID: 33847126]
    HCT-116 IC50
    > 8 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    [PMID: 31836446]
    HCT-116 IC50
    0.007 ug
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by SRB assay
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by SRB assay
    [PMID: 27393950]
    HCT-116 IC50
    0.007 μM
    Compound: DOX
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 27668963]
    HCT-116 IC50
    0.01 μM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells measured after 72 hrs by MTT assay
    [PMID: 31431364]
    HCT-116 GI50
    0.011 μM
    Compound: Doxorubicin
    Cytostatic activity against human HCT116 cells after 5 days by SRB assay
    Cytostatic activity against human HCT116 cells after 5 days by SRB assay
    [PMID: 21711054]
    HCT-116 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    10.1039/C4MD00371C
    HCT-116 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 24530030]
    HCT-116 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    [PMID: 25937235]
    HCT-116 IC50
    0.023 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 31264855]
    HCT-116 GI50
    0.023 μM
    Compound: Doxorubicin
    Tested for in vitro concentration required to inhibit growth by 50% against HCT116 human colon cancer cell line
    Tested for in vitro concentration required to inhibit growth by 50% against HCT116 human colon cancer cell line
    [PMID: 11755363]
    HCT-116 IC50
    0.037 μM
    Compound: adriamycin
    Antitumor activity against human HCT116 cells by methylene blue staining method
    Antitumor activity against human HCT116 cells by methylene blue staining method
    [PMID: 17656091]
    HCT-116 IC50
    0.05 μM
    Compound: Doxorubicine
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
    [PMID: 33422908]
    HCT-116 IC50
    0.05 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay
    [PMID: 30655216]
    HCT-116 IC50
    0.069 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 25462279]
    HCT-116 IC50
    0.07 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    [PMID: 27060757]
    HCT-116 IC50
    0.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    [PMID: 20846862]
    HCT-116 IC50
    0.07 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 27448912]
    HCT-116 IC50
    0.07 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 24780599]
    HCT-116 GI50
    0.08 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
    [PMID: 23871905]
    HCT-116 GI50
    0.08 μM
    Compound: Doxorubicin
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 29102177]
    HCT-116 GI50
    0.08 μM
    Compound: Doxorubicin
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28329730]
    HCT-116 IC50
    0.08 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs
    [PMID: 34601029]
    HCT-116 IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    [PMID: 21215623]
    HCT-116 IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
    [PMID: 32755677]
    HCT-116 IC50
    0.1 mM
    Compound: Dox
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 29459273]
    HCT-116 IC50
    0.1 μM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay
    [PMID: 31784322]
    HCT-116 IC50
    0.1 μM
    Compound: DOX
    Cytotoxicity against human HCT116 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human HCT116 cells measured after 72 hrs by Celltiter-Glo assay
    [PMID: 31820976]
    HCT-116 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 34082225]
    HCT-116 IC50
    0.1 μM
    Compound: Dox
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 30659997]
    HCT-116 IC50
    0.1 μM
    Compound: 5
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 29137865]
    HCT-116 IC50
    0.1 μM
    Compound: 1; Dox
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 26890118]
    HCT-116 IC50
    0.1 μM
    Compound: DOX
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 27016707]
    HCT-116 IC50
    0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT reduction assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT reduction assay
    [PMID: 28551177]
    HCT-116 IC50
    0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
    [PMID: 25937235]
    HCT-116 IC50
    0.11 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    [PMID: 31836446]
    HCT-116 IC50
    0.11 μM
    Compound: 1; Dox
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 26633734]
    HCT-116 IC50
    0.11 μM
    Compound: Dox
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 21144624]
    HCT-116 IC50
    0.12 μM
    Compound: Doxorubicin
    Toxicity in human HCT-116 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    Toxicity in human HCT-116 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
    [PMID: 31753515]
    HCT-116 GI50
    0.13 μM
    Compound: Doxorubicine
    Growth inhibition of human HCT116 cells after 2 days by sulforhodamine B assay
    Growth inhibition of human HCT116 cells after 2 days by sulforhodamine B assay
    [PMID: 20045222]
    HCT-116 IC50
    0.15 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 27341379]
    HCT-116 IC50
    0.15 μM
    Compound: DOXO
    Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 26142490]
    HCT-116 GI50
    0.15 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 24686011]
    HCT-116 GI50
    0.15 μM
    Compound: Adriamycin
    Growth inhibition of human HCT116 cells by sulforhodamine B assay
    Growth inhibition of human HCT116 cells by sulforhodamine B assay
    [PMID: 24650643]
    HCT-116 EC50
    0.16 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 35567964]
    HCT-116 IC50
    0.16 μM
    Compound: Dx
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    [PMID: 21444205]
    HCT-116 IC50
    0.18 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
    [PMID: 26280922]
    HCT-116 IC50
    0.18 μM
    Compound: Dox
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 25998504]
    HCT-116 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxic activity against human HCT116 cells incubated for 48 hrs by MTT assay
    Cytotoxic activity against human HCT116 cells incubated for 48 hrs by MTT assay
    [PMID: 28055219]
    HCT-116 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    [PMID: 36044031]
    HCT-116 IC50
    0.2 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    [PMID: 32428792]
    HCT-116 IC50
    0.2 μM
    Compound: ADM
    Cytotoxicity against human HCT116 cells by SRB method
    Cytotoxicity against human HCT116 cells by SRB method
    [PMID: 29144133]
    HCT-116 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells by SRB assay
    Cytotoxicity against human HCT116 cells by SRB assay
    [PMID: 26561719]
    HCT-116 IC50
    0.2 μM
    Compound: ADM
    Cytotoxic activity against human HCT116 cells by SRB method
    Cytotoxic activity against human HCT116 cells by SRB method
    [PMID: 25611519]
    HCT-116 IC50
    0.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    [PMID: 34778772]
    HCT-116 IC50
    0.21 μM
    Compound: Dox
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 33479619]
    HCT-116 IC50
    0.21 μM
    Compound: DOX
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 29660689]
    HCT-116 IC50
    0.21 μM
    Compound: DOXO
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 28818447]
    HCT-116 IC50
    0.21 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 24370114]
    HCT-116 IC50
    0.22 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    [PMID: 31836446]
    HCT-116 IC50
    0.221 μM
    Compound: Dox
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    [PMID: 30108718]
    HCT-116 IC50
    0.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as growth inhibition by MTT assay
    Cytotoxicity against human HCT116 cells assessed as growth inhibition by MTT assay
    [PMID: 24398294]
    HCT-116 IC50
    0.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 48 hrs by neutral red dye based assay
    Cytotoxicity against human HCT116 cells after 48 hrs by neutral red dye based assay
    [PMID: 29317147]
    HCT-116 IC50
    0.25 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells incubated for 48 hrs by WST8 assay
    Antiproliferative activity against human HCT116 cells incubated for 48 hrs by WST8 assay
    [PMID: 31679979]
    HCT-116 IC50
    0.25 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 48 hrs by WST8 assay
    Cytotoxicity against human HCT116 cells after 48 hrs by WST8 assay
    [PMID: 25163667]
    HCT-116 IC50
    0.27 μM
    Compound: DOX
    Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31999451]
    HCT-116 IC50
    0.286 μg/mL
    Compound: DOX
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 20722446]
    HCT-116 IC50
    0.29 μM
    Compound: DOX
    Antiproliferative activity against doxorubicin sensitive human HCT-116 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against doxorubicin sensitive human HCT-116 cells measured after 72 hrs by MTT assay
    [PMID: 35612499]
    HCT-116 EC50
    0.29 μM
    Compound: Doxorubicin
    Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs
    Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs
    [PMID: 19282188]
    HCT-116 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
    Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
    [PMID: 31403289]
    HCT-116 IC50
    0.3 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116 assessed as growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 assessed as growth inhibition measured after 72 hrs by MTT assay
    [PMID: 34902732]
    HCT-116 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 22749279]
    HCT-116 IC50
    0.31 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 28327308]
    HCT-116 IC50
    0.31 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 27886545]
    HCT-116 IC50
    0.33 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as effect on cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as effect on cell viability measured after 48 hrs by MTT assay
    [PMID: 27521588]
    HCT-116 IC50
    0.34 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    [PMID: 33261897]
    HCT-116 IC50
    0.34 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT 116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    Antiproliferative activity against human HCT 116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
    [PMID: 31962262]
    HCT-116 IC50
    0.34 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells expressing wild type p53 incubated for 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells expressing wild type p53 incubated for 72 hrs by MTS assay
    [PMID: 31158748]
    HCT-116 IC50
    0.34 μM
    Compound: DOXO
    Antiproliferative activity against p53 expressing human HCT116 cells after 96 hrs by MTS assay
    Antiproliferative activity against p53 expressing human HCT116 cells after 96 hrs by MTS assay
    [PMID: 26890119]
    HCT-116 IC50
    0.34 μM
    Compound: Dox
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    [PMID: 25247771]
    HCT-116 IC50
    0.34 μM
    Compound: DOX
    Cytotoxicity against human HCT-116 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
    [PMID: 35612499]
    HCT-116 IC50
    0.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    [PMID: 27080182]
    HCT-116 IC50
    0.38 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells deficient in p53 incubated for 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells deficient in p53 incubated for 72 hrs by MTS assay
    [PMID: 31158748]
    HCT-116 IC50
    0.38 μM
    Compound: DOXO
    Antiproliferative activity against p53 deficient human HCT116 cells after 96 hrs by MTS assay
    Antiproliferative activity against p53 deficient human HCT116 cells after 96 hrs by MTS assay
    [PMID: 26890119]
    HCT-116 IC50
    0.38 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by SRB assay
    Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by SRB assay
    [PMID: 26947606]
    HCT-116 GI50
    0.4 μM
    Compound: Doxorubicin
    Growth inhibition of human HCT116 cells after 2 days by MTT assay
    Growth inhibition of human HCT116 cells after 2 days by MTT assay
    [PMID: 20570145]
    HCT-116 IC50
    0.4 μM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 30429098]
    HCT-116 IC50
    0.4 μM
    Compound: Dox
    Cytotoxicity against human HCT116 cells by MTT assay
    Cytotoxicity against human HCT116 cells by MTT assay
    [PMID: 21983438]
    HCT-116 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    10.1039/C0MD00219D
    HCT-116 IC50
    0.41 μM
    Compound: adriamycin
    Cytotoxicity against human HCT116 cells by MTT assay
    Cytotoxicity against human HCT116 cells by MTT assay
    [PMID: 17125240]
    HCT-116 IC50
    0.467 μM
    Compound: Doxorubicin
    Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay
    Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay
    [PMID: 35694689]
    HCT-116 IC50
    0.477 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 25703298]
    HCT-116 IC50
    0.48 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 30783501]
    HCT-116 IC50
    0.48 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 p53+/+ cells assessed as reduction in cell viability after 72 hrs by RRA assay
    Cytotoxicity against human HCT-116 p53+/+ cells assessed as reduction in cell viability after 72 hrs by RRA assay
    [PMID: 33508467]
    HCT-116 IC50
    0.5 mM
    Compound: Dox
    Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
    [PMID: 29459273]
    HCT-116 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as reduction in cell survival after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell survival after 48 hrs by MTT assay
    [PMID: 28494255]
    HCT-116 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    [PMID: 33668008]
    HCT-116 IC50
    0.5 μM
    Compound: 5
    Antiproliferative activity against p53 deficient human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against p53 deficient human HCT116 cells after 72 hrs by MTT assay
    [PMID: 29137865]
    HCT-116 IC50
    0.5 μM
    Compound: 1; Dox
    Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
    [PMID: 26890118]
    HCT-116 GI50
    0.5 μM
    Compound: Dox
    Antiproliferative activity against p53-deficient human HCT-116 cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against p53-deficient human HCT-116 cells incubated for 72 hrs and measured by MTT assay
    [PMID: 35973342]
    HCT-116 IC50
    0.5 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay
    [PMID: 26222449]
    HCT-116 IC50
    0.52 μM
    Compound: Dox
    Cytotoxicity against human p53 knockout HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human p53 knockout HCT116 cells after 72 hrs by MTT assay
    [PMID: 21144624]
    HCT-116 IC50
    0.55 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31546197]
    HCT-116 GI50
    0.57 μM
    Compound: Dox
    Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    [PMID: 35533562]
    HCT-116 IC50
    0.579 μM
    Compound: 1
    Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
    Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
    [PMID: 33064004]
    HCT-116 GI50
    0.6 μM
    Compound: Dox
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    [PMID: 34634616]
    HCT-116 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against p53 knock out human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against p53 knock out human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 34082225]
    HCT-116 IC50
    0.6 μM
    Compound: Dox
    Cytotoxicity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
    [PMID: 30659997]
    HCT-116 IC50
    0.62 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT116 cells by SRB assay
    Cytotoxicity against human HCT116 cells by SRB assay
    [PMID: 17194596]
    HCT-116 IC50
    0.63 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    [PMID: 23291120]
    HCT-116 IC50
    0.65 μg/mL
    Compound: Dox
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    [PMID: 20399544]
    HCT-116 IC50
    0.7 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116 cells with inactivated p53 gene assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells with inactivated p53 gene assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    [PMID: 32428792]
    HCT-116 IC50
    0.74 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 26874404]
    HCT-116 GI50
    0.76 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by MTT assay
    [PMID: 35973342]
    HCT-116 IC50
    0.79 μM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
    [PMID: 29597166]
    HCT-116 IC50
    0.8 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116p53KO subline assessed as growth inhibition measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116p53KO subline assessed as growth inhibition measured after 72 hrs by MTT assay
    [PMID: 34902732]
    HCT-116 IC50
    0.87 μM
    Compound: DOX
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 35341920]
    HCT-116 IC50
    1.01 μM
    Compound: Doxorubicin
    Cytotoxicity in human HCT116 cells incubated for 48 hrs by MTT assay
    Cytotoxicity in human HCT116 cells incubated for 48 hrs by MTT assay
    [PMID: 28923381]
    HCT-116 IC50
    1.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    [PMID: 28554092]
    HCT-116 IC50
    1.1 μM
    Compound: DOX
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTT assay
    [PMID: 34323485]
    HCT-116 IC50
    1.19 μM
    Compound: Dox
    Anticancer activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by SRB assay
    Anticancer activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by SRB assay
    10.1007/s00044-012-0057-3
    HCT-116 IC50
    1.23 μM
    Compound: Doxorubicin
    Antiproliferative activity against p53-deficient human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against p53-deficient human HCT116 cells after 48 hrs by MTT assay
    [PMID: 28554092]
    HCT-116 IC50
    1.3 μg/mL
    Compound: Doxorubicin, Adriablastina
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B method
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B method
    [PMID: 21664013]
    HCT-116 IC50
    1.38 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells by MTT assay
    Cytotoxicity against human HCT116 cells by MTT assay
    [PMID: 24182355]
    HCT-116 IC50
    1.4 μM
    Compound: 1, DOX
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 25244612]
    HCT-116 IC50
    1.4 μM
    Compound: I
    Antiproliferative activity against human HCT116 cells expressing wild-type p53 after 72 hrs by MTT test
    Antiproliferative activity against human HCT116 cells expressing wild-type p53 after 72 hrs by MTT test
    [PMID: 17276690]
    HCT-116 IC50
    1.6 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells by MTT assay
    Cytotoxicity against human HCT-116 cells by MTT assay
    [PMID: 36325400]
    HCT-116 IC50
    1.78 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 p53-/- cells assessed as reduction in cell viability after 72 hrs by RRA assay
    Cytotoxicity against human HCT-116 p53-/- cells assessed as reduction in cell viability after 72 hrs by RRA assay
    [PMID: 33508467]
    HCT-116 IC50
    1.878 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    [PMID: 36240546]
    HCT-116 IC50
    1.96 μM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
    [PMID: 30245395]
    HCT-116 IC50
    1.96 μM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells harboring PI3Kalpha H1047R mutant after 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT116 cells harboring PI3Kalpha H1047R mutant after 72 hrs by CCK8 assay
    [PMID: 30071408]
    HCT-116 IC50
    1.96 μM
    Compound: DOX
    Cytotoxicity against against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 30340899]
    HCT-116 IC50
    19.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay
    [PMID: 32771798]
    HCT-116 IC50
    19.9 nM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 72 hrs by cell counting Kit-8 assay
    Cytotoxicity against human HCT116 cells after 72 hrs by cell counting Kit-8 assay
    [PMID: 25499433]
    HCT-116 IC50
    2.05 μM
    Compound: DOX
    Antiproliferative activity against doxorubicin resistant human HCT-116 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against doxorubicin resistant human HCT-116 cells measured after 72 hrs by MTT assay
    [PMID: 35612499]
    HCT-116 IC50
    2.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 24 hrs by WST assay
    Cytotoxicity against human HCT116 cells after 24 hrs by WST assay
    [PMID: 25881821]
    HCT-116 IC50
    2.38 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells by WST-8 assay
    Cytotoxicity against human HCT116 cells by WST-8 assay
    [PMID: 29295796]
    HCT-116 IC50
    2.4 μM
    Compound: Doxorubicin
    Anticancer activity against human HCT-116 cells by MTT assay
    Anticancer activity against human HCT-116 cells by MTT assay
    [PMID: 33421712]
    HCT-116 IC50
    2.56 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
    10.1007/s00044-013-0795-x
    HCT-116 IC50
    2.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
    [PMID: 31200236]
    HCT-116 GI50
    21.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay
    [PMID: 27614919]
    HCT-116 IC50
    22 nM
    Compound: doxorubicine
    Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay
    [PMID: 23072299]
    HCT-116 IC50
    22 nM
    Compound: Doxorubicine
    Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
    [PMID: 21142180]
    HCT-116 IC50
    3.29 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs
    [PMID: 34530384]
    HCT-116 IC50
    3.3 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 24 hrs by MTS assay
    Antiproliferative activity against human HCT116 cells after 24 hrs by MTS assay
    [PMID: 20813435]
    HCT-116 IC50
    3.36 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    [PMID: 34973507]
    HCT-116 IC50
    3.7 μM
    Compound: Dox
    Cytotoxicity against human HCT116 cells assessed as cell viability after 24 hrs by crystal violet staining assay
    Cytotoxicity against human HCT116 cells assessed as cell viability after 24 hrs by crystal violet staining assay
    [PMID: 26706352]
    HCT-116 IC50
    3.73 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    [PMID: 21723735]
    HCT-116 IC50
    366 nM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    [PMID: 30878835]
    HCT-116 IC50
    4.4 μM
    Compound: 1, DOX
    Antiproliferative activity against p53-deficient human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against p53-deficient human HCT116 cells after 72 hrs by MTT assay
    [PMID: 25244612]
    HCT-116 IC50
    4.4 μM
    Compound: I
    Antiproliferative activity against human p53 deficient HCT116 p53-/- cells after 72 hrs by MTT test
    Antiproliferative activity against human p53 deficient HCT116 p53-/- cells after 72 hrs by MTT test
    [PMID: 17276690]
    HCT-116 IC50
    4.8 μM
    Compound: Doxorubicin
    Anticancer activity against human HCT116 cells measured after 48 hrs by SRB assay
    Anticancer activity against human HCT116 cells measured after 48 hrs by SRB assay
    [PMID: 27112448]
    HCT-116 IC50
    49.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
    [PMID: 35271771]
    HCT-116 IC50
    5 mM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    [PMID: 23685942]
    HCT-116 IC50
    5 mM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    [PMID: 22440624]
    HCT-116 IC50
    5.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 34530384]
    HCT-116 IC50
    5.23 μM
    Compound: DOX
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    [PMID: 37054758]
    HCT-116 IC50
    5.23 μM
    Compound: DOX
    Anticancer activity against human HCT116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Anticancer activity against human HCT116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    [PMID: 32085964]
    HCT-116 IC50
    5.23 μM
    Compound: DOX
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    [PMID: 30015070]
    HCT-116 IC50
    5.23 μM
    Compound: DOX
    Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    [PMID: 36242988]
    HCT-116 IC50
    5.23 μM
    Compound: Dox
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 32527460]
    HCT-116 IC50
    5.23 μM
    Compound: DOX
    Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay
    [PMID: 35964425]
    HCT-116 IC50
    5.23 μM
    Compound: Dox
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 34126285]
    HCT-116 IC50
    5.23 μM
    Compound: Doxorubicin
    Antitumor activity against human HCT-116 cells assessed as inhibition of cell viability by MTT assay
    Antitumor activity against human HCT-116 cells assessed as inhibition of cell viability by MTT assay
    [PMID: 33065442]
    HCT-116 IC50
    5.23 μM
    Compound: DOX
    Antiproliferative activity against human HCT116 cells by MTT assay
    Antiproliferative activity against human HCT116 cells by MTT assay
    [PMID: 30216848]
    HCT-116 IC50
    5.95 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 24 to 96 hrs by MTS assay
    Cytotoxicity against human HCT116 cells after 24 to 96 hrs by MTS assay
    [PMID: 20303768]
    HCT-116 IC50
    56.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay
    [PMID: 33016067]
    HCT-116 IC50
    57.77 nM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay
    [PMID: 34795858]
    HCT-116 IC50
    6 nM
    Compound: doxorubicin
    Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
    [PMID: 19655762]
    HCT-116 IC50
    6.3 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    [PMID: 27894044]
    HCT-116 IC50
    6.86 μM
    Compound: Doxorubicin
    Antitumor activity against Homo sapiens (human) HCT116 cells assessed as cell growth inhibition after 48 hr by MTT assay
    Antitumor activity against Homo sapiens (human) HCT116 cells assessed as cell growth inhibition after 48 hr by MTT assay
    10.1007/s00044-013-0497-4
    HCT-116 IC50
    6.86 μM
    Compound: DOX
    Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
    [PMID: 22444025]
    HCT-116 IC50
    6.86 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    [PMID: 22119132]
    HCT-116 IC50
    6.86 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    [PMID: 22119131]
    HCT-116 IC50
    7.41 μM
    Compound: Dox
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    [PMID: 35635947]
    HCT-116 IC50
    7.7 μM
    Compound: adriamycin
    Cytotoxicity against human HCT116 cells after 4 days by MTT assay
    Cytotoxicity against human HCT116 cells after 4 days by MTT assay
    [PMID: 17194586]
    HCT-116 GI50
    70 nM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 24 to 72 hrs by MTS assay
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 24 to 72 hrs by MTS assay
    10.1039/C0MD00179A
    HCT-116 IC50
    761.45 nM
    Compound: Doxorubicin
    Anticancer activity against human HCT-116 cells overexpressing MMP9/MAO-A by MTT assay
    Anticancer activity against human HCT-116 cells overexpressing MMP9/MAO-A by MTT assay
    [PMID: 34116327]
    HCT-116 IC50
    8.07 μM
    Compound: Cpd I
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    [PMID: 33360576]
    HCT-116 IC50
    8.29 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 24 hrs by SRB assay
    Cytotoxicity against human HCT116 cells after 24 hrs by SRB assay
    [PMID: 30096580]
    HCT-116 IC50
    8.29 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay
    [PMID: 32361329]
    HCT-116 IC50
    8.7 μM
    Compound: ADR
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    10.1039/C2MD20270K
    HCT-116 IC50
    8.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    [PMID: 30660827]
    HCT-116 IC50
    8.8 nM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability by SRB assay
    [PMID: 30660827]
    HCT-116 IC50
    80 nM
    Compound: Doxorubicin
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    [PMID: 35213166]
    HCT-116 IC50
    810 nM
    Compound: DX
    Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr
    Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr
    [PMID: 15456268]
    HCT-116 IC50
    9.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 31323616]
    HCT-116 IC50
    9.63 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 33214036]
    HCT-116 IC50
    9.74 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
    [PMID: 28489373]
    HCT-15 GI50
    < 10 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    10.1039/C5MD00224A
    HCT-15 IC50
    > 1000 nM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay
    [PMID: 20690624]
    HCT-15 ED50
    0.006 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by sulforhodamine B method
    Cytotoxicity against human HCT15 cells by sulforhodamine B method
    [PMID: 12193011]
    HCT-15 IC50
    0.009 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 27010926]
    HCT-15 IC50
    0.01 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by MTT assay
    Cytotoxicity against human HCT15 cells by MTT assay
    [PMID: 17764956]
    HCT-15 IC50
    0.02 μg/mL
    Compound: doxorubicin
    Anticancer activity against human HCT15 cells after 72 hrs by sulforhodamine B assay
    Anticancer activity against human HCT15 cells after 72 hrs by sulforhodamine B assay
    [PMID: 19342127]
    HCT-15 IC50
    0.025 μM
    Compound: 1 (Doxorubicin)
    In vitro cytotoxic activity against human colon cancer cell line HCT15 after 72 hr of drug exposure determined by the SRB assay
    In vitro cytotoxic activity against human colon cancer cell line HCT15 after 72 hr of drug exposure determined by the SRB assay
    [PMID: 14980672]
    HCT-15 IC50
    0.028 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    [PMID: 20719504]
    HCT-15 IC50
    0.035 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    [PMID: 22483395]
    HCT-15 IC50
    0.037 μM
    Compound: Doxorubicin
    Anticancer activity against human HCT15 cells by sulforhodamine B assay
    Anticancer activity against human HCT15 cells by sulforhodamine B assay
    [PMID: 19819696]
    HCT-15 IC50
    0.038 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    [PMID: 20594848]
    HCT-15 ED50
    0.04 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    [PMID: 11325244]
    HCT-15 ED50
    0.05 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    [PMID: 15921415]
    HCT-15 IC50
    0.05 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by sulforhodamine B assay
    Cytotoxicity against human HCT15 cells by sulforhodamine B assay
    [PMID: 21684168]
    HCT-15 ED50
    0.071 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay
    [PMID: 19783438]
    HCT-15 GI50
    0.076 μM
    Compound: ADR
    Anticancer activity against human HCT-15 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
    Anticancer activity against human HCT-15 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
    [PMID: 34500188]
    HCT-15 GI50
    0.077 μM
    Compound: ADR
    Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by SRB assay
    [PMID: 30253887]
    HCT-15 GI50
    0.077 μM
    Compound: ADR
    Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    [PMID: 28870801]
    HCT-15 IC50
    0.08 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    [PMID: 15921426]
    HCT-15 IC50
    0.082 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    [PMID: 22951040]
    HCT-15 GI50
    0.0854 μM
    Compound: ADR
    Cytotoxicity against human HCT15 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT15 cells after 72 hrs by sulforhodamine B assay
    [PMID: 27096046]
    HCT-15 IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells assessed as cell death after 48 hrs by MTT assay
    Cytotoxicity against human HCT15 cells assessed as cell death after 48 hrs by MTT assay
    [PMID: 24215890]
    HCT-15 IC50
    0.1 μM
    Compound: Doxorubicin
    In vitro cytotoxic activity against HCT15 (colon cancer) cell lines by using SRB assay
    In vitro cytotoxic activity against HCT15 (colon cancer) cell lines by using SRB assay
    [PMID: 9873661]
    HCT-15 IC50
    0.1077 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by sulforhodamine B bioassay
    Cytotoxicity against human HCT15 cells by sulforhodamine B bioassay
    [PMID: 25098650]
    HCT-15 IC50
    0.109 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    [PMID: 25981688]
    HCT-15 IC50
    0.129 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    [PMID: 25466198]
    HCT-15 IC50
    0.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells assessed as growth inhibition by SRB assay
    Cytotoxicity against human HCT15 cells assessed as growth inhibition by SRB assay
    [PMID: 23634786]
    HCT-15 IC50
    0.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by sulforhodamine B assay
    Cytotoxicity against human HCT15 cells by sulforhodamine B assay
    [PMID: 23815260]
    HCT-15 IC50
    0.164 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    [PMID: 19435339]
    HCT-15 ED50
    0.164 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    [PMID: 18314958]
    HCT-15 GI50
    0.19 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT15 cells by SRB assay
    Antiproliferative activity against human HCT15 cells by SRB assay
    [PMID: 19394218]
    HCT-15 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    [PMID: 28641156]
    HCT-15 IC50
    0.225 μM
    Compound: Doxorubicin
    Anticancer activity against human HCT15 cells after 48 hrs by SRB assay
    Anticancer activity against human HCT15 cells after 48 hrs by SRB assay
    [PMID: 17070967]
    HCT-15 IC50
    0.23 μM
    Compound: Doxorubicine
    Inhibitory activity against HCT-15 colon cell line using sulforhodamine B (SRB) protein assay
    Inhibitory activity against HCT-15 colon cell line using sulforhodamine B (SRB) protein assay
    [PMID: 12039588]
    HCT-15 IC50
    0.251 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells after 3 days by SRB assay
    Cytotoxicity against human HCT15 cells after 3 days by SRB assay
    [PMID: 18321715]
    HCT-15 IC50
    0.27 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells after 48 hrs
    Cytotoxicity against human HCT15 cells after 48 hrs
    [PMID: 17673337]
    HCT-15 ED50
    0.35 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells by SRB method
    Cytotoxicity against human HCT15 cells by SRB method
    [PMID: 16252909]
    HCT-15 GI50
    0.45 μM
    Compound: ADR
    Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
    [PMID: 25953156]
    HCT-15 IC50
    0.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay
    [PMID: 18063366]
    HCT-15 IC50
    0.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    [PMID: 20176479]
    HCT-15 IC50
    0.872 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
    [PMID: 27856237]
    HCT-15 IC50
    1.03 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis
    Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis
    [PMID: 22503656]
    HCT-15 IC50
    1.08 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay
    Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay
    [PMID: 26361737]
    HCT-15 IC50
    1.08 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay
    Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay
    [PMID: 25481396]
    HCT-15 IC50
    1.13 μM
    Compound: DOX
    Antiproliferative activity against human HCT15 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by sulforhodamine B assay
    [PMID: 25981689]
    HCT-15 IC50
    1.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 2 days
    Cytotoxicity against human HCT15 cells after 2 days
    [PMID: 21601964]
    HCT-15 IC50
    1.23 μM
    Compound: adriamycin
    Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay
    Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay
    [PMID: 25936262]
    HCT-15 IC50
    1.25 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells by MTT assay
    Cytotoxicity against human HCT15 cells by MTT assay
    [PMID: 21115246]
    HCT-15 IC50
    1.28 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 2 days
    Cytotoxicity against human HCT15 cells after 2 days
    [PMID: 22318164]
    HCT-15 GI50
    1.34 μM
    Compound: ADR
    Antiproliferative activity against human HCT15 cells by SRB method
    Antiproliferative activity against human HCT15 cells by SRB method
    [PMID: 24835787]
    HCT-15 GI50
    1.34 μM
    Compound: ADR
    Antiproliferative activity against human HCT15 cells by SRB assay
    Antiproliferative activity against human HCT15 cells by SRB assay
    [PMID: 22738641]
    HCT-15 IC50
    1.38 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay
    Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay
    [PMID: 24013413]
    HCT-15 GI50
    1.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay
    [PMID: 23964644]
    HCT-15 GI50
    1.64 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    [PMID: 19596579]
    HCT-15 IC50
    1.67 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    [PMID: 17827007]
    HCT-15 IC50
    1.67 μM
    Compound: Doxorubicin
    Cytotoxic activity against HCT 15 human colon tumor cell line, using sulforhodamine B (SRB) assay.
    Cytotoxic activity against HCT 15 human colon tumor cell line, using sulforhodamine B (SRB) assay.
    [PMID: 14643344]
    HCT-15 IC50
    1.76 μM
    Compound: ADR
    Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay
    [PMID: 22819942]
    HCT-15 ED50
    1.8 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    10.1021/np960188t
    HCT-15 IC50
    16.4 nM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT15 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
    Antiproliferative activity against human HCT15 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
    [PMID: 31655432]
    HCT-15 IC50
    2.2 μM
    Compound: DOX
    Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay
    [PMID: 30429098]
    HCT-15 ED50
    2.4 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells by SRB assay
    Cytotoxicity against human HCT15 cells by SRB assay
    [PMID: 9392887]
    HCT-15 IC50
    3.33 μM
    Compound: DOX
    Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay
    Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay
    [PMID: 26334499]
    HCT-15 IC50
    3.76 μM
    Compound: Dox
    Cytotoxicity against human HCT15 cells after 2 days
    Cytotoxicity against human HCT15 cells after 2 days
    [PMID: 24904965]
    HCT-15 IC50
    5 nM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    [PMID: 22858298]
    HCT-15 GI50
    6.46 μM
    Compound: Doxorubicin hydrochloride, NSC 123127
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    [PMID: 23871905]
    HCT-15 GI50
    6.46 μM
    Compound: Doxorubicin
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 29102177]
    HCT-15 GI50
    6.46 μM
    Compound: Doxorubicin
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
    [PMID: 28329730]
    HCT-15 GI50
    7.92 μM
    Compound: Doxorubicin
    Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay
    Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay
    [PMID: 19394218]
    HCT-15 IC50
    81 nM
    Compound: doxorubicin
    Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay
    Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay
    [PMID: 19655762]
    HCT-29 IC50
    2.5 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT29 cells after 4 days by MTT assay
    Cytotoxicity against human HCT29 cells after 4 days by MTT assay
    [PMID: 21704436]
    HCT-8 IC50
    0.01 μg/mL
    Compound: Dox
    Cytotoxicity against Homo sapiens (human) HCT8 cells after 72 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HCT8 cells after 72 hr by MTT assay
    10.1007/s00044-011-9894-8
    HCT-8 IC50
    0.02 μM
    Compound: Dox
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    [PMID: 25147145]
    HCT-8 IC50
    0.02 μM
    Compound: D
    Antineoplastic activity against human HCT8 cells after 72 hrs by MTT assay
    Antineoplastic activity against human HCT8 cells after 72 hrs by MTT assay
    [PMID: 22000949]
    HCT-8 IC50
    0.02 μM
    Compound: doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    [PMID: 21381705]
    HCT-8 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    [PMID: 20971532]
    HCT-8 IC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    [PMID: 19406535]
    HCT-8 IC50
    0.03 μM
    Compound: Dox
    Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 31306817]
    HCT-8 IC50
    0.04 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 3 days by MTT assay
    Cytotoxicity against human HCT8 cells after 3 days by MTT assay
    [PMID: 19159272]
    HCT-8 IC50
    0.04 μg/mL
    Compound: Dox
    Anticancer activity against Homo sapiens (human) HCT8 cells assessed as inhibition of cell survival after 72 hr by MTT assay
    Anticancer activity against Homo sapiens (human) HCT8 cells assessed as inhibition of cell survival after 72 hr by MTT assay
    10.1007/s00044-012-0236-2
    HCT-8 IC50
    0.04 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    [PMID: 19084293]
    HCT-8 IC50
    0.04 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    [PMID: 18586355]
    HCT-8 IC50
    0.04 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    [PMID: 17827021]
    HCT-8 IC50
    0.04 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    [PMID: 15787450]
    HCT-8 IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    [PMID: 27363939]
    HCT-8 IC50
    0.06 μg/mL
    Compound: Doxo
    Cytotoxicity against human HCT8 cells for 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells for 72 hrs by MTT assay
    [PMID: 21334795]
    HCT-8 IC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    [PMID: 21115213]
    HCT-8 IC50
    0.06 μM
    Compound: DOXO
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    [PMID: 19947600]
    HCT-8 IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 69 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 69 hrs by MTT assay
    [PMID: 19780590]
    HCT-8 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells by colorimetric method
    Cytotoxicity against human HCT8 cells by colorimetric method
    [PMID: 24387625]
    HCT-8 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
    [PMID: 22250891]
    HCT-8 IC50
    0.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 24530030]
    HCT-8 IC50
    0.19 μM
    Compound: DOXO
    Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 26142490]
    HCT-8 IC50
    0.42 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT8 cells by MTT assay
    Cytotoxicity against human HCT8 cells by MTT assay
    [PMID: 22070654]
    HCT-8 IC50
    0.8 μM
    Compound: adriamycin
    Cytotoxicity against human HCT8 cells by MTT assay
    Cytotoxicity against human HCT8 cells by MTT assay
    [PMID: 17190442]
    HCT-8 IC50
    1.17 μM
    Compound: DOX
    Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 27149641]
    HCT-8 IC50
    1.5 μM
    Compound: doxorubicine
    Cytotoxic activity against human HCT8 cells after 69 hrs by MTT assay
    Cytotoxic activity against human HCT8 cells after 69 hrs by MTT assay
    [PMID: 19788290]
    HCT-8 IC50
    19.6 μM
    Compound: Dox
    Cytotoxicity against human HCT8 cells under hypoxic condition after 24 hrs by crystal violet method
    Cytotoxicity against human HCT8 cells under hypoxic condition after 24 hrs by crystal violet method
    [PMID: 25375258]
    HCT-8 IC50
    2.4 μM
    Compound: Dox
    Cytotoxicity against human HCT8 cells under normoxic condition after 24 hrs by crystal violet method
    Cytotoxicity against human HCT8 cells under normoxic condition after 24 hrs by crystal violet method
    [PMID: 25375258]
    HCT-8 IC50
    3.4 μM
    Compound: DOX
    Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method
    Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method
    [PMID: 25061803]
    HCT-8 IC50
    7.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HCT8 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT8 cells after 48 hrs by MTT assay
    [PMID: 30660827]
    HEK293 IC50
    > 100 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293 cells by MTT assay
    Cytotoxicity against HEK293 cells by MTT assay
    [PMID: 24287557]
    HEK293 IC50
    > 200 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 4 hrs by MTT assay
    [PMID: 30773423]
    HEK293 IC50
    > 200 μM
    Compound: Doxorubicin
    In vitro cytotoxicity against HEK293 cells assessed as growth inhibition by MTT assay
    In vitro cytotoxicity against HEK293 cells assessed as growth inhibition by MTT assay
    [PMID: 24742385]
    HEK293 IC50
    0.01 μM
    Compound: Adriamycin
    Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay
    Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay
    [PMID: 21721528]
    HEK293 IC50
    0.018 μM
    Compound: DOX
    Antiproliferative activity against human HEK293 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human HEK293 cells measured after 72 hrs by MTT assay
    [PMID: 31431364]
    HEK293 IC50
    0.02 μM
    Compound: DOX
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 30340899]
    HEK293 IC50
    0.04 μM
    Compound: ADM
    Cytotoxic activity against human HEK293 cells by SRB method
    Cytotoxic activity against human HEK293 cells by SRB method
    [PMID: 25611519]
    HEK293 IC50
    0.064 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293 cells after 24 hrs by SRB method
    Cytotoxicity against HEK293 cells after 24 hrs by SRB method
    [PMID: 18429610]
    HEK293 IC50
    0.106 μM
    Compound: Dox
    Cytotoxicity against HEK-293 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method
    Cytotoxicity against HEK-293 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method
    [PMID: 34236840]
    HEK293 IC50
    0.36 μM
    Compound: DX
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    [PMID: 29681486]
    HEK293 IC50
    0.42 μM
    Compound: Adriamycin
    Cytotoxicity against human HEK293 cells transfected with plasmid expressing MDR1 after 72 hrs by MTT assay
    Cytotoxicity against human HEK293 cells transfected with plasmid expressing MDR1 after 72 hrs by MTT assay
    [PMID: 21721528]
    HEK293 IC50
    0.46 μM
    Compound: DX
    Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by formazan dye-based EZ4U assay
    Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by formazan dye-based EZ4U assay
    [PMID: 30108984]
    HEK293 IC50
    0.46 μM
    Compound: Dox
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U Non-radioactive cell proliferation assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U Non-radioactive cell proliferation assay
    [PMID: 28372935]
    HEK293 IC50
    0.46 μM
    Compound: DX
    Antiproliferative activity against human HEK293 cells assessed as cell viability after 48 hrs by formazan EZ4U dye based assay
    Antiproliferative activity against human HEK293 cells assessed as cell viability after 48 hrs by formazan EZ4U dye based assay
    [PMID: 26690914]
    HEK293 IC50
    0.46 μM
    Compound: DX
    Toxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U label based assay
    Toxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U label based assay
    [PMID: 26052884]
    HEK293 IC50
    0.46 μM
    Compound: doxorubicin
    Antiproliferative activity against HEK293 cells at 0.01 to 250 uM after 48 hrs by formazan based EZ4U assay
    Antiproliferative activity against HEK293 cells at 0.01 to 250 uM after 48 hrs by formazan based EZ4U assay
    [PMID: 25868743]
    HEK293 IC50
    0.69 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
    Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
    [PMID: 25300819]
    HEK293 IC50
    0.7 μM
    Compound: Doxorubicin
    Antiproliferative activity against HEK293 cells after 72 hrs by XTT assay
    Antiproliferative activity against HEK293 cells after 72 hrs by XTT assay
    10.1039/C1MD00234A
    HEK293 GI50
    0.8 μM
    Compound: Dox
    Antiproliferative activity against human HEK293 cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human HEK293 cells incubated for 72 hrs and measured by MTT assay
    [PMID: 35973342]
    HEK293 IC50
    0.9 μM
    Compound: doxorubicin
    Cytotoxicity against transformed human HEK293 cells after 24 to 48 hrs by MTT assay
    Cytotoxicity against transformed human HEK293 cells after 24 to 48 hrs by MTT assay
    [PMID: 21058726]
    HEK293 IC50
    1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    [PMID: 35526504]
    HEK293 IC50
    1 μM
    Compound: ADR
    Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay
    Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay
    [PMID: 22819942]
    HEK293 IC50
    1.006 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293 cells after 24 hrs by MTT assay
    Cytotoxicity against HEK293 cells after 24 hrs by MTT assay
    10.1007/s00044-013-0784-0
    HEK293 IC50
    1.06 μM
    Compound: Adriamycin
    Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay
    [PMID: 24582982]
    HEK293 IC50
    1.2 μM
    Compound: DOX
    Antiproliferative activity against human HEK293 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HEK293 cells after 72 hrs by MTT assay
    [PMID: 30429098]
    HEK293 IC50
    1.34 μM
    Compound: Adriamycin
    Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis
    Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis
    [PMID: 22503656]
    HEK293 IC50
    1.65 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    [PMID: 34124677]
    HEK293 IC50
    10 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    [PMID: 28818768]
    HEK293 IC50
    11.34 mM
    Compound: DOX
    Growth inhibition of human HEK293 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Growth inhibition of human HEK293 cells assessed as cell viability incubated for 48 hrs by MTT assay
    [PMID: 31648875]
    HEK293 IC50
    142.8 μM
    Compound: 12
    Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
    Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
    [PMID: 29852328]
    HEK293 IC50
    148.4 μM
    Compound: 21
    Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay
    Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay
    [PMID: 29289880]
    HEK293 IC50
    16.7 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    [PMID: 35526504]
    HEK293 IC50
    160 μM
    Compound: Doxorubicin
    Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
    Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
    [PMID: 22541068]
    HEK293 IC50
    2.1 μM
    Compound: Doxorubicin
    Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    [PMID: 28923382]
    HEK293 IC50
    240 μM
    Compound: Doxorubicin
    Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
    Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
    [PMID: 22541068]
    HEK293 IC50
    3.07 μM
    Compound: Adriamycin
    Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay
    Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay
    [PMID: 24013413]
    HEK293 IC50
    3.13 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 27816268]
    HEK293 IC50
    3.9 μM
    Compound: Doxorubicin
    Growth inhibition of HEK293 cells after 48 hrs by MTT assay
    Growth inhibition of HEK293 cells after 48 hrs by MTT assay
    [PMID: 30072225]
    HEK293 IC50
    41 μM
    Compound: Doxorubicin
    Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
    Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
    [PMID: 22541068]
    HEK293 IC50
    44.4 μM
    Compound: DOX
    Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
    Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
    [PMID: 27108400]
    HEK293 IC50
    455 nM
    Compound: DX
    Cytotoxicity against HEK293 cells assessed as reduction of cell viability after 48 hrs by formazan dye-based EZ4U test
    Cytotoxicity against HEK293 cells assessed as reduction of cell viability after 48 hrs by formazan dye-based EZ4U test
    [PMID: 24996140]
    HEK293 IC50
    5.68 μM
    Compound: DOX
    Antiproliferative activity against HEK293 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    Antiproliferative activity against HEK293 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    [PMID: 31671309]
    HEK293 IC50
    5.68 μM
    Compound: DOX
    Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
    Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
    [PMID: 30576904]
    HEK293 IC50
    6.1 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    [PMID: 35526504]
    HEK293 IC50
    6.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293 cells assessed as inhibition of cell growth after overnight incubation by MTT assay
    Cytotoxicity against human HEK293 cells assessed as inhibition of cell growth after overnight incubation by MTT assay
    [PMID: 32165076]
    HEK293 IC50
    7.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    [PMID: 27496212]
    HEK293 IC50
    7.41 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293 cells after 48 hrs by MTT assay
    Cytotoxicity against HEK293 cells after 48 hrs by MTT assay
    [PMID: 24607876]
    HEK-293T IC50
    0.75 μM
    Compound: DOX
    Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay
    Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay
    [PMID: 35612499]
    HEK-293T IC50
    0.75 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in presence of 10% FBS
    Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in presence of 10% FBS
    [PMID: 26298501]
    HEK-293T IC50
    0.84 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in absence of 10% FBS
    Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in absence of 10% FBS
    [PMID: 26298501]
    HEK-293T IC50
    1.051 μM
    Compound: Dox
    Cytotoxicity in HEK293T cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay
    Cytotoxicity in HEK293T cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay
    [PMID: 31542715]
    HEK-293T IC50
    1.13 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293T cells after 48 hrs by MTT assay
    Cytotoxicity against HEK293T cells after 48 hrs by MTT assay
    [PMID: 30170925]
    HEK-293T CC50
    1.13 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293T cells after 48 hrs by MTT assay
    Cytotoxicity against HEK293T cells after 48 hrs by MTT assay
    [PMID: 30103191]
    HEK-293T IC50
    1.2 μM
    Compound: Dox
    Cytotoxicity against HEK293T cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    Cytotoxicity against HEK293T cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    [PMID: 27055942]
    HEK-293T IC50
    3.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay
    Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay
    [PMID: 27173802]
    HEK-293T IC50
    3.59 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay
    Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay
    [PMID: 29573910]
    HEK-293T IC50
    3.77 μM
    Compound: Doxorubicin
    Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    [PMID: 35367708]
    HEK-293T IC50
    3.77 μM
    Compound: Doxorubicin
    Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 31404864]
    HEL IC50
    0.42 μM
    Compound: Doxorubicin
    Antiproliferative activity against HEL cells after 72 hrs by MTT assay
    Antiproliferative activity against HEL cells after 72 hrs by MTT assay
    [PMID: 30500683]
    HEL IC50
    2.13 μM
    Compound: Doxorubicin
    Cytotoxicity against HEL cells after 48 hrs by MTT assay
    Cytotoxicity against HEL cells after 48 hrs by MTT assay
    [PMID: 28390228]
    HeLa GI50
    < 0.01 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
    [PMID: 25827522]
    HeLa GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human HeLa cells by SRB assay
    Cytotoxicity against human HeLa cells by SRB assay
    10.1007/s00044-013-0855-2
    HeLa IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    10.1007/s00044-011-9884-x
    HeLa IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 23079527]
    HeLa IC50
    < 1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 21996519]
    HeLa IC50
    > 1 μM
    Compound: Doxorubicin
    Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 35059132]
    HeLa IC50
    0.008 mM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 3 days by MTT assay
    Cytotoxicity against human HeLa cells after 3 days by MTT assay
    [PMID: 22520152]
    HeLa IC50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell survival after 24 hrs by XTT assay
    Cytotoxicity against human HeLa cells assessed as cell survival after 24 hrs by XTT assay
    [PMID: 25059501]
    HeLa IC50
    0.016 μM
    Compound: DOX
    Antitumor activity against Homo sapiens (human) HeLa cells assessed as inhibition of cell proliferation after 48 hr by SRB assay
    Antitumor activity against Homo sapiens (human) HeLa cells assessed as inhibition of cell proliferation after 48 hr by SRB assay
    10.1007/s00044-012-0051-9
    HeLa GI50
    0.023 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells by SRB assay
    Antiproliferative activity against human HeLa cells by SRB assay
    [PMID: 31546197]
    HeLa IC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay
    [PMID: 27080175]
    HeLa GI50
    0.031 μM
    Compound: Doxorubicin
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    [PMID: 26067381]
    HeLa IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 20207049]
    HeLa IC50
    0.04 μM
    Compound: DOX
    Antitumor activity against human HeLa cells after 72 hrs by MTT assay
    Antitumor activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 17935309]
    HeLa IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 19278239]
    HeLa GI50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 27889456]
    HeLa IC50
    0.05 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    [PMID: 28257197]
    HeLa IC50
    0.051 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    [PMID: 34973507]
    HeLa IC50
    0.053 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HeLa cells after 96 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HeLa cells after 96 hr by MTT assay
    10.1007/s00044-010-9340-3
    HeLa IC50
    0.06 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 22555152]
    HeLa IC50
    0.065 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
    [PMID: 31557614]
    HeLa IC50
    0.065 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 25259516]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 6 days by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 6 days by MTT assay
    [PMID: 32653698]
    HeLa IC50
    0.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human Hela cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human Hela cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    [PMID: 33340938]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    [PMID: 30746062]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 28427016]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 28135634]
    HeLa IC50
    0.07 μM
    Compound: Dox
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
    [PMID: 27231128]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
    [PMID: 26720155]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 24021462]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 20359789]
    HeLa IC50
    0.07 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 18783950]
    HeLa IC50
    0.07 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay
    [PMID: 19053767]
    HeLa IC50
    0.07 μM
    Compound: doxo
    Antiproliferative activity against human HeLa cells by MTT assay
    Antiproliferative activity against human HeLa cells by MTT assay
    [PMID: 16913700]
    HeLa GI50
    0.073 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
    [PMID: 27209232]
    HeLa GI50
    0.073 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as reduction in net protein increase after 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells assessed as reduction in net protein increase after 48 hrs by SRB assay
    [PMID: 25462234]
    HeLa GI50
    0.073 μM
    Compound: Doxorubicin
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    [PMID: 25264072]
    HeLa GI50
    0.083 μM
    Compound: Doxorubicin
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    [PMID: 27964883]
    HeLa IC50
    0.09 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
    [PMID: 36693198]
    HeLa GI50
    0.09 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
    [PMID: 26994690]
    HeLa GI50
    0.093 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 30360625]
    HeLa ED50
    0.1 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells after 3 days by MTT assay
    Cytotoxicity against human HeLa cells after 3 days by MTT assay
    [PMID: 16252910]
    HeLa IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by CCK8 assay
    Cytotoxicity against human HeLa cells after 72 hrs by CCK8 assay
    [PMID: 28398051]
    HeLa IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT method
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT method
    [PMID: 25932671]
    HeLa IC50
    0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay
    [PMID: 26947606]
    HeLa IC50
    0.11 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 30389295]
    HeLa IC50
    0.13 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 21496972]
    HeLa ED50
    0.14 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells by methylene blue staining method
    Cytotoxicity against human HeLa cells by methylene blue staining method
    [PMID: 15921421]
    HeLa IC50
    0.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
    [PMID: 31820973]
    HeLa IC50
    0.14 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by XTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by XTT assay
    [PMID: 27227682]
    HeLa IC50
    0.154 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 25462279]
    HeLa IC50
    0.16 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 18692939]
    HeLa IC50
    0.163 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 21158422]
    HeLa IC50
    0.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 22414612]
    HeLa IC50
    0.19 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
    [PMID: 19647439]
    HeLa IC50
    0.2 mM
    Compound: Dox
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 29459273]
    HeLa IC50
    0.2 μM
    Compound: Doxo
    Antiproliferative activity against human HeLa cells assessed as cell viability measured after 4 days by MTT assay
    Antiproliferative activity against human HeLa cells assessed as cell viability measured after 4 days by MTT assay
    [PMID: 31869654]
    HeLa IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 34082225]
    HeLa IC50
    0.2 μM
    Compound: 2
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 33974416]
    HeLa IC50
    0.2 μM
    Compound: Dox
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 30659997]
    HeLa IC50
    0.2 μM
    Compound: Dox
    Antiproliferative activity in human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity in human HeLa cells after 72 hrs by MTT assay
    [PMID: 30268824]
    HeLa IC50
    0.2 μM
    Compound: 5
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 29137865]
    HeLa IC50
    0.2 μM
    Compound: 1; Dox
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 26633734]
    HeLa IC50
    0.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 24012378]
    HeLa IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 19394829]
    HeLa IC50
    0.21 μM
    Compound: ADM
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 25984840]
    HeLa IC50
    0.21 μM
    Compound: ADM
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 25529742]
    HeLa IC50
    0.21 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 72 hrs MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs MTT assay
    [PMID: 25247772]
    HeLa ED50
    0.22 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 15104488]
    HeLa IC50
    0.22 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay
    Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay
    [PMID: 25163667]
    HeLa IC50
    0.221 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT reduction assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT reduction assay
    [PMID: 28551177]
    HeLa IC50
    0.23 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells after 48 hrs by MTT assay
    Anticancer activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 21641694]
    HeLa IC50
    0.24 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 21708464]
    HeLa IC50
    0.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells incubated for 72 hrs by MTT assay
    [PMID: 32040324]
    HeLa IC50
    0.256 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells at 50 uM by MTT reduction assay
    Cytotoxicity against human HeLa cells at 50 uM by MTT reduction assay
    [PMID: 33276991]
    HeLa IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 26972921]
    HeLa GI50
    0.3 μM
    Compound: Dox
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    [PMID: 34634616]
    HeLa IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 44 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 44 hrs by SRB assay
    10.1007/s00044-013-0788-9
    HeLa IC50
    0.32 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 28358196]
    HeLa GI50
    0.33 μM
    Compound: Doxorubicin
    Growth inhibition of Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    Growth inhibition of Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    10.1007/s00044-012-0232-6
    HeLa IC50
    0.33 μM
    Compound: Doxorubicin
    Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay
    Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay
    [PMID: 25160837]
    HeLa IC50
    0.33 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells by MTT assay
    Antiproliferative activity against human HeLa cells by MTT assay
    [PMID: 20171108]
    HeLa IC50
    0.337 μM
    Compound: Dox
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 25998504]
    HeLa IC50
    0.34 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 24 and 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 24 and 72 hrs by MTT assay
    [PMID: 24941130]
    HeLa IC50
    0.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 4 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 4 hrs by MTT assay
    [PMID: 30773423]
    HeLa IC50
    0.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay
    [PMID: 24953027]
    HeLa IC50
    0.36 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 24487188]
    HeLa IC50
    0.36 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 25453799]
    HeLa IC50
    0.37 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells incubated for 24 hrs by MTT assay
    Anticancer activity against human HeLa cells incubated for 24 hrs by MTT assay
    [PMID: 28579122]
    HeLa IC50
    0.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells incubated for 48 hrs by WST8 assay
    Antiproliferative activity against human HeLa cells incubated for 48 hrs by WST8 assay
    [PMID: 31679979]
    HeLa IC50
    0.41 μM
    Compound: adriamycin
    Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay
    Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay
    [PMID: 19072548]
    HeLa IC50
    0.429 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 48 hrs by MTT assay
    [PMID: 36652792]
    HeLa IC50
    0.43 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in presence of 10% FBS
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in presence of 10% FBS
    [PMID: 26298501]
    HeLa IC50
    0.45 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 25172420]
    HeLa IC50
    0.45 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 23911578]
    HeLa IC50
    0.45 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in absence of 10% FBS
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in absence of 10% FBS
    [PMID: 26298501]
    HeLa IC50
    0.451 μM
    Compound: DOXO
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 29685681]
    HeLa IC50
    0.451 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 24113366]
    HeLa IC50
    0.451 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 23764302]
    HeLa IC50
    0.47 μM
    Compound: adriamycin
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
    [PMID: 26295905]
    HeLa IC50
    0.47 μM
    Compound: ADM
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    [PMID: 25089733]
    HeLa IC50
    0.48 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 46 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 46 hrs by MTT assay
    [PMID: 29138027]
    HeLa IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    [PMID: 32324401]
    HeLa IC50
    0.5 μM
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTS assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTS assay
    [PMID: 25490132]
    HeLa IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 29702447]
    HeLa IC50
    0.5 μM
    Compound: ADM
    Cytotoxic activity against human HeLa cells by MTT method
    Cytotoxic activity against human HeLa cells by MTT method
    [PMID: 25611519]
    HeLa IC50
    0.5 μM
    Compound: ADM
    Cytotoxicity against human HeLa cells by SRB method
    Cytotoxicity against human HeLa cells by SRB method
    [PMID: 29144133]
    HeLa IC50
    0.509 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by MTT assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by MTT assay
    [PMID: 23932340]
    HeLa IC50
    0.509 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 24287557]
    HeLa IC50
    0.51 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 26381063]
    HeLa IC50
    0.51 μM
    Compound: Doxorubicin
    In vitro cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay
    In vitro cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay
    [PMID: 24742385]
    HeLa IC50
    0.52 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells measured after 2 days by MTT assay
    Cytotoxicity against human HeLa cells measured after 2 days by MTT assay
    [PMID: 26334499]
    HeLa IC50
    0.54 μg/mL
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells by MTT assay
    Anticancer activity against human HeLa cells by MTT assay
    [PMID: 31404864]
    HeLa IC50
    0.55 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31546197]
    HeLa IC50
    0.59 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
    [PMID: 34978808]
    HeLa IC50
    0.6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 30679134]
    HeLa IC50
    0.6 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 26386603]
    HeLa IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 22749279]
    HeLa IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition by MTT assay
    [PMID: 27187861]
    HeLa IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 25241926]
    HeLa IC50
    0.606 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 28406643]
    HeLa IC50
    0.62 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 19689125]
    HeLa IC50
    0.66 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 30170925]
    HeLa CC50
    0.66 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 30103191]
    HeLa IC50
    0.68 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 18440233]
    HeLa IC50
    0.69 μM
    Compound: Doxorubicin
    Cytotoxicity against p53 repressed human HeLa cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against p53 repressed human HeLa cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 31324563]
    HeLa IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT asasy
    Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT asasy
    [PMID: 28615134]
    HeLa GI50
    0.7 μM
    Compound: Dox
    Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    [PMID: 35533562]
    HeLa IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 25172418]
    HeLa IC50
    0.71 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay
    Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay
    10.1007/s00044-012-0370-x
    HeLa IC50
    0.71 μM
    Compound: Doxorubicine
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 22014995]
    HeLa IC50
    0.73 μM
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 19819703]
    HeLa GI50
    0.76 μM
    Compound: Dox
    Antiproliferative activity against human HeLa cells incubated for 72 hrs and measured by MTT assay
    Antiproliferative activity against human HeLa cells incubated for 72 hrs and measured by MTT assay
    [PMID: 35973342]
    HeLa IC50
    0.78 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 27060757]
    HeLa IC50
    0.8 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 17918910]
    HeLa IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    [PMID: 30654238]
    HeLa IC50
    0.8 μM
    Compound: Dox
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by MTT assay
    [PMID: 31765156]
    HeLa IC50
    0.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
    [PMID: 31404864]
    HeLa IC50
    0.834 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 26638041]
    HeLa IC50
    0.85 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 23992864]
    HeLa IC50
    0.88 μM
    Compound: adriamycin
    Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay
    Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay
    [PMID: 25936262]
    HeLa IC50
    0.9 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 25462233]
    HeLa IC50
    0.93 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay
    10.1039/C5MD00581G
    HeLa IC50
    0.97 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 24182355]
    HeLa IC50
    1 x 10-2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by XTT assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by XTT assay
    [PMID: 23470139]
    HeLa IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay
    Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay
    [PMID: 25481396]
    HeLa IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells incubated for 48 hrs by MTT assay
    [PMID: 33421712]
    HeLa IC50
    1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 19632833]
    HeLa IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells by neutral red method
    Cytotoxicity against human HeLa cells by neutral red method
    [PMID: 26291474]
    HeLa IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 2 days
    Cytotoxicity against human HeLa cells after 2 days
    [PMID: 21601964]
    HeLa IC50
    1.009 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by SRB method
    Cytotoxicity against human HeLa cells after 24 hrs by SRB method
    [PMID: 18429610]
    HeLa IC50
    1.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by CCK8 assay
    Cytotoxicity against human HeLa cells by CCK8 assay
    [PMID: 29452840]
    HeLa IC50
    1.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 32866757]
    HeLa IC50
    1.089 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 28482219]
    HeLa IC50
    1.107 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    [PMID: 32707525]
    HeLa IC50
    1.1073 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells by MTT assay
    Antiproliferative activity against human HeLa cells by MTT assay
    [PMID: 31404864]
    HeLa IC50
    1.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    10.1039/C3MD00013C
    HeLa IC50
    1.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    [PMID: 22182926]
    HeLa IC50
    1.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells expressing estrogen receptor after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells expressing estrogen receptor after 48 hrs by MTT assay
    10.1039/C2MD20327H
    HeLa IC50
    1.17 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 30108986]
    HeLa IC50
    1.17 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    [PMID: 25737400]
    HeLa IC50
    1.17 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 25619894]
    HeLa IC50
    1.17 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 24148837]
    HeLa IC50
    1.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 1 hr by SRB assay
    Cytotoxicity against human HeLa cells after 1 hr by SRB assay
    [PMID: 22770744]
    HeLa IC50
    1.2 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells measured after 48 hrs by MTT assay
    Anticancer activity against human HeLa cells measured after 48 hrs by MTT assay
    [PMID: 33421712]
    HeLa IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 26398312]
    HeLa IC50
    1.2 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 28886509]
    HeLa IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 33766771]
    HeLa IC50
    1.2 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells after 72 hrs by Sulforhodamine B-stain assay
    Antiproliferative activity against human HeLa cells after 72 hrs by Sulforhodamine B-stain assay
    [PMID: 27484508]
    HeLa IC50
    1.21 μM
    Compound: Dox
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 30615450]
    HeLa IC50
    1.258 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 26301558]
    HeLa IC50
    1.28 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    10.1039/C4MD00566J
    HeLa IC50
    1.3 μM
    Compound: Doxorubicin
    Cytotoxic activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxic activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 25966052]
    HeLa IC50
    1.31 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 24582982]
    HeLa IC50
    1.43 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 48 hrs by SRB method
    Cytotoxicity against human HeLa cells after 48 hrs by SRB method
    [PMID: 25933593]
    HeLa IC50
    1.44 μM
    Compound: doxo
    Antiproliferative activity against human HeLa cells assessed as decrease in cell viability measured after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as decrease in cell viability measured after 72 hrs by MTT assay
    [PMID: 30763817]
    HeLa IC50
    1.45 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 2 days
    Cytotoxicity against human HeLa cells after 2 days
    [PMID: 22318164]
    HeLa IC50
    1.5 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 24941129]
    HeLa IC50
    1.5 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 22044164]
    HeLa IC50
    1.51 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 26330077]
    HeLa IC50
    1.59 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 26948541]
    HeLa IC50
    1.6 x 10-2 μM
    Compound: adriamycin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 19285863]
    HeLa IC50
    1.64 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 21534590]
    HeLa IC50
    1.68 μM
    Compound: Dox
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 26494582]
    HeLa IC50
    1.69 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 30500683]
    HeLa IC50
    1.73 μM
    Compound: Doxo
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 29129513]
    HeLa IC50
    1.78 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 26708114]
    HeLa IC50
    1.8 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells by MTT assay
    Anticancer activity against human HeLa cells by MTT assay
    [PMID: 33421712]
    HeLa IC50
    1.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT reduction assay
    Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT reduction assay
    [PMID: 33421712]
    HeLa IC50
    1.81 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HeLa cells incubated for 24 hrs by MTT assay
    [PMID: 29409753]
    HeLa IC50
    1.82 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 29172084]
    HeLa IC50
    1.862 μM
    Compound: Doxorubicin
    Anti-proliferative activity against human HeLa cells measured after 48 hrs by MTT assay
    Anti-proliferative activity against human HeLa cells measured after 48 hrs by MTT assay
    [PMID: 27744185]
    HeLa IC50
    1.91 μM
    Compound: II
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 29289881]
    HeLa IC50
    1.94 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    [PMID: 32631552]
    HeLa IC50
    1.96 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
    [PMID: 36126331]
    HeLa IC50
    1.995 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 29501940]
    HeLa GI50
    10.7 μM
    Compound: DOX
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    [PMID: 28433679]
    HeLa IC50
    10.78 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell viability by SRB assay
    Cytotoxicity against human HeLa cells assessed as cell viability by SRB assay
    [PMID: 26022842]
    HeLa IC50
    11 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 11473441]
    HeLa IC50
    11.5 μM
    Compound: Doxo
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 27597408]
    HeLa IC50
    13 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    [PMID: 35526504]
    HeLa IC50
    14 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 31015907]
    HeLa CC50
    2 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by methylene blue staining
    Cytotoxicity against human HeLa cells after 72 hrs by methylene blue staining
    [PMID: 20153202]
    HeLa IC50
    2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31938458]
    HeLa IC50
    2 μM
    Compound: adriamycin
    Cytotoxicity against human HeLa cells under deem light after 96 hrs by MTT assay
    Cytotoxicity against human HeLa cells under deem light after 96 hrs by MTT assay
    [PMID: 17993275]
    HeLa IC50
    2.05 μM
    Compound: Doxorubicin
    Growth inhibition of human HeLa cells by MTT assay
    Growth inhibition of human HeLa cells by MTT assay
    [PMID: 28147307]
    HeLa IC50
    2.089 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 28462842]
    HeLa IC50
    2.09 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    [PMID: 34700239]
    HeLa IC50
    2.1 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    [PMID: 34363936]
    HeLa IC50
    2.2 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 23218718]
    HeLa IC50
    2.23 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 29421568]
    HeLa IC50
    2.29 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells after 48 hrs by MTT assay
    Anticancer activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 25615796]
    HeLa IC50
    2.3 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Alamar blue staining based fluorescence assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Alamar blue staining based fluorescence assay
    [PMID: 28291684]
    HeLa IC50
    2.45 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells treated for 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells treated for 72 hrs by MTT assay
    [PMID: 35344904]
    HeLa EC50
    2.5 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
    10.1007/s00044-012-0294-5
    HeLa IC50
    2.57 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 27015609]
    HeLa IC50
    2.63 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 26264845]
    HeLa IC50
    2.684 μg/mL
    Compound: ADM
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 25862199]
    HeLa IC50
    2.78 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by MTT assay
    [PMID: 32631524]
    HeLa IC50
    2.9 x 10-1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
    [PMID: 20619940]
    HeLa IC50
    20.93 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 22818039]
    HeLa IC50
    21.9 μM
    Compound: DXR
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by XTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by XTT assay
    [PMID: 26649907]
    HeLa IC50
    3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by DAPI staining based assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by DAPI staining based assay
    [PMID: 33461146]
    HeLa IC50
    3.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    [PMID: 23835482]
    HeLa IC50
    3.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa after 24 hrs by MTT assay
    Cytotoxicity against human HeLa after 24 hrs by MTT assay
    [PMID: 20056520]
    HeLa IC50
    3.24 μM
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    [PMID: 19128861]
    HeLa IC50
    3.24 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs incubation by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs incubation by MTT assay
    [PMID: 24856067]
    HeLa IC50
    3.3 μM
    Compound: adriamycin
    Cytotoxicity against human HeLa cells after 4 days by MTT assay
    Cytotoxicity against human HeLa cells after 4 days by MTT assay
    [PMID: 17194586]
    HeLa IC50
    3.3 μM
    Compound: DOX
    Inhibition of topoisomerase 2 in human HeLa cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Inhibition of topoisomerase 2 in human HeLa cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    [PMID: 30846253]
    HeLa IC50
    3.33 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 24 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 24 hrs by MTT assay
    [PMID: 36652792]
    HeLa IC50
    3.55 μM
    Compound: DOX
    Antineoplastic activity against human HeLa cells measured after 36 hrs by MTT assay
    Antineoplastic activity against human HeLa cells measured after 36 hrs by MTT assay
    [PMID: 30746067]
    HeLa IC50
    3.57 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25594739]
    HeLa IC50
    3.64 μg/mL
    Compound: DOX
    Antitumor activity against human HeLa cells after 48 hrs by MTT assay
    Antitumor activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 20599299]
    HeLa IC50
    3.7 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 4 days by MTT assay
    Cytotoxicity against human HeLa cells after 4 days by MTT assay
    [PMID: 21704436]
    HeLa IC50
    3.9 μM
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells assessed as growth inhibition measured after 48 hrs by XTT assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition measured after 48 hrs by XTT assay
    [PMID: 23547843]
    HeLa IC50
    3.92 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 26542964]
    HeLa IC50
    3.97 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 31404864]
    HeLa IC50
    3.99 μM
    Compound: AMD
    Antiproliferative activity against human HeLa cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells measured after 48 hrs by MTT assay
    [PMID: 27639364]
    HeLa IC50
    30.21 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells after 48 hrs by SRB assay
    Anticancer activity against human HeLa cells after 48 hrs by SRB assay
    [PMID: 24077528]
    HeLa IC50
    37 nM
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay
    Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay
    [PMID: 20180542]
    HeLa IC50
    4 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
    [PMID: 27618204]
    HeLa IC50
    4.1 μM
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 23748152]
    HeLa IC50
    4.16 nM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell viability after 5 days by cell viability analyzer
    Cytotoxicity against human HeLa cells assessed as cell viability after 5 days by cell viability analyzer
    [PMID: 26291039]
    HeLa IC50
    4.61 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    [PMID: 35367708]
    HeLa IC50
    4.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 28254167]
    HeLa IC50
    5 mM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    [PMID: 23685942]
    HeLa IC50
    5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 27173802]
    HeLa IC50
    5.17 μM
    Compound: Doxorubicin
    Antitumor activity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Antitumor activity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    [PMID: 30138804]
    HeLa IC50
    5.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    [PMID: 27769619]
    HeLa IC50
    5.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    [PMID: 26252628]
    HeLa IC50
    5.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 29573910]
    HeLa IC50
    5.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 22304344]
    HeLa IC50
    5.57 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    [PMID: 37054758]
    HeLa IC50
    5.57 μM
    Compound: DOX
    Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    [PMID: 32085964]
    HeLa IC50
    5.57 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa after 24 hrs by MTT assay
    Antiproliferative activity against human HeLa after 24 hrs by MTT assay
    [PMID: 30826188]
    HeLa IC50
    5.57 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
    [PMID: 36242988]
    HeLa IC50
    5.57 μM
    Compound: Dox
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 32527460]
    HeLa IC50
    5.57 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 29702448]
    HeLa IC50
    5.57 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells by MTT assay
    Antiproliferative activity against human HeLa cells by MTT assay
    [PMID: 30216848]
    HeLa IC50
    5.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay
    [PMID: 34223162]
    HeLa IC50
    55 nM
    Compound: doxorubicin
    Cytotoxicity against human HeLa cells after 120 hrs by WST8 assay
    Cytotoxicity against human HeLa cells after 120 hrs by WST8 assay
    [PMID: 20180542]
    HeLa IC50
    57.8 μM
    Compound: DOX
    Antitumor activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antitumor activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 35859879]
    HeLa IC50
    6 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 25453802]
    HeLa IC50
    6.3 μM
    Compound: ADR
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    10.1039/C2MD20270K
    HeLa IC50
    6.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 30660827]
    HeLa GI50
    6.7 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    [PMID: 29316526]
    HeLa IC50
    6.94 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 24607876]
    HeLa IC50
    7.01 μM
    Compound: Doxo
    Cytotoxicity against human HeLa cells measured after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells measured after 24 hrs by MTT assay
    [PMID: 31104996]
    HeLa IC50
    7.04 μM
    Compound: DOX
    Anticancer activity against human HeLa cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay
    [PMID: 25064350]
    HeLa IC50
    7.18 μM
    Compound: Dox
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay
    [PMID: 28129977]
    HeLa IC50
    7.2 μM
    Compound: DX
    Cytotoxicity against human HeLa cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HeLa cells after 48 hrs by sulforhodamine B assay
    10.1039/C5MD00513B
    HeLa IC50
    7.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    [PMID: 35526504]
    HeLa GI50
    7.51 μM
    Compound: Doxo
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 26513642]
    HeLa IC50
    7.71 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    [PMID: 23994327]
    HeLa IC50
    7.9 μM
    Compound: DOX
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    [PMID: 31589431]
    HeLa IC50
    71 nM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay
    [PMID: 28600080]
    HeLa IC50
    780 nM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 30172625]
    HeLa IC50
    8.1 μM
    Compound: Doxorubicin
    Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT based microplate ELISA reader analysis
    Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT based microplate ELISA reader analysis
    [PMID: 34438126]
    HeLa IC50
    8.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by trypan blue-based hemacytometer counting analysis
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by trypan blue-based hemacytometer counting analysis
    [PMID: 28756265]
    HeLa IC50
    8.66 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 30398868]
    HeLa IC50
    8.72 μg/mL
    Compound: DOX
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    [PMID: 19932530]
    HeLa IC50
    8.87 μM
    Compound: DOX
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 35964425]
    HeLa IC50
    8.96 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by WST-8 assay
    Cytotoxicity against human HeLa cells by WST-8 assay
    [PMID: 29295796]
    HeLa IC50
    9.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 26873414]
    HeLa IC50
    90 nM
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 35059132]
    HeLa S3 IC50
    < 0.1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HeLaS3 cells by MTT assay
    Antiproliferative activity against human HeLaS3 cells by MTT assay
    [PMID: 29072457]
    HeLa S3 IC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLaS3 cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLaS3 cells after 48 hrs by MTT assay
    [PMID: 26963142]
    HeLa S3 IC50
    0.03 μM
    Compound: Doxorubicin
    Cytotoxicity against human HeLaS3 cells by MTT assay
    Cytotoxicity against human HeLaS3 cells by MTT assay
    [PMID: 30719909]
    HeLa S3 IC50
    0.12 μM
    Compound: Doxorubicin
    Cytotoxicity in human HeLaS3 cells incubated for 72 hrs by MTT assay
    Cytotoxicity in human HeLaS3 cells incubated for 72 hrs by MTT assay
    [PMID: 30978023]
    HeLa S3 IC50
    0.15 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human HeLa S3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity activity against human HeLa S3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 32627543]
    Hep 3B2 IC50
    0.14 μM
    Compound: Doxorubucin
    Cytotoxicity against human Hep3B cells by MTT assay
    Cytotoxicity against human Hep3B cells by MTT assay
    [PMID: 20718475]
    Hep 3B2 IC50
    0.2 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human Hep3B cells by MTT assay
    Cytotoxicity against human Hep3B cells by MTT assay
    [PMID: 18973388]
    Hep 3B2 IC50
    0.27 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells by MTT assay
    Cytotoxicity against human Hep3B cells by MTT assay
    [PMID: 18590313]
    Hep 3B2 IC50
    0.29 μM
    Compound: DOX
    Cytotoxicity against human Hep3B cells measured after 48 hrs by MTT assay
    Cytotoxicity against human Hep3B cells measured after 48 hrs by MTT assay
    [PMID: 23290052]
    Hep 3B2 IC50
    0.31 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    [PMID: 15387653]
    Hep 3B2 IC50
    0.41 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    [PMID: 19691312]
    Hep 3B2 IC50
    0.42 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells by MTT assay
    Cytotoxicity against human Hep3B cells by MTT assay
    [PMID: 21106454]
    Hep 3B2 IC50
    0.45 μg/mL
    Compound: doxo
    Cytotoxicity against human Hep3B cells by MTT method
    Cytotoxicity against human Hep3B cells by MTT method
    [PMID: 17417907]
    Hep 3B2 IC50
    0.48 μM
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    [PMID: 18547115]
    Hep 3B2 IC50
    0.59 μM
    Compound: doxorubicin
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    [PMID: 18419154]
    Hep 3B2 IC50
    0.6 μM
    Compound: Doxo
    Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay
    Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay
    [PMID: 20334960]
    Hep 3B2 IC50
    0.62 μM
    Compound: doxorubicin
    Cytotoxicity against human Hep3B cells after 72 hrs by MTT colorimetric method
    Cytotoxicity against human Hep3B cells after 72 hrs by MTT colorimetric method
    [PMID: 17622129]
    Hep 3B2 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells by MTT assay
    Cytotoxicity against human Hep3B cells by MTT assay
    [PMID: 21425785]
    Hep 3B2 IC50
    1.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human Hep3B cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    [PMID: 34838335]
    Hep 3B2 IC50
    1.03 μM
    Compound: Doxo
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    Cytotoxicity against human Hep3B cells after 3 days by MTT assay
    [PMID: 21800859]
    Hep 3B2 IC50
    1.15 μM
    Compound: Dox
    Cytotoxicity against human Hep3B cells by MTT assay
    Cytotoxicity against human Hep3B cells by MTT assay
    [PMID: 28262527]
    Hep 3B2 IC50
    1.31 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human Hep3B cells by MTT assay
    Cytotoxicity against human Hep3B cells by MTT assay
    [PMID: 22413887]
    Hep 3B2 IC50
    1.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay
    [PMID: 30660827]
    Hep 3B2 IC50
    13.25 μM
    Compound: Dox
    Antiproliferative activity against human Hep3B cells for 24 hrs by MTT assay
    Antiproliferative activity against human Hep3B cells for 24 hrs by MTT assay
    [PMID: 24929289]
    Hep 3B2 IC50
    16 μM
    Compound: DOX
    Cytotoxicity against human Hep3B cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human Hep3B cells measured after 72 hrs by Celltiter-Glo assay
    [PMID: 31820976]
    Hep 3B2 IC50
    2.4 μM
    Compound: Doxorubicin
    Growth inhibition of human Hep3B cells by MTT assay
    Growth inhibition of human Hep3B cells by MTT assay
    [PMID: 28916158]
    Hep 3B2 IC50
    4.5 μM
    Compound: Dox
    Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
    Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
    [PMID: 28865276]
    Hep 3B2 EC50
    5.6 μM
    Compound: doxorubicin
    Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay
    Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay
    [PMID: 20455578]
    HEp-2 IC50
    0.04 μM
    Compound: DOX
    Antitumor activity against human Hep2 cells after 72 hrs by MTT assay
    Antitumor activity against human Hep2 cells after 72 hrs by MTT assay
    [PMID: 17935309]
    HEp-2 IC50
    0.04 μM
    Compound: doxo
    Antiproliferative activity against human Hep2 cell line by MTT assay
    Antiproliferative activity against human Hep2 cell line by MTT assay
    [PMID: 16913700]
    HEp-2 IC50
    0.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Hep2 cells after 24 hrs
    Cytotoxicity against human Hep2 cells after 24 hrs
    [PMID: 20207452]
    HEp-2 IC50
    0.42 μM
    Compound: doxorubicin
    Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay
    Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay
    [PMID: 18281125]
    HEp-2 IC50
    0.42 μM
    Compound: doxorubicin
    Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay
    Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay
    [PMID: 17400463]
    HEp-2 IC50
    0.51 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Hep2 cells after 48 hrs by neutral red assay
    Antiproliferative activity against human Hep2 cells after 48 hrs by neutral red assay
    [PMID: 29885574]
    HEp-2 IC50
    1.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human Hep2 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    Cytotoxicity against human Hep2 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
    [PMID: 29329071]
    HEp-2 IC50
    1.29 μM
    Compound: Doxorubicin
    Cytotoxicity against human Hep2 cells after 72 hrs by MTT assay
    Cytotoxicity against human Hep2 cells after 72 hrs by MTT assay
    [PMID: 27116711]
    HEp-2 IC50
    1.3 μM
    Compound: Doxorubicin
    Growth inhibition of human Hep2 cells after 72 hrs by MTT assay
    Growth inhibition of human Hep2 cells after 72 hrs by MTT assay
    [PMID: 28189083]
    HEp-2 IC50
    1.5 μM
    Compound: Adriamycin
    Cytotoxicity against human Hep2 cells by neutral red method
    Cytotoxicity against human Hep2 cells by neutral red method
    [PMID: 26291474]
    HEp-2 IC50
    1.78 μM
    Compound: DOX
    Cytotoxicity against against human Hep2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against against human Hep2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 30340899]
    HEp-2 IC50
    6.32 μM
    Compound: Doxorubicin
    Antiproliferative activity against human Hep2 after 24 hrs by MTT assay
    Antiproliferative activity against human Hep2 after 24 hrs by MTT assay
    [PMID: 30826188]
    HEp-2 IC50
    8.54 μM
    Compound: DOX
    Antiproliferative activity against human HEp-2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HEp-2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    [PMID: 37054758]
    HEp-2 IC50
    8.7 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) Hep2 cells by MTT assay
    Cytotoxicity against Homo sapiens (human) Hep2 cells by MTT assay
    10.1007/s00044-012-0370-x
    HEp-2 IC50
    8.7 μM
    Compound: Doxorubicine
    Cytotoxicity against human Hep2 cells by MTT assay
    Cytotoxicity against human Hep2 cells by MTT assay
    [PMID: 22014995]
    HepG2 IC50
    < 2.94 μM
    Compound: Doxorubicin
    Inhibition of proliferation of human HepG2 cells after 72 hrs by XTT assay
    Inhibition of proliferation of human HepG2 cells after 72 hrs by XTT assay
    [PMID: 20810194]
    HepG2 EC50
    > 10 μM
    Compound: doxorubicin
    Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay
    Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay
    [PMID: 20455578]
    HepG2 IC50
    > 40 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    [PMID: 12608856]
    HepG2 IC50
    > 50 μM
    Compound: DOX
    Cytotoxicity against human doxorubicin-resistant HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human doxorubicin-resistant HepG2 cells after 48 hrs by MTT assay
    [PMID: 27889629]
    HepG2 IC50
    > 75 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    [PMID: 27843113]
    HepG2 IC50
    0.007 ug
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by SRB assay
    [PMID: 27393950]
    HepG2 IC50
    0.009 mM
    Compound: DOX
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    [PMID: 22520152]
    HepG2 GI50
    0.01 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 27889456]
    HepG2 IC50
    0.01 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    [PMID: 30826510]
    HepG2 IC50
    0.017 g/L
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay
    10.1007/s00044-010-9433-z
    HepG2 IC50
    0.02 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 27886545]
    HepG2 CC50
    0.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay
    [PMID: 25282267]
    HepG2 IC50
    0.04 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
    [PMID: 31403289]
    HepG2 GI50
    0.04 μM
    Compound: Dox
    Growth inhibition of human HepG2 cells by MTT assay
    Growth inhibition of human HepG2 cells by MTT assay
    [PMID: 31330449]
    HepG2 IC50
    0.05 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 22555152]
    HepG2 CC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 32088496]
    HepG2 IC50
    0.06 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 34782182]
    HepG2 IC50
    0.06 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells by SRB method
    Cytotoxicity against human HepG2 cells by SRB method
    [PMID: 18181575]
    HepG2 IC50
    0.069 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31999451]
    HepG2 IC50
    0.08 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    [PMID: 23802716]
    HepG2 IC50
    0.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by CCK8 assay
    Cytotoxicity against human HepG2 cells after 72 hrs by CCK8 assay
    [PMID: 28398051]
    HepG2 IC50
    0.1 μM
    Compound: doxorubicin
    Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
    Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
    [PMID: 18313307]
    HepG2 IC50
    0.16 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    [PMID: 19691312]
    HepG2 IC50
    0.16 μM
    Compound: ADM; DOX
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 31491611]
    HepG2 IC50
    0.17 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 18590313]
    HepG2 IC50
    0.17 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 6 days by MTT method
    Cytotoxicity against human HepG2 cells after 6 days by MTT method
    [PMID: 16309317]
    HepG2 IC50
    0.18 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    [PMID: 16252914]
    HepG2 IC50
    0.18 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 22413887]
    HepG2 IC50
    0.19 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    [PMID: 15387653]
    HepG2 IC50
    0.19 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay
    [PMID: 23290052]
    HepG2 GI50
    0.19 μM
    Compound: DOX
    Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
    Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
    [PMID: 30336023]
    HepG2 GI50
    0.19 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 29705710]
    HepG2 IC50
    0.19 μM
    Compound: DOX
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 21496972]
    HepG2 IC50
    0.19 μM
    Compound: Doxorubucin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 20718475]
    HepG2 IC50
    0.2 μg/mL
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 18973388]
    HepG2 IC50
    0.2 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human Hep G2 cells by MTT colorimetric method
    Cytotoxicity against human Hep G2 cells by MTT colorimetric method
    [PMID: 17125220]
    HepG2 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 28277681]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    [PMID: 34364164]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 32795774]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 32652409]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 32292551]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 30655943]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 30092366]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTT assay
    [PMID: 29885575]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 27654395]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay
    [PMID: 27155463]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 25846065]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 25791675]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 25559208]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicine
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 24946216]
    HepG2 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 24650715]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 24080103]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 22889559]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 22608675]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 21852132]
    HepG2 CC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 21741131]
    HepG2 IC50
    0.2 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 19926173]
    HepG2 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 19482476]
    HepG2 IC50
    0.2 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 17981462]
    HepG2 IC50
    0.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    Cytotoxicity against human HepG2 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
    [PMID: 36970146]
    HepG2 IC50
    0.21 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
    [PMID: 31836446]
    HepG2 IC50
    0.22 μg/mL
    Compound: Doxorubicin
    Cytotoxic activity against human HepG2 cells by MTT assay
    Cytotoxic activity against human HepG2 cells by MTT assay
    [PMID: 28366267]
    HepG2 IC50
    0.23 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as survival after 3 days by crystal violet staining
    Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as survival after 3 days by crystal violet staining
    10.1007/s00044-012-0025-y
    HepG2 IC50
    0.23 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 3 days by MTT assay
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 3 days by MTT assay
    10.1007/s00044-011-9903-y
    HepG2 IC50
    0.23 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 21106454]
    HepG2 IC50
    0.23 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by fluorescein diacetate dye based fluorometric microculture assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by fluorescein diacetate dye based fluorometric microculture assay
    [PMID: 28038943]
    HepG2 GI50
    0.25 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
    [PMID: 26561866]
    HepG2 IC50
    0.26 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    [PMID: 21741833]
    HepG2 IC50
    0.29 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 21174408]
    HepG2 IC50
    0.3 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 16724859]
    HepG2 IC50
    0.3 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    [PMID: 24050254]
    HepG2 IC50
    0.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    10.1039/C5MD00163C
    HepG2 IC50
    0.3 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 19632833]
    HepG2 EC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
    [PMID: 26320088]
    HepG2 IC50
    0.3 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 29975532]
    HepG2 IC50
    0.36 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 25314138]
    HepG2 IC50
    0.37 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 4 days by MTT assay
    Cytotoxicity against human HepG2 cells after 4 days by MTT assay
    [PMID: 19824618]
    HepG2 IC50
    0.37 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 20846862]
    HepG2 IC50
    0.38 μM
    Compound: Doxorubicin
    Growth inhibition of human HepG2 cells incubated for 48 hrs by MTT assay
    Growth inhibition of human HepG2 cells incubated for 48 hrs by MTT assay
    [PMID: 27080187]
    HepG2 IC50
    0.39 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells by MTT assay
    Antiproliferative activity against human HepG2 cells by MTT assay
    [PMID: 36089748]
    HepG2 IC50
    0.392 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell viability incubated for 72 hrs by cellTiter 96 AQueous non-radioactive cell proliferation assay
    Cytotoxicity against human HepG2 cells assessed as cell viability incubated for 72 hrs by cellTiter 96 AQueous non-radioactive cell proliferation assay
    [PMID: 28797771]
    HepG2 IC50
    0.4 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay
    [PMID: 32223924]
    HepG2 IC50
    0.4 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by neutral red-based assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by neutral red-based assay
    [PMID: 26469557]
    HepG2 IC50
    0.4 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay
    [PMID: 25490132]
    HepG2 IC50
    0.4 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 25747499]
    HepG2 IC50
    0.41 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 23992864]
    HepG2 IC50
    0.42 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay
    [PMID: 24969014]
    HepG2 IC50
    0.42 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay
    Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay
    10.1007/s00044-012-0402-6
    HepG2 IC50
    0.425 μM
    Compound: DOX
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 35341920]
    HepG2 IC50
    0.45 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells by MTT assay
    Anticancer activity against human HepG2 cells by MTT assay
    [PMID: 31404864]
    HepG2 IC50
    0.46 μg/mL
    Compound: doxo
    Cytotoxicity against human HepG2 cells by MTT method
    Cytotoxicity against human HepG2 cells by MTT method
    [PMID: 17417907]
    HepG2 IC50
    0.467 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay
    Anticancer activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay
    [PMID: 35694689]
    HepG2 IC50
    0.48 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
    [PMID: 24852278]
    HepG2 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 200 uM incubated for 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 200 uM incubated for 24 hrs by MTT assay
    [PMID: 31926469]
    HepG2 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    [PMID: 25554367]
    HepG2 IC50
    0.5 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    [PMID: 31148449]
    HepG2 IC50
    0.5 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 21641694]
    HepG2 IC50
    0.5 μM
    Compound: Doxo
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 20334960]
    HepG2 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    10.1039/C3MD00166K
    HepG2 IC50
    0.5 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 24182355]
    HepG2 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 21425785]
    HepG2 IC50
    0.5 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by SRB assay
    Cytotoxicity against human HepG2 cells by SRB assay
    [PMID: 29035560]
    HepG2 IC50
    0.5 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT colorimetric method
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT colorimetric method
    [PMID: 17622129]
    HepG2 IC50
    0.52 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 30389295]
    HepG2 IC50
    0.54 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 27371926]
    HepG2 IC50
    0.54 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 28262527]
    HepG2 IC50
    0.55 μM
    Compound: DX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    [PMID: 29681486]
    HepG2 IC50
    0.55 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31704206]
    HepG2 IC50
    0.57 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 26397393]
    HepG2 IC50
    0.57 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 25019480]
    HepG2 IC50
    0.58 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 26386603]
    HepG2 IC50
    0.59 μg/mL
    Compound: Dox
    Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay
    [PMID: 20399544]
    HepG2 IC50
    0.59 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 23806110]
    HepG2 IC50
    0.6 μg/mL
    Compound: Doxorubicine
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    [PMID: 24177357]
    HepG2 IC50
    0.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 24300737]
    HepG2 IC50
    0.62 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    [PMID: 32438251]
    HepG2 IC50
    0.62 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 48 hrs by neutral red assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by neutral red assay
    [PMID: 29885574]
    HepG2 IC50
    0.63 μM
    Compound: Doxo
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    [PMID: 21800859]
    HepG2 IC50
    0.64 μg/mL
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    [PMID: 34973507]
    HepG2 IC50
    0.64 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    [PMID: 18419154]
    HepG2 IC50
    0.66 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    [PMID: 34838335]
    HepG2 EC50
    0.67 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 35567964]
    HepG2 IC50
    0.67 μM
    Compound: DOX
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 32996316]
    HepG2 IC50
    0.68 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 29421568]
    HepG2 IC50
    0.68 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTT assay
    [PMID: 27422336]
    HepG2 IC50
    0.69 μM
    Compound: DOX
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    [PMID: 33276990]
    HepG2 IC50
    0.69 μM
    Compound: ADM
    Growth inhibition of human HepG2 cells after 48 hrs by WST8 assay
    Growth inhibition of human HepG2 cells after 48 hrs by WST8 assay
    [PMID: 16499322]
    HepG2 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay
    [PMID: 27300257]
    HepG2 GI50
    0.7 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    [PMID: 34634616]
    HepG2 IC50
    0.7 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 22749279]
    HepG2 IC50
    0.7 μM
    Compound: Dox
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    [PMID: 31765156]
    HepG2 IC50
    0.7 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells after 72 hrs by sulforhodamine B assay
    [PMID: 30132670]
    HepG2 IC50
    0.72 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay
    [PMID: 31926469]
    HepG2 IC50
    0.72 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    [PMID: 30654238]
    HepG2 IC50
    0.72 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 26874404]
    HepG2 IC50
    0.74 μM
    Compound: Dox
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 35339100]
    HepG2 IC50
    0.74 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 25419616]
    HepG2 CC50
    0.77 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 120 hrs by MTS assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 120 hrs by MTS assay
    [PMID: 32590115]
    HepG2 IC50
    0.77 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay
    [PMID: 25537271]
    HepG2 IC50
    0.79 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    10.1007/s00044-013-0777-z
    HepG2 IC50
    0.79 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 25078311]
    HepG2 IC50
    0.79 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 24836071]
    HepG2 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    [PMID: 32324401]
    HepG2 IC50
    0.8 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 26586599]
    HepG2 IC50
    0.82 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    Cytotoxicity against human HepG2 cells after 3 days by MTT assay
    [PMID: 18547115]
    HepG2 IC50
    0.87 μM
    Compound: AMD
    Anticancer activity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay
    [PMID: 25812966]
    HepG2 IC50
    0.877 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
    Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
    [PMID: 24231309]
    HepG2 IC50
    0.9 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by neutral red
    Cytotoxicity against human HepG2 cells after 48 hrs by neutral red
    [PMID: 23891181]
    HepG2 IC50
    0.9 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 28704759]
    HepG2 IC50
    0.919 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by SRB assay
    Cytotoxicity against human HepG2 cells by SRB assay
    [PMID: 34128674]
    HepG2 IC50
    0.95 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    10.1039/C3MD00013C
    HepG2 IC50
    0.954 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 20832916]
    HepG2 IC50
    0.99 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells by SRB assay
    Anticancer activity against human HepG2 cells by SRB assay
    [PMID: 34128674]
    HepG2 IC50
    1 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay
    [PMID: 21094049]
    HepG2 IC50
    1 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 32371335]
    HepG2 IC50
    1 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 28919340]
    HepG2 IC50
    1 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 32627543]
    HepG2 IC50
    1 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by neutral red assay
    Cytotoxicity against human HepG2 cells after 48 hrs by neutral red assay
    [PMID: 24900509]
    HepG2 IC50
    1.01 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 29909338]
    HepG2 IC50
    1.02 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 23871222]
    HepG2 IC50
    1.05 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells by MTT assay
    Anticancer activity against human HepG2 cells by MTT assay
    [PMID: 25743216]
    HepG2 IC50
    1.07 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 30719909]
    HepG2 IC50
    1.08 μM
    Compound: Dox
    Anticancer activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by SRB assay
    Anticancer activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by SRB assay
    10.1007/s00044-012-0057-3
    HepG2 IC50
    1.1 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT microcultured tetrazolium assay
    Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT microcultured tetrazolium assay
    [PMID: 25096298]
    HepG2 IC50
    1.12 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 32866757]
    HepG2 IC50
    1.13 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by CCK8 assay
    Cytotoxicity against human HepG2 cells by CCK8 assay
    [PMID: 29452840]
    HepG2 IC50
    1.15 μM
    Compound: Adriamycin
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 24582982]
    HepG2 IC50
    1.18 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 3 days by microplate reader analysis
    Cytotoxicity against human HepG2 cells after 3 days by microplate reader analysis
    [PMID: 32705864]
    HepG2 IC50
    1.2 μM
    Compound: DOX
    Antineoplastic activity against human HepG2 cells measured after 36 hrs by MTT assay
    Antineoplastic activity against human HepG2 cells measured after 36 hrs by MTT assay
    [PMID: 30746067]
    HepG2 IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay
    10.1007/s00044-011-9884-x
    HepG2 IC50
    1.2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 27797185]
    HepG2 IC50
    1.2 μM
    Compound: ADM
    Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
    Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
    [PMID: 15730243]
    HepG2 IC50
    1.2 μM
    Compound: ADM
    Cytotoxicity against human Hep G2 by WST-8 assay
    Cytotoxicity against human Hep G2 by WST-8 assay
    [PMID: 16933868]
    HepG2 IC50
    1.2 μM
    Compound: adriamycin
    Cytotoxicity against human HepG2 cells by rapid colorimetric assay
    Cytotoxicity against human HepG2 cells by rapid colorimetric assay
    [PMID: 19585998]
    HepG2 IC50
    1.21 μg/mL
    Compound: Doxorubicin
    Anticancer activity against human cells HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    Anticancer activity against human cells HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
    [PMID: 25042338]
    HepG2 IC50
    1.21 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 30771605]
    HepG2 IC50
    1.22 μM
    Compound: adriamycin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
    [PMID: 26295905]
    HepG2 IC50
    1.22 μM
    Compound: ADM
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
    [PMID: 25089733]
    HepG2 IC50
    1.3 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    [PMID: 34323485]
    HepG2 IC50
    1.34 μM
    Compound: AMD
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 26900656]
    HepG2 IC50
    1.37 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 31057738]
    HepG2 GI50
    1.4 μM
    Compound: Doxorubicin
    Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay
    Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay
    [PMID: 26163220]
    HepG2 IC50
    1.43 μM
    Compound: Doxorubicin
    Cytotoxicity in human HepG2 cells incubated for 72 hrs by MTT assay
    Cytotoxicity in human HepG2 cells incubated for 72 hrs by MTT assay
    [PMID: 30978023]
    HepG2 IC50
    1.5 μM
    Compound: DOX
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 28756264]
    HepG2 IC50
    1.51 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    [PMID: 32682198]
    HepG2 IC50
    1.54 μM
    Compound: DOXO
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by alamar blue assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by alamar blue assay
    [PMID: 21797280]
    HepG2 IC50
    1.54 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by Alamar blue assay
    Cytotoxicity against human HepG2 cells after 48 hrs by Alamar blue assay
    [PMID: 20931970]
    HepG2 IC50
    1.54 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 26963142]
    HepG2 IC50
    1.6 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 21708464]
    HepG2 IC50
    1.6 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 19583252]
    HepG2 IC50
    1.61 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 25615796]
    HepG2 IC50
    1.69 μM
    Compound: Dox
    Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as reduction of cell survival after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as reduction of cell survival after 48 hr by MTT assay
    10.1007/s00044-012-0150-7
    HepG2 IC50
    1.7 x 10-1 μM
    Compound: doxorubicin
    Growth inhibition of human HepG2 cells after 72 hrs by SRB assay
    Growth inhibition of human HepG2 cells after 72 hrs by SRB assay
    [PMID: 18512984]
    HepG2 IC50
    1.8 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
    [PMID: 34363936]
    HepG2 IC50
    1.89 μM
    Compound: DOX
    Growth inhibition of human HepG2 cells after 48 hrs by MTT assay
    Growth inhibition of human HepG2 cells after 48 hrs by MTT assay
    [PMID: 29509413]
    HepG2 CC50
    1.95 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 29792325]
    HepG2 IC50
    1.969 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    [PMID: 34700239]
    HepG2 IC50
    10 nM
    Compound: Dox
    Anticancer activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    Anticancer activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    [PMID: 31740054]
    HepG2 IC50
    10 μM
    Compound: Doxorubicin
    Antiproliferative activity against doxorubicin resistant human HepG2 cells for 24 hrs in presence of c-phycocyanin by MTT assay
    Antiproliferative activity against doxorubicin resistant human HepG2 cells for 24 hrs in presence of c-phycocyanin by MTT assay
    [PMID: 34128674]
    HepG2 IC50
    10.15 μM
    Compound: Doxorubicin
    Cytotoxicity activity against human HepG2 cells by MTT assay
    Cytotoxicity activity against human HepG2 cells by MTT assay
    [PMID: 26873414]
    HepG2 IC50
    10.4 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 31323616]
    HepG2 GI50
    10.7 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
    [PMID: 29316526]
    HepG2 ED50
    102 μM
    Compound: doxorubicin
    Antitumor activity against human HepG2 cells after 24 hrs by MTT assay
    Antitumor activity against human HepG2 cells after 24 hrs by MTT assay
    [PMID: 17482824]
    HepG2 IC50
    12.5 μM
    Compound: Adriamycin
    Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay
    [PMID: 24974349]
    HepG2 IC50
    130 nM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    [PMID: 35213166]
    HepG2 IC50
    14.7 μM
    Compound: Dox
    Cytotoxicity against human HepG2 Cells by MTT/Trypan Blue Exclusion Assay
    Cytotoxicity against human HepG2 Cells by MTT/Trypan Blue Exclusion Assay
    [PMID: 31129455]
    HepG2 IC50
    17.54 μM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 21620529]
    HepG2 IC50
    18.03 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells assessed as cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell viability measured after 24 hrs by MTT assay
    [PMID: 33183865]
    HepG2 IC50
    18.7 μM
    Compound: 12
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 29852328]
    HepG2 IC50
    19 nM
    Compound: Doxorubicin
    Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay
    [PMID: 21296467]
    HepG2 IC50
    19 μg/mL
    Compound: doxorubicin
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay
    10.1007/s00044-010-9436-9
    HepG2 IC50
    2 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 48 hrs by Neutral Red assay
    Cytotoxicity against human HepG2 cells after 48 hrs by Neutral Red assay
    10.1039/C3MD00097D
    HepG2 IC50
    2.03 μM
    Compound: ADM
    Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
    [PMID: 20932754]
    HepG2 IC50
    2.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    [PMID: 26821210]
    HepG2 IC50
    2.1 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 29702447]
    HepG2 IC50
    2.17 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 94 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 94 hrs by MTT assay
    [PMID: 21868138]
    HepG2 IC50
    2.3 μM
    Compound: Doxorubicin
    Hepatotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Hepatotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 33439019]
    HepG2 IC50
    2.32 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    [PMID: 33352388]
    HepG2 IC50
    2.35 μM
    Compound: Doxorubicin
    Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    [PMID: 34124677]
    HepG2 IC50
    2.41 x 10-1 μg/mL
    Compound: adriamycin
    Cytotoxicity against human HepG2 cells after 12 days by methylene blue colorimetric method
    Cytotoxicity against human HepG2 cells after 12 days by methylene blue colorimetric method
    [PMID: 11473425]
    HepG2 IC50
    2.41 x 10-1 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells after 3 days
    Cytotoxicity against human HepG2 cells after 3 days
    [PMID: 11975482]
    HepG2 IC50
    2.5 mM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    [PMID: 23685942]
    HepG2 IC50
    2.5 mM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 22440624]
    HepG2 IC50
    2.5 nM
    Compound: Doxorubicin
    Inhibition of TRK in human HepG2 cells after 48 hrs by ELISA
    Inhibition of TRK in human HepG2 cells after 48 hrs by ELISA
    [PMID: 24013411]
    HepG2 IC50
    2.511 μM
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 28462842]
    HepG2 IC50
    2.594 μM
    Compound: Doxorubicin
    Anti-proliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    Anti-proliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    [PMID: 27744185]
    HepG2 IC50
    2.6 μM
    Compound: DOX
    Inhibition of topoisomerase 2 in human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    Inhibition of topoisomerase 2 in human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
    [PMID: 30846253]
    HepG2 IC50
    2.67 μM
    Compound: AMD
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    [PMID: 27639364]
    HepG2 IC50
    2.68 μM
    Compound: doxorubicin
    Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
    10.1007/s00044-013-0795-x
    HepG2 IC50
    2.7 μM
    Compound: DOX
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
    [PMID: 34450496]